# HEALTH ANNUAL STATEMENT

AS OF DECEMBER 31, 2018
OF THE CONDITION AND AFFAIRS OF THE

# Aetna Better Health of Michigan Inc.

NAIC Group Code 0001 (Current) 0001 (Prior) NAIC Company Code 12193 Employer's ID Number 20-1052897

Organized under the Laws of Michigan, State of Domicile or Port of Entry MI

Country of Domicile United States of America

Licensed as business type: Health Maintenance Organization

Is HMO Federally Qualified? Yes [ ] No [ X ]

Incorporated/Organized 04/22/2004 Commenced Business 10/01/2004

Statutory Home Office 1333 Gratiot, Ste. 400 (Street and Number), Detroit, MI, US 48207 (City or Town, State, Country and Zip Code)

Main Administrative Office 1333 Gratiot, Ste. 400 (Street and Number)
Detroit, MI, US 48207 (City or Town, State, Country and Zip Code) 313-465-1519 (Area Code) (Telephone Number)

Mail Address 1333 Gratiot, Ste. 400 (Street and Number or P.O. Box), Detroit, MI, US 48207 (City or Town, State, Country and Zip Code)

Primary Location of Books and Records 1333 Gratiot, Ste. 400 (Street and Number)
Detroit, MI, US 48207 (City or Town, State, Country and Zip Code) 313-465-1519 (Area Code) (Telephone Number)

Internet Website Address www.aetnabetterhealth.com

Statutory Statement Contact Frank Ferris Chronister III (Name) 717-541-5742 (Area Code) (Telephone Number)
StatutoryReporting@aetna.com (E-mail Address) 717-526-2888 (FAX Number)

## OFFICERS

Chief Executive Officer and President Randy Joo Hwan Hyun # Chief Financial Officer Debra Jean Bacon
Vice President and Secretary Robert Mark Kessler

## OTHER

Kevin James Casey, Senior Investment Officer
Frank Ferris Chronister III, Corporate Controller
John Patrick Maroney, Vice President and Treasurer

## DIRECTORS OR TRUSTEES

Beverly Ann Allen
Debra Jean Bacon
Janet Ruth Grant
Randy Joo Hwan Hyun #
Harvey Douglas Turner

The officers of this reporting entity being duly sworn, each depose and say that they are the described officers of said reporting entity, and that on the reporting period stated above, all of the herein described assets were the absolute property of the said reporting entity, free and clear from any liens or claims thereon, except as herein stated, and that this statement, together with related exhibits, schedules and explanations therein contained, annexed or referred to, is a full and true statement of all the assets and liabilities and of the condition and affairs of the said reporting entity as of the reporting period stated above, and of its income and deductions therefrom for the period ended, and have been completed in accordance with the NAIC Annual Statement Instructions and Accounting Practices and Procedures manual except to the extent that: (1) state law may differ; or, (2) that state rules or regulations require differences in reporting not related to accounting practices and procedures, according to the best of their information, knowledge and belief, respectively. Furthermore, the scope of this attestation by the described officers also includes the related corresponding electronic filing with the NAIC, when required, that is an exact copy (except for formatting differences due to electronic filing) of the enclosed statement. The electronic filing may be requested by various regulators in lieu of or in addition to the enclosed statement.

| Randy Joo Hwan Hyun<br>Chief Executive Officer and President | Robert Mark Kessler<br>Vice President and Secretary | Debra Jean Bacon<br>Chief Financial Officer |
|---|---|---|
| State of..... Arizona<br>County of..... Maricopa | State of..... Arizona<br>County of..... Maricopa | State of..... Arizona<br>County of..... Maricopa |
| Subscribed and sworn to before me this<br>11 day of February, 2019 | Subscribed and sworn to before me this<br>11 day of February, 2019 | Subscribed and sworn to before me this<br>11 day of February, 2019 |
| NOTARY PUBLIC (Seal) | NOTARY PUBLIC (Seal) | NOTARY PUBLIC (Seal) |

JANEEN NEWHOUSE
Notary Public, State of Arizona
Maricopa County
Commission # 557912
My Commission Expires
February 08, 2023

JANEEN NEWHOUSE
Notary Public, State of Arizona
Maricopa County
Commission # 557912
My Commission Expires
February 08, 2023

JANEEN NEWHOUSE
Notary Public, State of Arizona
Maricopa County
Commission # 557912
My Commission Expires
February 08, 2023

a. Is this an original filing? ..... Yes [ X ] No [ ]
b. If no,
1. State the amendment number .....
2. Date filed .....
3. Number of pages attached.....

# ASSETS

| | | Current Year 1 Assets | 2 Nonadmitted Assets | 3 Net Admitted Assets (Cols. 1 - 2) | Prior Year 4 Net Admitted Assets |
|---|---|---|---|---|---|
| 1. | Bonds (Schedule D) | 15,879,939 | | 15,879,939 | 1,200,283 |
| 2. | Stocks (Schedule D): | | | | |
| | 2.1 Preferred stocks | 0 | | 0 | 0 |
| | 2.2 Common stocks | 0 | | 0 | 0 |
| 3. | Mortgage loans on real estate (Schedule B): | | | | |
| | 3.1 First liens | | | 0 | |
| | 3.2 Other than first liens | | | 0 | |
| 4. | Real estate (Schedule A): | | | | |
| | 4.1 Properties occupied by the company (less $ ..... encumbrances) | | | 0 | |
| | 4.2 Properties held for the production of income (less $ ..... encumbrances) | | | 0 | |
| | 4.3 Properties held for sale (less $ ..... encumbrances) | | | 0 | |
| 5. | Cash ($ 1,975,406 , Schedule E - Part 1), cash equivalents ($ 81,240,100 , Schedule E - Part 2) and short-term investments ($ 0 , Schedule DA) | 83,215,506 | | 83,215,506 | 104,400,250 |
| 6. | Contract loans, (including $ ..... premium notes) | | | 0 | |
| 7. | Derivatives (Schedule DB) | | | 0 | 0 |
| 8. | Other invested assets (Schedule BA) | | | 0 | 0 |
| 9. | Receivables for securities | | | 0 | |
| 10. | Securities lending reinvested collateral assets (Schedule DL) | | | 0 | 0 |
| 11. | Aggregate write-ins for invested assets | 0 | 0 | 0 | 0 |
| 12. | Subtotals, cash and invested assets (Lines 1 to 11) | 99,095,445 | 0 | 99,095,445 | 105,600,533 |
| 13. | Title plants less $ ..... charged off (for Title insurers only) | | | 0 | |
| 14. | Investment income due and accrued | 99,356 | 0 | 99,356 | 1,543 |
| 15. | Premiums and considerations: | | | | |
| | 15.1 Uncollected premiums and agents' balances in the course of collection | 20,495,292 | 0 | 20,495,292 | 8,367,702 |
| | 15.2 Deferred premiums and agents' balances and installments booked but deferred and not yet due (including $ ..... earned but unbilled premiums) | | | 0 | |
| | 15.3 Accrued retrospective premiums ($ ..... ) and contracts subject to redetermination ($ 8,499 ) | 8,499 | 0 | 8,499 | 937,690 |
| 16. | Reinsurance: | | | | |
| | 16.1 Amounts recoverable from reinsurers | 0 | 0 | 0 | 0 |
| | 16.2 Funds held by or deposited with reinsured companies | | | 0 | |
| | 16.3 Other amounts receivable under reinsurance contracts | | | 0 | |
| 17. | Amounts receivable relating to uninsured plans | 9,980,642 | 0 | 9,980,642 | 3,337,772 |
| 18.1 | Current federal and foreign income tax recoverable and interest thereon | 0 | 0 | 0 | 0 |
| 18.2 | Net deferred tax asset | 2,249,464 | 0 | 2,249,464 | 4 |
| 19. | Guaranty funds receivable or on deposit | 0 | 0 | 0 | |
| 20. | Electronic data processing equipment and software | 0 | 0 | 0 | |
| 21. | Furniture and equipment, including health care delivery assets ($ ..... ) | 0 | 0 | 0 | |
| 22. | Net adjustment in assets and liabilities due to foreign exchange rates | 0 | 0 | 0 | |
| 23. | Receivables from parent, subsidiaries and affiliates | 0 | 0 | 0 | |
| 24. | Health care ($ 4,289,867 ) and other amounts receivable | 9,672,423 | 5,382,556 | 4,289,867 | 3,248,418 |
| 25. | Aggregate write-ins for other than invested assets | 268,530 | 0 | 268,530 | 0 |
| 26. | Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25) | 141,869,651 | 5,382,556 | 136,487,095 | 121,493,662 |
| 27. | From Separate Accounts, Segregated Accounts and Protected Cell Accounts | | | 0 | |
| 28. | Total (Lines 26 and 27) | 141,869,651 | 5,382,556 | 136,487,095 | 121,493,662 |
| | **DETAILS OF WRITE-INS** | | | | |
| 1101. | | | | | |
| 1102. | | | | | |
| 1103. | | | | | |
| 1198. | Summary of remaining write-ins for Line 11 from overflow page | 0 | 0 | 0 | 0 |
| 1199. | Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above) | 0 | 0 | 0 | 0 |
| 2501. | Intangible Assets and Amortization | 0 | 0 | 0 | 0 |
| 2502. | State Tax Recoverable | 268,530 | 0 | 268,530 | 0 |
| 2503. | | | | | |
| 2598. | Summary of remaining write-ins for Line 25 from overflow page | 0 | 0 | 0 | 0 |
| 2599. | Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above) | 268,530 | 0 | 268,530 | 0 |

# LIABILITIES, CAPITAL AND SURPLUS

| | | Current Year | | | Prior Year |
|---|---|---|---|---|---|
| | | 1 | 2 | 3 | 4 |
| | | Covered | Uncovered | Total | Total |
| 1. | Claims unpaid (less $ 0 reinsurance ceded) | 45,238,957 | 7,048,326 | 52,287,283 | 60,512,631 |
| 2. | Accrued medical incentive pool and bonus amounts | 2,126,256 | | 2,126,256 | 1,659,140 |
| 3. | Unpaid claims adjustment expenses | 1,781,884 | | 1,781,884 | 900,118 |
| 4. | Aggregate health policy reserves, including the liability of $ 0 for medical loss ratio rebate per the Public Health Service Act | 406,976 | | 406,976 | 0 |
| 5. | Aggregate life policy reserves | 0 | | 0 | |
| 6. | Property/casualty unearned premium reserves | 0 | | 0 | |
| 7. | Aggregate health claim reserves | 0 | | 0 | |
| 8. | Premiums received in advance | 0 | | 0 | |
| 9. | General expenses due or accrued | 728,465 | | 728,465 | 1,050,590 |
| 10.1 | Current federal and foreign income tax payable and interest thereon (including $ on realized capital gains (losses)) | 1,362,768 | | 1,362,768 | 1,683,256 |
| 10.2 | Net deferred tax liability | 0 | | 0 | |
| 11. | Ceded reinsurance premiums payable | 0 | | 0 | |
| 12. | Amounts withheld or retained for the account of others | 0 | | 0 | |
| 13. | Remittances and items not allocated | 162,351 | | 162,351 | 116,201 |
| 14. | Borrowed money (including $ current) and interest thereon $ (including $ current) | 0 | | 0 | |
| 15. | Amounts due to parent, subsidiaries and affiliates | 12,697,485 | | 12,697,485 | 11,540,776 |
| 16. | Derivatives | 0 | | 0 | |
| 17. | Payable for securities | 0 | | 0 | |
| 18. | Payable for securities lending | 0 | | 0 | |
| 19. | Funds held under reinsurance treaties (with $ authorized reinsurers, $ 0 unauthorized reinsurers and $ 0 certified reinsurers) | 0 | | 0 | |
| 20. | Reinsurance in unauthorized and certified ($ ) companies | 0 | | 0 | |
| 21. | Net adjustments in assets and liabilities due to foreign exchange rates | | | 0 | |
| 22. | Liability for amounts held under uninsured plans | 9,876,370 | | 9,876,370 | 1,945,188 |
| 23. | Aggregate write-ins for other liabilities (including $ current) | 460,765 | 0 | 460,765 | 579,846 |
| 24. | Total liabilities (Lines 1 to 23) | 74,842,277 | 7,048,326 | 81,890,603 | 79,987,746 |
| 25. | Aggregate write-ins for special surplus funds | XXX | XXX | 0 | 7,117,000 |
| 26. | Common capital stock | XXX | XXX | 10 | 10 |
| 27. | Preferred capital stock | XXX | XXX | | |
| 28. | Gross paid in and contributed surplus | XXX | XXX | 35,600,990 | 35,600,990 |
| 29. | Surplus notes | XXX | XXX | 0 | |
| 30. | Aggregate write-ins for other than special surplus funds | XXX | XXX | 0 | 0 |
| 31. | Unassigned funds (surplus) | XXX | XXX | 18,995,492 | (1,212,084) |
| 32. | Less treasury stock, at cost: | | | | |
| | 32.1 shares common (value included in Line 26 $ ) | XXX | XXX | | |
| | 32.2 shares preferred (value included in Line 27 $ ) | XXX | XXX | | |
| 33. | Total capital and surplus (Lines 25 to 31 minus Line 32) | XXX | XXX | 54,596,492 | 41,505,916 |
| 34. | Total liabilities, capital and surplus (Lines 24 and 33) | XXX | XXX | 136,487,095 | 121,493,662 |
| | **DETAILS OF WRITE-INS** | | | | |
| 2301. | Abandoned Property Liability | 460,765 | 0 | 460,765 | 579,846 |
| 2302. | | | | | |
| 2303. | | | | | |
| 2398. | Summary of remaining write-ins for Line 23 from overflow page | 0 | 0 | 0 | 0 |
| 2399. | Totals (Lines 2301 thru 2303 plus 2398)(Line 23 above) | 460,765 | 0 | 460,765 | 579,846 |
| 2501. | Estimated Health Insurance Fee accrual | XXX | XXX | 0 | 7,117,000 |
| 2502. | | XXX | XXX | | |
| 2503. | | XXX | XXX | | |
| 2598. | Summary of remaining write-ins for Line 25 from overflow page | XXX | XXX | 0 | 0 |
| 2599. | Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above) | XXX | XXX | 0 | 7,117,000 |
| 3001. | | XXX | XXX | | |
| 3002. | | XXX | XXX | | |
| 3003. | | XXX | XXX | | |
| 3098. | Summary of remaining write-ins for Line 30 from overflow page | XXX | XXX | 0 | 0 |
| 3099. | Totals (Lines 3001 thru 3003 plus 3098)(Line 30 above) | XXX | XXX | 0 | 0 |

# STATEMENT OF REVENUE AND EXPENSES

| | | Current Year 1 Uncovered | Current Year 2 Total | Prior Year 3 Total |
|---|---|---|---|---|
| 1. | Member Months | XXX | 557,267 | 633,085 |
| 2. | Net premium income ( including $ non-health premium income) | XXX | 294,941,753 | 347,251,282 |
| 3. | Change in unearned premium reserves and reserve for rate credits | XXX | (1,336,167) | 2,260,180 |
| 4. | Fee-for-service (net of $ medical expenses) | XXX | 0 | 0 |
| 5. | Risk revenue | XXX | 0 | 0 |
| 6. | Aggregate write-ins for other health care related revenues | XXX | 0 | 0 |
| 7. | Aggregate write-ins for other non-health revenues | XXX | 0 | 0 |
| 8. | Total revenues (Lines 2 to 7) | XXX | 293,605,586 | 349,511,462 |
| | **Hospital and Medical:** | | | |
| 9. | Hospital/medical benefits | 24,815,393 | 184,090,455 | 235,097,330 |
| 10. | Other professional services | 611,393 | 4,535,558 | 12,484,924 |
| 11. | Outside referrals | 0 | 0 | 0 |
| 12. | Emergency room and out-of-area | 2,227,864 | 16,527,179 | 16,733,805 |
| 13. | Prescription drugs | | 28,583,692 | 37,696,422 |
| 14. | Aggregate write-ins for other hospital and medical | 0 | 0 | 0 |
| 15. | Incentive pool, withhold adjustments and bonus amounts | | 1,257,071 | 1,640,709 |
| 16. | Subtotal (Lines 9 to 15) | 27,654,650 | 234,993,955 | 303,653,190 |
| | **Less:** | | | |
| 17. | Net reinsurance recoveries | | 95,234 | 70,459 |
| 18. | Total hospital and medical (Lines 16 minus 17) | 27,654,650 | 234,898,721 | 303,582,731 |
| 19. | Non-health claims (net) | | | |
| 20. | Claims adjustment expenses, including $ 16,457,474 cost containment expenses | | 17,807,549 | 20,497,384 |
| 21. | General administrative expenses | | 25,159,649 | 24,127,033 |
| 22. | Increase in reserves for life and accident and health contracts (including $ increase in reserves for life only) | | 0 | 0 |
| 23. | Total underwriting deductions (Lines 18 through 22) | 27,654,650 | 277,865,919 | 348,207,148 |
| 24. | Net underwriting gain or (loss) (Lines 8 minus 23) | XXX | 15,739,667 | 1,304,314 |
| 25. | Net investment income earned (Exhibit of Net Investment Income, Line 17) | | 2,420,869 | 1,083,335 |
| 26. | Net realized capital gains (losses) less capital gains tax of $ (178) | | (123,121) | (4,876) |
| 27. | Net investment gains (losses) (Lines 25 plus 26) | 0 | 2,297,748 | 1,078,459 |
| 28. | Net gain or (loss) from agents' or premium balances charged off [(amount recovered $ ) (amount charged off $ )] | | | |
| 29. | Aggregate write-ins for other income or expenses | 0 | (317,100) | (316,800) |
| 30. | Net income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus 27 plus 28 plus 29) | XXX | 17,720,315 | 2,065,973 |
| 31. | Federal and foreign income taxes incurred | XXX | 4,803,972 | (1,098,312) |
| 32. | Net income (loss) (Lines 30 minus 31) | XXX | 12,916,343 | 3,164,285 |
| | **DETAILS OF WRITE-INS** | | | |
| 0601. | | XXX | | |
| 0602. | | XXX | | |
| 0603 | | XXX | | |
| 0698. | Summary of remaining write-ins for Line 6 from overflow page | XXX | 0 | 0 |
| 0699. | Totals (Lines 0601 thru 0603 plus 0698)(Line 6 above) | XXX | 0 | 0 |
| 0701. | | XXX | | |
| 0702. | | XXX | | |
| 0703 | | XXX | | |
| 0798. | Summary of remaining write-ins for Line 7 from overflow page | XXX | 0 | 0 |
| 0799. | Totals (Lines 0701 thru 0703 plus 0798)(Line 7 above) | XXX | 0 | 0 |
| 1401. | | | | |
| 1402. | | | | |
| 1403. | | | | |
| 1498. | Summary of remaining write-ins for Line 14 from overflow page | 0 | 0 | 0 |
| 1499. | Totals (Lines 1401 thru 1403 plus 1498)(Line 14 above) | 0 | 0 | 0 |
| 2901. | Intangible Assets and Amortization | 0 | (317,100) | (316,800) |
| 2902. | | | | |
| 2903 | | | | |
| 2998. | Summary of remaining write-ins for Line 29 from overflow page | 0 | 0 | 0 |
| 2999. | Totals (Lines 2901 thru 2903 plus 2998)(Line 29 above) | 0 | (317,100) | (316,800) |

# STATEMENT OF REVENUE AND EXPENSES (Continued)

| | | 1<br>Current Year | 2<br>Prior Year |
|---|---|---|---|
| | **CAPITAL AND SURPLUS ACCOUNT** | | |
| 33. | Capital and surplus prior reporting year | 41,505,916 | 34,160,858 |
| 34. | Net income or (loss) from Line 32 | 12,916,343 | 3,164,285 |
| 35. | Change in valuation basis of aggregate policy and claim reserves | | |
| 36. | Change in net unrealized capital gains (losses) less capital gains tax of $ 0 | | |
| 37. | Change in net unrealized foreign exchange capital gain or (loss) | | |
| 38. | Change in net deferred income tax | 2,249,460 | (3,347,888) |
| 39. | Change in nonadmitted assets | 2,024,773 | (2,471,339) |
| 40 | Change in unauthorized and certified reinsurance | 0 | 0 |
| 41. | Change in treasury stock | 0 | 0 |
| 42. | Change in surplus notes | 0 | 0 |
| 43. | Cumulative effect of changes in accounting principles | | |
| 44. | Capital Changes: | | |
| | 44.1 Paid in | 0 | 0 |
| | 44.2 Transferred from surplus (Stock Dividend) | 0 | |
| | 44.3 Transferred to surplus | | |
| 45. | Surplus adjustments: | | |
| | 45.1 Paid in | 0 | 10,000,000 |
| | 45.2 Transferred to capital (Stock Dividend) | | |
| | 45.3 Transferred from capital | | |
| 46. | Dividends to stockholders | (4,100,000) | |
| 47. | Aggregate write-ins for gains or (losses) in surplus | 0 | 0 |
| 48. | Net change in capital and surplus (Lines 34 to 47) | 13,090,576 | 7,345,058 |
| 49. | Capital and surplus end of reporting period (Line 33 plus 48) | 54,596,492 | 41,505,916 |
| | **DETAILS OF WRITE-INS** | | |
| 4701. | | | |
| 4702. | | | |
| 4703. | | | |
| 4798. | Summary of remaining write-ins for Line 47 from overflow page | 0 | 0 |
| 4799. | Totals (Lines 4701 thru 4703 plus 4798)(Line 47 above) | 0 | 0 |

# CASH FLOW

| | | 1<br>Current Year | 2<br>Prior Year |
|---|---|---|---|
| | **Cash from Operations** | | |
| 1. | Premiums collected net of reinsurance | 282,814,163 | 341,453,742 |
| 2. | Net investment income | 2,318,432 | 1,084,210 |
| 3. | Miscellaneous income | 0 | 0 |
| 4. | Total (Lines 1 through 3) | 285,132,595 | 342,537,951 |
| 5. | Benefit and loss related payments | 241,990,729 | 306,529,103 |
| 6. | Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts | | |
| 7. | Commissions, expenses paid and aggregate write-ins for deductions | 41,436,345 | 43,879,162 |
| 8. | Dividends paid to policyholders | | |
| 9. | Federal and foreign income taxes paid (recovered) net of $ tax on capital gains (losses) | 5,124,282 | (4,782,014) |
| 10. | Total (Lines 5 through 9) | 288,551,356 | 345,626,251 |
| 11. | Net cash from operations (Line 4 minus Line 10) | (3,418,761) | (3,088,300) |
| | **Cash from Investments** | | |
| 12. | Proceeds from investments sold, matured or repaid: | | |
| | 12.1 Bonds | 1,285,782 | 0 |
| | 12.2 Stocks | 0 | 0 |
| | 12.3 Mortgage loans | 0 | 0 |
| | 12.4 Real estate | 0 | 0 |
| | 12.5 Other invested assets | 0 | 0 |
| | 12.6 Net gains or (losses) on cash, cash equivalents and short-term investments | (854) | 7 |
| | 12.7 Miscellaneous proceeds | 0 | 0 |
| | 12.8 Total investment proceeds (Lines 12.1 to 12.7) | 1,284,928 | 7 |
| 13. | Cost of investments acquired (long-term only): | | |
| | 13.1 Bonds | 16,083,259 | 0 |
| | 13.2 Stocks | 0 | 0 |
| | 13.3 Mortgage loans | 0 | 0 |
| | 13.4 Real estate | 0 | 0 |
| | 13.5 Other invested assets | 0 | 0 |
| | 13.6 Miscellaneous applications | 0 | 0 |
| | 13.7 Total investments acquired (Lines 13.1 to 13.6) | 16,083,259 | 0 |
| 14. | Net increase (decrease) in contract loans and premium notes | 0 | 0 |
| 15. | Net cash from investments (Line 12.8 minus Line 13.7 minus Line 14) | (14,798,331) | 7 |
| | **Cash from Financing and Miscellaneous Sources** | | |
| 16. | Cash provided (applied): | | |
| | 16.1 Surplus notes, capital notes | 0 | 0 |
| | 16.2 Capital and paid in surplus, less treasury stock | 0 | 10,000,000 |
| | 16.3 Borrowed funds | 0 | 0 |
| | 16.4 Net deposits on deposit-type contracts and other insurance liabilities | 0 | 0 |
| | 16.5 Dividends to stockholders | 4,100,000 | 0 |
| | 16.6 Other cash provided (applied) | 1,132,348 | (5,550,676) |
| 17. | Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6) | (2,967,652) | 4,449,324 |
| | **RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS** | | |
| 18. | Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17) | (21,184,744) | 1,361,031 |
| 19. | Cash, cash equivalents and short-term investments: | | |
| | 19.1 Beginning of year | 104,400,250 | 103,039,218 |
| | 19.2 End of year (Line 18 plus Line 19.1) | 83,215,506 | 104,400,250 |

Note: Supplemental disclosures of cash flow information for non-cash transactions:

| | | |
|---|---|---|
| | | |

# ANALYSIS OF OPERATIONS BY LINES OF BUSINESS

| | 1<br>Total | 2<br>Comprehensive (Hospital & Medical) | 3<br>Medicare Supplement | 4<br>Dental Only | 5<br>Vision Only | 6<br>Federal Employees Health Benefits Plan | 7<br>Title XVIII Medicare | 8<br>Title XIX Medicaid | 9<br>Other Health | 10<br>Other Non-Health |
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Net premium income | 294,941,753 | | | | | | 155,940,103 | 139,001,650 | | |
| 2. Change in unearned premium reserves and reserve for rate credit | (1,336,167) | | | | | | (1,336,167) | | | |
| 3. Fee-for-service (net of $ ..... medical expenses) | 0 | | | | | | | | | XXX |
| 4. Risk revenue | 0 | | | | | | | | | XXX |
| 5. Aggregate write-ins for other health care related revenues | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | XXX |
| 6. Aggregate write-ins for other non-health care related revenues | 0 | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | 0 |
| 7. Total revenues (Lines 1 to 6) | 293,605,586 | 0 | 0 | 0 | 0 | 0 | 154,603,936 | 139,001,650 | 0 | 0 |
| 8. Hospital/medical benefits | 184,090,455 | | | | | | 110,526,070 | 73,564,385 | | XXX |
| 9. Other professional services | 4,535,558 | | | | | | 2,217,702 | 2,317,856 | | XXX |
| 10. Outside referrals | 0 | | | | | | | | | XXX |
| 11. Emergency room and out-of-area | 16,527,179 | | | | | | 5,347,012 | 11,180,167 | | XXX |
| 12. Prescription drugs | 28,583,692 | | | | | | 7,736,484 | 20,847,208 | | XXX |
| 13. Aggregate write-ins for other hospital and medical | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | XXX |
| 14. Incentive pool, withhold adjustments and bonus amounts | 1,257,071 | | | | | | | 1,257,071 | | XXX |
| 15. Subtotal (Lines 8 to 14) | 234,993,955 | 0 | 0 | 0 | 0 | 0 | 125,827,268 | 109,166,687 | 0 | XXX |
| 16. Net reinsurance recoveries | 95,234 | | | | | | 58,774 | 36,460 | | XXX |
| 17. Total medical and hospital (Lines 15 minus 16) | 234,898,721 | 0 | 0 | 0 | 0 | 0 | 125,768,494 | 109,130,227 | 0 | XXX |
| 18. Non-health claims (net) | 0 | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | |
| 19. Claims adjustment expenses including $ 16,457,474 cost containment expenses | 17,807,549 | | | | | | 9,415,117 | 8,392,432 | | |
| 20. General administrative expenses | 25,159,649 | 0 | 0 | 0 | | 0 | 12,246,854 | 12,912,795 | | |
| 21. Increase in reserves for accident and health contracts | 0 | | | | | | | | | XXX |
| 22. Increase in reserves for life contracts | 0 | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | |
| 23. Total underwriting deductions (Lines 17 to 22) | 277,865,919 | 0 | 0 | 0 | 0 | 0 | 147,430,465 | 130,435,454 | 0 | 0 |
| 24. Total underwriting gain or (loss) (Line 7 minus Line 23) | 15,739,667 | 0 | 0 | 0 | 0 | 0 | 7,173,471 | 8,566,196 | 0 | 0 |
| DETAILS OF WRITE-INS | | | | | | | | | | |
| 0501. | | | | | | | | | | XXX |
| 0502. | | | | | | | | | | XXX |
| 0503. | | | | | | | | | | XXX |
| 0598. Summary of remaining write-ins for Line 5 from overflow page | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | XXX |
| 0599. Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | XXX |
| 0601. | | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | |
| 0602. | | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | |
| 0603. | | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | |
| 0698. Summary of remaining write-ins for Line 6 from overflow page | 0 | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | 0 |
| 0699. Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above) | 0 | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | 0 |
| 1301. | | | | | | | | | | XXX |
| 1302. | | | | | | | | | | XXX |
| 1303. | | | | | | | | | | XXX |
| 1398. Summary of remaining write-ins for Line 13 from overflow page | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | XXX |
| 1399. Totals (Lines 1301 thru 1303 plus 1398) (Line 13 above) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | XXX |

# UNDERWRITING AND INVESTMENT EXHIBIT

## PART 1 - PREMIUMS

| | Line of Business | 1<br>Direct Business | 2<br>Reinsurance Assumed | 3<br>Reinsurance Ceded | 4<br>Net Premium Income (Cols. 1 + 2 - 3) |
|---|---|---|---|---|---|
| 1. | Comprehensive (hospital and medical) | | | | 0 |
| 2. | Medicare Supplement | | | | 0 |
| 3. | Dental only | | | | 0 |
| 4. | Vision only | | | | 0 |
| 5. | Federal Employees Health Benefits Plan | 0 | | | 0 |
| 6. | Title XVIII - Medicare | 156,031,893 | | 91,789 | 155,940,104 |
| 7. | Title XIX - Medicaid | 139,452,620 | | 450,971 | 139,001,649 |
| 8. | Other health | | | | 0 |
| 9. | Health subtotal (Lines 1 through 8) | 295,484,513 | 0 | 542,760 | 294,941,753 |
| 10. | Life | 0 | | | 0 |
| 11. | Property/casualty | 0 | | | 0 |
| 12. | Totals (Lines 9 to 11) | 295,484,513 | 0 | 542,760 | 294,941,753 |

# UNDERWRITING AND INVESTMENT EXHIBIT

## PART 2 - CLAIMS INCURRED DURING THE YEAR

| | 1<br>Total | 2<br>Comprehensive (Hospital & Medical) | 3<br>Medicare Supplement | 4<br>Dental Only | 5<br>Vision Only | 6<br>Federal Employees Health Benefits Plan | 7<br>Title XVIII Medicare | 8<br>Title XIX Medicaid | 9<br>Other Health | 10<br>Other Non-Health |
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Payments during the year: | | | | | | | | | | |
| 1.1 Direct | 241,296,008 | | | | | | 129,809,352 | 111,486,656 | | |
| 1.2 Reinsurance assumed | 0 | | | | | | | | | |
| 1.3 Reinsurance ceded | 95,233 | | | | | | 58,774 | 36,459 | | |
| 1.4 Net | 241,200,775 | 0 | 0 | 0 | 0 | 0 | 129,750,578 | 111,450,197 | 0 | 0 |
| 2. Paid medical incentive pools and bonuses | 789,955 | | | | | | | 789,955 | | |
| 3. Claim liability December 31, current year from Part 2A: | | | | | | | | | | |
| 3.1 Direct | 52,287,283 | 0 | 0 | 0 | 0 | 0 | 24,891,850 | 27,395,433 | 0 | 0 |
| 3.2 Reinsurance assumed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 3.3 Reinsurance ceded | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 3.4 Net | 52,287,283 | 0 | 0 | 0 | 0 | 0 | 24,891,850 | 27,395,433 | 0 | 0 |
| 4. Claim reserve December 31, current year from Part 2D: | | | | | | | | | | |
| 4.1 Direct | 0 | | | | | | | | | |
| 4.2 Reinsurance assumed | 0 | | | | | | | | | |
| 4.3 Reinsurance ceded | 0 | | | | | | | | | |
| 4.4 Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 5. Accrued medical incentive pools and bonuses, current year | 2,126,256 | | | | | | | 2,126,256 | | |
| 6. Net healthcare receivables (a) | (666,225) | | | | | | 880,184 | (1,546,409) | | |
| 7. Amounts recoverable from reinsurers December 31, current year | 0 | | | | | | | | | |
| 8. Claim liability December 31, prior year from Part 2A: | | | | | | | | | | |
| 8.1 Direct | 60,512,631 | 0 | 0 | 0 | 0 | 0 | 27,993,749 | 32,518,882 | 0 | 0 |
| 8.2 Reinsurance assumed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 8.3 Reinsurance ceded | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 8.4 Net | 60,512,631 | 0 | 0 | 0 | 0 | 0 | 27,993,749 | 32,518,882 | 0 | 0 |
| 9. Claim reserve December 31, prior year from Part 2D: | | | | | | | | | | |
| 9.1 Direct | 0 | | | | | | | | | |
| 9.2 Reinsurance assumed | 0 | | | | | | | | | |
| 9.3 Reinsurance ceded | 0 | | | | | | | | | |
| 9.4 Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 10. Accrued medical incentive pools and bonuses, prior year | 1,659,140 | | | | | | | 1,659,140 | | |
| 11. Amounts recoverable from reinsurers December 31, prior year | 0 | | | | | | | | | |
| 12. Incurred Benefits: | | | | | | | | | | |
| 12.1 Direct | 233,736,885 | 0 | 0 | 0 | 0 | 0 | 125,827,269 | 107,909,616 | 0 | 0 |
| 12.2 Reinsurance assumed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 12.3 Reinsurance ceded | 95,233 | 0 | 0 | 0 | 0 | 0 | 58,774 | 36,459 | 0 | 0 |
| 12.4 Net | 233,641,652 | 0 | 0 | 0 | 0 | 0 | 125,768,495 | 107,873,157 | 0 | 0 |
| 13. Incurred medical incentive pools and bonuses | 1,257,071 | 0 | 0 | 0 | 0 | 0 | 0 | 1,257,071 | 0 | 0 |

(a) Excludes $ ..... loans or advances to providers not yet expensed.

# UNDERWRITING AND INVESTMENT EXHIBIT

## PART 2A - CLAIMS LIABILITY END OF CURRENT YEAR

| | 1<br>Total | 2<br>Comprehensive (Hospital & Medical) | 3<br>Medicare Supplement | 4<br>Dental Only | 5<br>Vision Only | 6<br>Federal Employees Health Benefits Plan | 7<br>Title XVIII Medicare | 8<br>Title XIX Medicaid | 9<br>Other Health | 10<br>Other Non-Health |
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Reported in Process of Adjustment: | | | | | | | | | | |
| 1.1 Direct | 11,820 | 0 | 0 | 0 | 0 | 0 | 11,820 | 0 | 0 | 0 |
| 1.2 Reinsurance assumed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1.3 Reinsurance ceded | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1.4 Net | 11,820 | 0 | 0 | 0 | 0 | 0 | 11,820 | 0 | 0 | 0 |
| 2. Incurred but Unreported: | | | | | | | | | | |
| 2.1 Direct | 52,275,463 | 0 | 0 | 0 | 0 | 0 | 24,880,030 | 27,395,433 | 0 | 0 |
| 2.2 Reinsurance assumed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2.3 Reinsurance ceded | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2.4 Net | 52,275,463 | 0 | 0 | 0 | 0 | 0 | 24,880,030 | 27,395,433 | 0 | 0 |
| 3. Amounts Withheld from Paid Claims and Capitations: | | | | | | | | | | |
| 3.1 Direct | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 3.2 Reinsurance assumed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 3.3 Reinsurance ceded | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 3.4 Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 4. TOTALS: | | | | | | | | | | |
| 4.1 Direct | 52,287,283 | 0 | 0 | 0 | 0 | 0 | 24,891,850 | 27,395,433 | 0 | 0 |
| 4.2 Reinsurance assumed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 4.3 Reinsurance ceded | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 4.4 Net | 52,287,283 | 0 | 0 | 0 | 0 | 0 | 24,891,850 | 27,395,433 | 0 | 0 |

# UNDERWRITING AND INVESTMENT EXHIBIT

## PART 2B - ANALYSIS OF CLAIMS UNPAID - PRIOR YEAR - NET OF REINSURANCE

| Line of Business | Claims Paid During the Year | | Claim Reserve and Claim Liability December 31 of Current Year | | 5 | 6 |
|---|---|---|---|---|---|---|
| | 1<br>On Claims Incurred Prior to January 1 of Current Year | 2<br>On Claims Incurred During the Year | 3<br>On Claims Unpaid December 31 of Prior Year | 4<br>On Claims Incurred During the Year | Claims Incurred In Prior Years (Columns 1 + 3) | Estimated Claim Reserve and Claim Liability December 31 of Prior Year |
| 1. Comprehensive (hospital and medical) | | | | | 0 | 0 |
| 2. Medicare Supplement | | | | | 0 | 0 |
| 3. Dental Only | | | | | 0 | 0 |
| 4. Vision Only | | | | | 0 | 0 |
| 5. Federal Employees Health Benefits Plan | | | | | 0 | 0 |
| 6. Title XVIII - Medicare | 17,343,181 | 112,407,397 | 1,436,841 | 23,455,009 | 18,780,022 | 27,993,749 |
| 7 Title XIX - Medicaid | 15,362,900 | 96,087,297 | 5,517,146 | 21,878,287 | 20,880,046 | 32,518,882 |
| 8. Other health | | | | | 0 | 0 |
| 9. Health subtotal (Lines 1 to 8) | 32,706,081 | 208,494,694 | 6,953,987 | 45,333,296 | 39,660,068 | 60,512,631 |
| 10. Healthcare receivables (a) | | 9,672,423 | | | 0 | 10,338,648 |
| 11. Other non-health | | | | | 0 | 0 |
| 12. Medical incentive pools and bonus amounts | | 789,955 | | 2,126,256 | 0 | 1,659,140 |
| 13. Totals (Lines 9 - 10 + 11 + 12) | 32,706,081 | 199,612,226 | 6,953,987 | 47,459,552 | 39,660,068 | 51,833,123 |

(a) Excludes $ ..... loans or advances to providers not yet expensed.

# UNDERWRITING AND INVESTMENT EXHIBIT

## PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

($000 Omitted)

### Section A - Paid Health Claims - Comprehensive (Hospital & Medical)

| Year in Which Losses Were Incurred | Cumulative Net Amounts Paid | | | | |
|---|---|---|---|---|---|
| | 1<br>2014 | 2<br>2015 | 3<br>2016 | 4<br>2017 | 5<br>2018 |
| 1. Prior | 57 | 57 | 57 | 57 | 57 |
| 2. 2014 | 942 | 1,099 | 1,099 | 1,099 | 1,099 |
| 3. 2015 | XXX | 1,235 | 1,235 | 1,235 | 1,235 |
| 4. 2016 | XXX | XXX | (3) | (3) | (3) |
| 5. 2017 | XXX | XXX | XXX | | 0 |
| 6. 2018 | XXX | XXX | XXX | XXX | |

### Section B - Incurred Health Claims - Comprehensive (Hospital & Medical)

| Year in Which Losses Were Incurred | Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year | | | | |
|---|---|---|---|---|---|
| | 1<br>2014 | 2<br>2015 | 3<br>2016 | 4<br>2017 | 5<br>2018 |
| 1. Prior | 32 | 32 | 32 | 32 | 32 |
| 2. 2014 | 1,130 | 1,286 | 1,286 | 1,286 | 1,286 |
| 3. 2015 | XXX | 1,374 | 1,374 | 1,374 | 1,374 |
| 4. 2016 | XXX | XXX | (3) | (3) | (3) |
| 5. 2017 | XXX | XXX | XXX | 0 | 0 |
| 6. 2018 | XXX | XXX | XXX | XXX | 0 |

### Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Comprehensive (Hospital & Medical)

| Years in which Premiums were Earned and Claims were Incurred | 1<br>Premiums Earned | 2<br>Claims Payment | 3<br>Claim Adjustment Expense Payments | 4<br>(Col. 3/2) Percent | 5<br>Claim and Claim Adjustment Expense Payments (Col. 2 + 3) | 6<br>(Col. 5/1) Percent | 7<br>Claims Unpaid | 8<br>Unpaid Claims Adjustment Expenses | 9<br>Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8) | 10<br>(Col. 9/1) Percent |
|---|---|---|---|---|---|---|---|---|---|---|
| 1. 2014 | 2,552 | 1,099 | | 0.0 | 1,099 | 43.1 | | | 1,099 | 43.1 |
| 2. 2015 | 3,219 | 1,235 | | 0.0 | 1,235 | 38.4 | | | 1,235 | 38.4 |
| 3. 2016 | | (3) | | 0.0 | (3) | 0.0 | | | (3) | 0.0 |
| 4. 2017 | 0 | 0 | | 0.0 | 0 | 0.0 | | | 0 | 0.0 |
| 5. 2018 | 0 | 0 | | 0.0 | 0 | 0.0 | | | 0 | 0.0 |

# UNDERWRITING AND INVESTMENT EXHIBIT

## PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

($000 Omitted)

### Section A - Paid Health Claims - Medicare Supplement

| Year in Which Losses Were Incurred | Cumulative Net Amounts Paid | | | | |
|---|---|---|---|---|---|
| | 1<br>2014 | 2<br>2015 | 3<br>2016 | 4<br>2017 | 5<br>2018 |
| 1. Prior | 0 | 0 | 0 | 0 | 0 |
| 2. 2014 | | | | | 0 |
| 3. 2015 | XXX | | | | 0 |
| 4. 2016 | XXX | XXX | | | 0 |
| 5. 2017 | XXX | XXX | XXX | | 0 |
| 6. 2018 | XXX | XXX | XXX | XXX | 0 |

### Section B - Incurred Health Claims - Medicare Supplement

| Year in Which Losses Were Incurred | Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year | | | | |
|---|---|---|---|---|---|
| | 1<br>2014 | 2<br>2015 | 3<br>2016 | 4<br>2017 | 5<br>2018 |
| 1. Prior | 0 | 0 | 0 | 0 | 0 |
| 2. 2014 | | | | | 0 |
| 3. 2015 | XXX | | | | 0 |
| 4. 2016 | XXX | XXX | | | 0 |
| 5. 2017 | XXX | XXX | XXX | | 0 |
| 6. 2018 | XXX | XXX | XXX | XXX | 0 |

### Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Medicare Supplement

| Years in which Premiums were Earned and Claims were Incurred | 1<br>Premiums Earned | 2<br>Claims Payment | 3<br>Claim Adjustment Expense Payments | 4<br>(Col. 3/2) Percent | 5<br>Claim and Claim Adjustment Expense Payments (Col. 2 + 3) | 6<br>(Col. 5/1) Percent | 7<br>Claims Unpaid | 8<br>Unpaid Claims Adjustment Expenses | 9<br>Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8) | 10<br>(Col. 9/1) Percent |
|---|---|---|---|---|---|---|---|---|---|---|
| 1. 2014 | | 0 | 0 | 0.0 | 0 | 0.0 | | | 0 | 0.0 |
| 2. 2015 | | | | 0.0 | 0 | 0.0 | | | 0 | 0.0 |
| 3. 2016 | | | | 0.0 | 0 | 0.0 | | | 0 | 0.0 |
| 4. 2017 | | | | 0.0 | 0 | 0.0 | | | 0 | 0.0 |
| 5. 2018 | | | | 0.0 | 0 | 0.0 | | | 0 | 0.0 |

# UNDERWRITING AND INVESTMENT EXHIBIT

## PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

($000 Omitted)

### Section A - Paid Health Claims - Dental Only

| Year in Which Losses Were Incurred | Cumulative Net Amounts Paid | | | | |
|---|---|---|---|---|---|
| | 1<br>2014 | 2<br>2015 | 3<br>2016 | 4<br>2017 | 5<br>2018 |
| 1. Prior | 0 | 0 | 0 | 0 | 0 |
| 2. 2014 | | | | | 0 |
| 3. 2015 | XXX | | | | 0 |
| 4. 2016 | XXX | XXX | | | 0 |
| 5. 2017 | XXX | XXX | XXX | | 0 |
| 6. 2018 | XXX | XXX | XXX | XXX | 0 |

### Section B - Incurred Health Claims - Dental Only

| Year in Which Losses Were Incurred | Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year | | | | |
|---|---|---|---|---|---|
| | 1<br>2014 | 2<br>2015 | 3<br>2016 | 4<br>2017 | 5<br>2018 |
| 1. Prior | 0 | 0 | 0 | 0 | 0 |
| 2. 2014 | | | | | 0 |
| 3. 2015 | XXX | | | | 0 |
| 4. 2016 | XXX | XXX | | | 0 |
| 5. 2017 | XXX | XXX | XXX | | 0 |
| 6. 2018 | XXX | XXX | XXX | XXX | 0 |

### Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Dental Only

| Years in which Premiums were Earned and Claims were Incurred | 1<br>Premiums Earned | 2<br>Claims Payment | 3<br>Claim Adjustment Expense Payments | 4<br>(Col. 3/2) Percent | 5<br>Claim and Claim Adjustment Expense Payments (Col. 2 + 3) | 6<br>(Col. 5/1) Percent | 7<br>Claims Unpaid | 8<br>Unpaid Claims Adjustment Expenses | 9<br>Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8) | 10<br>(Col. 9/1) Percent |
|---|---|---|---|---|---|---|---|---|---|---|
| 1. 2014 | | | | 0.0 | 0 | 0.0 | | | 0 | 0.0 |
| 2. 2015 | | | | 0.0 | 0 | 0.0 | | | 0 | 0.0 |
| 3. 2016 | | | | 0.0 | 0 | 0.0 | | | 0 | 0.0 |
| 4. 2017 | | | | 0.0 | 0 | 0.0 | | | 0 | 0.0 |
| 5. 2018 | | | | 0.0 | 0 | 0.0 | | | 0 | 0.0 |

# UNDERWRITING AND INVESTMENT EXHIBIT

## PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

($000 Omitted)

### Section A - Paid Health Claims - Vision Only

| Year in Which Losses Were Incurred | Cumulative Net Amounts Paid | | | | |
|---|---|---|---|---|---|
| | 1<br>2014 | 2<br>2015 | 3<br>2016 | 4<br>2017 | 5<br>2018 |
| 1. Prior | 0 | 0 | 0 | 0 | 0 |
| 2. 2014 | | | | | 0 |
| 3. 2015 | XXX | | | | 0 |
| 4. 2016 | XXX | XXX | | | 0 |
| 5. 2017 | XXX | XXX | XXX | | 0 |
| 6. 2018 | XXX | XXX | XXX | XXX | 0 |

### Section B - Incurred Health Claims - Vision Only

| Year in Which Losses Were Incurred | Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year | | | | |
|---|---|---|---|---|---|
| | 1<br>2014 | 2<br>2015 | 3<br>2016 | 4<br>2017 | 5<br>2018 |
| 1. Prior | 0 | 0 | 0 | 0 | |
| 2. 2014 | | | | | |
| 3. 2015 | XXX | | | | |
| 4. 2016 | XXX | XXX | | | |
| 5. 2017 | XXX | XXX | XXX | | |
| 6. 2018 | XXX | XXX | XXX | XXX | |

### Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Vision Only

| Years in which Premiums were Earned and Claims were Incurred | 1<br>Premiums Earned | 2<br>Claims Payment | 3<br>Claim Adjustment Expense Payments | 4<br>(Col. 3/2) Percent | 5<br>Claim and Claim Adjustment Expense Payments (Col. 2 + 3) | 6<br>(Col. 5/1) Percent | 7<br>Claims Unpaid | 8<br>Unpaid Claims Adjustment Expenses | 9<br>Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8) | 10<br>(Col. 9/1) Percent |
|---|---|---|---|---|---|---|---|---|---|---|
| 1. 2014 | | | | 0.0 | 0 | 0.0 | | | 0 | 0.0 |
| 2. 2015 | | | | 0.0 | 0 | 0.0 | | | 0 | 0.0 |
| 3. 2016 | | | | 0.0 | 0 | 0.0 | | | 0 | 0.0 |
| 4. 2017 | | | | 0.0 | 0 | 0.0 | | | 0 | 0.0 |
| 5. 2018 | | | | 0.0 | 0 | 0.0 | | | 0 | 0.0 |

# UNDERWRITING AND INVESTMENT EXHIBIT

## PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

($000 Omitted)

### Section A - Paid Health Claims - Federal Employees Health Benefits Plan Premium

| Year in Which Losses Were Incurred | Cumulative Net Amounts Paid | | | | |
|---|---|---|---|---|---|
| | 1<br>2014 | 2<br>2015 | 3<br>2016 | 4<br>2017 | 5<br>2018 |
| 1. Prior | 0 | 0 | 0 | 0 | |
| 2. 2014 | | | | | |
| 3. 2015 | XXX | | | | |
| 4. 2016 | XXX | XXX | | | |
| 5. 2017 | XXX | XXX | XXX | | |
| 6. 2018 | XXX | XXX | XXX | XXX | |

### Section B - Incurred Health Claims - Federal Employees Health Benefits Plan Premium

| Year in Which Losses Were Incurred | Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year | | | | |
|---|---|---|---|---|---|
| | 1<br>2014 | 2<br>2015 | 3<br>2016 | 4<br>2017 | 5<br>2018 |
| 1. Prior | 0 | 0 | 0 | 0 | 0 |
| 2. 2014 | | | | | 0 |
| 3. 2015 | XXX | | | | 0 |
| 4. 2016 | XXX | XXX | | | 0 |
| 5. 2017 | XXX | XXX | XXX | | 0 |
| 6. 2018 | XXX | XXX | XXX | XXX | 0 |

### Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Federal Employees Health Benefits Plan Premium

| Years in which Premiums were Earned and Claims were Incurred | 1<br>Premiums Earned | 2<br>Claims Payment | 3<br>Claim Adjustment Expense Payments | 4<br>(Col. 3/2) Percent | 5<br>Claim and Claim Adjustment Expense Payments (Col. 2 + 3) | 6<br>(Col. 5/1) Percent | 7<br>Claims Unpaid | 8<br>Unpaid Claims Adjustment Expenses | 9<br>Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8) | 10<br>(Col. 9/1) Percent |
|---|---|---|---|---|---|---|---|---|---|---|
| 1. 2014 | | | | 0.0 | 0 | 0.0 | | | 0 | 0.0 |
| 2. 2015 | | | | 0.0 | 0 | 0.0 | | | 0 | 0.0 |
| 3. 2016 | | | | 0.0 | 0 | 0.0 | | | 0 | 0.0 |
| 4. 2017 | | | | 0.0 | 0 | 0.0 | | | 0 | 0.0 |
| 5. 2018 | | | | 0.0 | 0 | 0.0 | | | 0 | 0.0 |

# UNDERWRITING AND INVESTMENT EXHIBIT

## PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

($000 Omitted)

### Section A - Paid Health Claims - Title XVIII

| Year in Which Losses Were Incurred | Cumulative Net Amounts Paid | | | | |
|---|---|---|---|---|---|
| | 1<br>2014 | 2<br>2015 | 3<br>2016 | 4<br>2017 | 5<br>2018 |
| 1. Prior | 0 | 0 | 0 | 0 | 0 |
| 2. 2014 | | | 0 | 0 | 0 |
| 3. 2015 | XXX | 25,570 | 37,880 | 37,880 | 37,880 |
| 4. 2016 | XXX | XXX | 58,222 | 76,451 | 76,451 |
| 5. 2017 | XXX | XXX | XXX | 97,389 | 114,732 |
| 6. 2018 | XXX | XXX | XXX | XXX | 108,900 |

### Section B - Incurred Health Claims - Title XVIII

| Year in Which Losses Were Incurred | Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year | | | | |
|---|---|---|---|---|---|
| | 1<br>2014 | 2<br>2015 | 3<br>2016 | 4<br>2017 | 5<br>2018 |
| 1. Prior | 0 | 0 | 0 | 0 | 0 |
| 2. 2014 | | | 0 | 0 | 0 |
| 3. 2015 | XXX | 44,186 | 56,703 | 56,703 | 56,703 |
| 4. 2016 | XXX | XXX | 75,583 | 96,236 | 96,236 |
| 5. 2017 | XXX | XXX | XXX | 122,959 | 141,739 |
| 6. 2018 | XXX | XXX | XXX | XXX | 132,355 |

### Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XVIII

| Years in which Premiums were Earned and Claims were Incurred | 1<br>Premiums Earned | 2<br>Claims Payment | 3<br>Claim Adjustment Expense Payments | 4<br>(Col. 3/2) Percent | 5<br>Claim and Claim Adjustment Expense Payments (Col. 2 + 3) | 6<br>(Col. 5/1) Percent | 7<br>Claims Unpaid | 8<br>Unpaid Claims Adjustment Expenses | 9<br>Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8) | 10<br>(Col. 9/1) Percent |
|---|---|---|---|---|---|---|---|---|---|---|
| 1. 2014 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 | 0.0 |
| 2. 2015 | 48,936 | 37,880 | 0 | 0.0 | 37,880 | 77.4 | 0 | 0 | 37,880 | 77.4 |
| 3. 2016 | 88,468 | 76,451 | 0 | 0.0 | 76,451 | 86.4 | 0 | 0 | 76,451 | 86.4 |
| 4. 2017 | 151,620 | 114,732 | 0 | 0.0 | 114,732 | 75.7 | 1,437 | 0 | 116,169 | 76.6 |
| 5. 2018 | 154,696 | 108,900 | 9,415 | 8.6 | 118,315 | 76.5 | 23,455 | 938 | 142,708 | 92.3 |

# UNDERWRITING AND INVESTMENT EXHIBIT

## PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

($000 Omitted)

### Section A - Paid Health Claims - Title XIX

| Year in Which Losses Were Incurred | Cumulative Net Amounts Paid | | | | |
|---|---|---|---|---|---|
| | 1<br>2014 | 2<br>2015 | 3<br>2016 | 4<br>2017 | 5<br>2018 |
| 1. Prior | 8,537 | 8,537 | 8,537 | 8,537 | 8,537 |
| 2. 2014 | 136,155 | 153,212 | 153,212 | 153,212 | 153,212 |
| 3. 2015 | XXX | 140,011 | 171,952 | 171,952 | 171,952 |
| 4. 2016 | XXX | XXX | 184,295 | 210,683 | 210,683 |
| 5. 2017 | XXX | XXX | XXX | 162,381 | 177,744 |
| 6. 2018 | XXX | XXX | XXX | XXX | 90,712 |

### Section B - Incurred Health Claims - Title XIX

| Year in Which Losses Were Incurred | Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year | | | | |
|---|---|---|---|---|---|
| | 1<br>2014 | 2<br>2015 | 3<br>2016 | 4<br>2017 | 5<br>2018 |
| 1. Prior | 17,010 | 17,010 | 17,010 | 17,010 | 17,010 |
| 2. 2014 | 154,941 | 171,923 | 171,923 | 171,923 | 171,923 |
| 3. 2015 | XXX | 183,123 | 218,245 | 218,245 | 218,245 |
| 4. 2016 | XXX | XXX | 226,522 | 257,395 | 257,395 |
| 5. 2017 | XXX | XXX | XXX | 192,074 | 212,954 |
| 6. 2018 | XXX | XXX | XXX | XXX | 114,717 |

### Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XIX

| Years in which Premiums were Earned and Claims were Incurred | 1<br>Premiums Earned | 2<br>Claims Payment | 3<br>Claim Adjustment Expense Payments | 4<br>(Col. 3/2) Percent | 5<br>Claim and Claim Adjustment Expense Payments (Col. 2 + 3) | 6<br>(Col. 5/1) Percent | 7<br>Claims Unpaid | 8<br>Unpaid Claims Adjustment Expenses | 9<br>Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8) | 10<br>(Col. 9/1) Percent |
|---|---|---|---|---|---|---|---|---|---|---|
| 1. 2014 | 185,436 | 153,212 | 0 | 0.0 | 153,212 | 82.6 | 0 | 0 | 153,212 | 82.6 |
| 2. 2015 | 230,497 | 171,952 | 0 | 0.0 | 171,952 | 74.6 | 0 | 0 | 171,952 | 74.6 |
| 3. 2016 | 250,288 | 210,683 | 0 | 0.0 | 210,683 | 84.2 | 0 | 0 | 210,683 | 84.2 |
| 4. 2017 | 197,891 | 177,744 | 0 | 0.0 | 177,744 | 89.8 | 5,517 | 0 | 183,261 | 92.6 |
| 5. 2018 | 139,453 | 90,712 | 8,392 | 9.3 | 99,104 | 71.1 | 24,005 | 844 | 123,953 | 88.9 |

# UNDERWRITING AND INVESTMENT EXHIBIT

## PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

($000 Omitted)

### Section A - Paid Health Claims - Other

| Year in Which Losses Were Incurred | Cumulative Net Amounts Paid | | | | |
|---|---|---|---|---|---|
| | 1<br>2014 | 2<br>2015 | 3<br>2016 | 4<br>2017 | 5<br>2018 |
| 1. Prior | 0 | 0 | 0 | 0 | 0 |
| 2. 2014 | | | | | 0 |
| 3. 2015 | XXX | | | | 0 |
| 4. 2016 | XXX | XXX | | | 0 |
| 5. 2017 | XXX | XXX | XXX | | 0 |
| 6. 2018 | XXX | XXX | XXX | XXX | 0 |

### Section B - Incurred Health Claims - Other

| Year in Which Losses Were Incurred | Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year | | | | |
|---|---|---|---|---|---|
| | 1<br>2014 | 2<br>2015 | 3<br>2016 | 4<br>2017 | 5<br>2018 |
| 1. Prior | 0 | 0 | 0 | 0 | 0 |
| 2. 2014 | | | | | 0 |
| 3. 2015 | XXX | | | | 0 |
| 4. 2016 | XXX | XXX | | | 0 |
| 5. 2017 | XXX | XXX | XXX | | 0 |
| 6. 2018 | XXX | XXX | XXX | XXX | 0 |

### Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Other

| Years in which Premiums were Earned and Claims were Incurred | 1<br>Premiums Earned | 2<br>Claims Payment | 3<br>Claim Adjustment Expense Payments | 4<br>(Col. 3/2) Percent | 5<br>Claim and Claim Adjustment Expense Payments (Col. 2 + 3) | 6<br>(Col. 5/1) Percent | 7<br>Claims Unpaid | 8<br>Unpaid Claims Adjustment Expenses | 9<br>Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8) | 10<br>(Col. 9/1) Percent |
|---|---|---|---|---|---|---|---|---|---|---|
| 1. 2014 | | | | 0.0 | 0 | 0.0 | | | 0 | 0.0 |
| 2. 2015 | | | | 0.0 | 0 | 0.0 | | | 0 | 0.0 |
| 3. 2016 | | | | 0.0 | 0 | 0.0 | | | 0 | 0.0 |
| 4. 2017 | | | | 0.0 | 0 | 0.0 | | | 0 | 0.0 |
| 5. 2018 | | | | 0.0 | 0 | 0.0 | | | 0 | 0.0 |

# UNDERWRITING AND INVESTMENT EXHIBIT

## PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

($000 Omitted)

### Section A - Paid Health Claims - Grand Total

| Year in Which Losses Were Incurred | Cumulative Net Amounts Paid | | | | |
|---|---|---|---|---|---|
| | 1<br>2014 | 2<br>2015 | 3<br>2016 | 4<br>2017 | 5<br>2018 |
| 1. Prior | 8,594 | 8,594 | 8,594 | 8,594 | 8,594 |
| 2. 2014 | 137,097 | 154,311 | 154,311 | 154,311 | 154,311 |
| 3. 2015 | XXX | 166,816 | 211,067 | 211,067 | 211,067 |
| 4. 2016 | XXX | XXX | 242,514 | 287,131 | 287,131 |
| 5. 2017 | XXX | XXX | XXX | 259,770 | 292,476 |
| 6. 2018 | XXX | XXX | XXX | XXX | 199,612 |

### Section B - Incurred Health Claims - Grand Total

| Year in Which Losses Were Incurred | Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year | | | | |
|---|---|---|---|---|---|
| | 1<br>2014 | 2<br>2015 | 3<br>2016 | 4<br>2017 | 5<br>2018 |
| 1. Prior | 17,042 | 17,042 | 17,042 | 17,042 | 17,042 |
| 2. 2014 | 156,071 | 173,209 | 173,209 | 173,209 | 173,209 |
| 3. 2015 | XXX | 228,683 | 276,322 | 276,322 | 276,322 |
| 4. 2016 | XXX | XXX | 302,102 | 353,628 | 353,628 |
| 5. 2017 | XXX | XXX | XXX | 315,033 | 354,693 |
| 6. 2018 | XXX | XXX | XXX | XXX | 247,072 |

### Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Grand Total

| Years in which Premiums were Earned and Claims were Incurred | 1<br>Premiums Earned | 2<br>Claims Payment | 3<br>Claim Adjustment Expense Payments | 4<br>(Col. 3/2) Percent | 5<br>Claim and Claim Adjustment Expense Payments (Col. 2 + 3) | 6<br>(Col. 5/1) Percent | 7<br>Claims Unpaid | 8<br>Unpaid Claims Adjustment Expenses | 9<br>Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8) | 10<br>(Col. 9/1) Percent |
|---|---|---|---|---|---|---|---|---|---|---|
| 1. 2014 | 187,988 | 154,311 | 0 | 0.0 | 154,311 | 82.1 | 0 | 0 | 154,311 | 82.1 |
| 2. 2015 | 282,652 | 211,067 | 0 | 0.0 | 211,067 | 74.7 | 0 | 0 | 211,067 | 74.7 |
| 3. 2016 | 338,756 | 287,131 | 0 | 0.0 | 287,131 | 84.8 | 0 | 0 | 287,131 | 84.8 |
| 4. 2017 | 349,511 | 292,476 | 0 | 0.0 | 292,476 | 83.7 | 6,954 | 0 | 299,430 | 85.7 |
| 5. 2018 | 294,149 | 199,612 | 17,807 | 8.9 | 217,419 | 73.9 | 47,460 | 1,782 | 266,661 | 90.7 |

# UNDERWRITING AND INVESTMENT EXHIBIT

## PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY

| | 1<br>Total | 2<br>Comprehensive (Hospital & Medical) | 3<br>Medicare Supplement | 4<br>Dental Only | 5<br>Vision Only | 6<br>Federal Employees Health Benefits Plan | 7<br>Title XVIII Medicare | 8<br>Title XIX Medicaid | 9<br>Other |
|---|---|---|---|---|---|---|---|---|---|
| 1. Unearned premium reserves | 0 | | | | | | | | |
| 2. Additional policy reserves (a) | 0 | | | | | | | | |
| 3. Reserve for future contingent benefits | 0 | | | | | | | | |
| 4. Reserve for rate credits or experience rating refunds (including $ 0 ) for investment income | 406,976 | | | | | | 406,976 | | |
| 5. Aggregate write-ins for other policy reserves | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 6. Totals (gross) | 406,976 | 0 | 0 | 0 | 0 | 0 | 406,976 | 0 | 0 |
| 7. Reinsurance ceded | 0 | | | | | | | | |
| 8. Totals (Net)(Page 3, Line 4) | 406,976 | 0 | 0 | 0 | 0 | 0 | 406,976 | 0 | 0 |
| 9. Present value of amounts not yet due on claims | 0 | | | | | | | | |
| 10. Reserve for future contingent benefits | 0 | | | | | | | | |
| 11. Aggregate write-ins for other claim reserves | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 12. Totals (gross) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 13. Reinsurance ceded | 0 | | | | | | | | |
| 14. Totals (Net)(Page 3, Line 7) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DETAILS OF WRITE-INS | | | | | | | | | |
| 0501. | | | | | | | | | |
| 0502. | | | | | | | | | |
| 0503. | | | | | | | | | |
| 0598. Summary of remaining write-ins for Line 5 from overflow page | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0599. Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1101. | | | | | | | | | |
| 1102. | | | | | | | | | |
| 1103. | | | | | | | | | |
| 1198. Summary of remaining write-ins for Line 11 from overflow page | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1199. Totals (Lines 1101 thru 1103 plus 1198) (Line 11 above) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

(a) Includes $ ..... premium deficiency reserve.

# UNDERWRITING AND INVESTMENT EXHIBIT

## PART 3 - ANALYSIS OF EXPENSES

| | Claim Adjustment Expenses | | 3 | 4 | 5 |
|---|---|---|---|---|---|
| | 1<br>Cost Containment Expenses | 2<br>Other Claim Adjustment Expenses | General Administrative Expenses | Investment Expenses | Total |
| 1. Rent ($ ..... for occupancy of own building) | | 21,200 | 494,215 | 3,620 | 519,035 |
| 2. Salary, wages and other benefits | 11,829,834 | 765,887 | 6,024,324 | 64,724 | 18,684,769 |
| 3. Commissions (less $ ..... ceded plus $ ..... assumed) | | | | | 0 |
| 4. Legal fees and expenses | 132,009 | 8,546 | 67,225 | 72 | 207,852 |
| 5. Certifications and accreditation fees | | | | | 0 |
| 6. Auditing, actuarial and other consulting services | | 99,557 | 2,320,848 | 25,059 | 2,445,464 |
| 7. Traveling expenses | | 21,028 | 490,198 | 1,078 | 512,304 |
| 8. Marketing and advertising | | 23,837 | 555,686 | | 579,523 |
| 9. Postage, express and telephone | | 31,612 | 736,927 | 735 | 769,274 |
| 10. Printing and office supplies | | 12,568 | 292,981 | 136 | 305,685 |
| 11. Occupancy, depreciation and amortization | | | | | 0 |
| 12. Equipment | | 20,505 | 477,998 | 2,091 | 500,594 |
| 13. Cost or depreciation of EDP equipment and software | | 45,294 | 1,055,880 | 1,478 | 1,102,652 |
| 14. Outsourced services including EDP, claims, and other services | 3,398,018 | 219,994 | 1,730,435 | 9,649 | 5,358,096 |
| 15. Boards, bureaus and association fees | 25,746 | 1,667 | 13,111 | 60 | 40,584 |
| 16. Insurance, except on real estate | | 8,828 | 205,785 | 55 | 214,668 |
| 17. Collection and bank service charges | | 157 | 3,668 | 7,065 | 10,890 |
| 18. Group service and administration fees | | | | | 0 |
| 19. Reimbursements by uninsured plans | | | | | 0 |
| 20. Reimbursements from fiscal intermediaries | | | | | 0 |
| 21. Real estate expenses | | | 364,827 | 26 | 364,853 |
| 22. Real estate taxes | | | 53,674 | | 53,674 |
| 23. Taxes, licenses and fees: | | | | | |
| 23.1 State and local insurance taxes | | | 220,442 | | 220,442 |
| 23.2 State premium taxes | | | | | 0 |
| 23.3 Regulatory authority licenses and fees | | | 56,591 | | 56,591 |
| 23.4 Payroll taxes | 1,071,867 | 69,395 | 545,847 | 5,628 | 1,692,737 |
| 23.5 Other (excluding federal income and real estate taxes) | | | 8,688,697 | | 8,688,697 |
| 24. Investment expenses not included elsewhere | | | | | 0 |
| 25. Aggregate write-ins for expenses | 0 | 0 | 760,290 | 0 | 760,290 |
| 26. Total expenses incurred (Lines 1 to 25) | 16,457,474 | 1,350,075 | 25,159,649 | 121,476 | (a) 43,088,674 |
| 27. Less expenses unpaid December 31, current year | 1,646,791 | 135,093 | 728,465 | | 2,510,349 |
| 28. Add expenses unpaid December 31, prior year | 808,696 | 91,422 | 1,050,590 | | 1,950,708 |
| 29. Amounts receivable relating to uninsured plans, prior year | | | 3,337,772 | | 3,337,772 |
| 30. Amounts receivable relating to uninsured plans, current year | | | 9,980,642 | | 9,980,642 |
| 31. Total expenses paid (Lines 26 minus 27 plus 28 minus 29 plus 30) | 15,619,379 | 1,306,404 | 32,124,644 | 121,476 | 49,171,903 |
| **DETAILS OF WRITE-INS** | | | | | |
| 2501. Miscellaneous | | | (121,476) | | (121,476) |
| 2502. Loss adjustment expense | | | 881,766 | | 881,766 |
| 2503. | | | | | |
| 2598. Summary of remaining write-ins for Line 25 from overflow page | 0 | 0 | 0 | 0 | 0 |
| 2599. Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above) | 0 | 0 | 760,290 | 0 | 760,290 |

(a) Includes management fees of $ 33,241,177 to affiliates and $ ..... to non-affiliates.

# EXHIBIT OF NET INVESTMENT INCOME

| | | 1<br>Collected During Year | 2<br>Earned During Year |
|---|---|---|---|
| 1. | U.S. government bonds | (a) 121,878 | 219,692 |
| 1.1 | Bonds exempt from U.S. tax | (a) | |
| 1.2 | Other bonds (unaffiliated) | (a) 0 | 0 |
| 1.3 | Bonds of affiliates | (a) | |
| 2.1 | Preferred stocks (unaffiliated) | (b) | |
| 2.11 | Preferred stocks of affiliates | (b) | |
| 2.2 | Common stocks (unaffiliated) | | |
| 2.21 | Common stocks of affiliates | | |
| 3. | Mortgage loans | (c) | |
| 4. | Real estate | (d) | |
| 5 | Contract Loans | | |
| 6 | Cash, cash equivalents and short-term investments | (e) 2,322,653 | 2,322,653 |
| 7 | Derivative instruments | (f) | |
| 8. | Other invested assets | | |
| 9. | Aggregate write-ins for investment income | 0 | 0 |
| 10. | Total gross investment income | 2,444,531 | 2,542,345 |
| 11. | Investment expenses | | (g) 115,848 |
| 12. | Investment taxes, licenses and fees, excluding federal income taxes | | (g) 5,628 |
| 13. | Interest expense | | (h) |
| 14. | Depreciation on real estate and other invested assets | | (i) |
| 15. | Aggregate write-ins for deductions from investment income | | 0 |
| 16. | Total deductions (Lines 11 through 15) | | 121,476 |
| 17. | Net investment income (Line 10 minus Line 16) | | 2,420,869 |
| | **DETAILS OF WRITE-INS** | | |
| 0901. | | | |
| 0902. | | | |
| 0903. | | | |
| 0998. | Summary of remaining write-ins for Line 9 from overflow page | 0 | 0 |
| 0999. | Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above) | 0 | 0 |
| 1501. | | | |
| 1502. | | | |
| 1503. | | | |
| 1598. | Summary of remaining write-ins for Line 15 from overflow page | | 0 |
| 1599. | Totals (Lines 1501 thru 1503 plus 1598) (Line 15, above) | | 0 |

(a) Includes $ 5,419 accrual of discount less $ 795 amortization of premium and less $ 29,188 paid for accrued interest on purchases.

(b) Includes $ ..... accrual of discount less $ ..... amortization of premium and less $ ..... paid for accrued dividends on purchases.

(c) Includes $ ..... accrual of discount less $ ..... amortization of premium and less $ ..... paid for accrued interest on purchases.

(d) Includes $ ..... for company's occupancy of its own buildings; and excludes $ ..... interest on encumbrances.

(e) Includes $ ..... accrual of discount less $ ..... amortization of premium and less $ ..... paid for accrued interest on purchases.

(f) Includes $ ..... accrual of discount less $ ..... amortization of premium.

(g) Includes $. 2,322,118 investment expenses and $ ..... investment taxes, licenses and fees, excluding federal income taxes, attributable to segregated and Separate Accounts.

(h) Includes $ ..... interest on surplus notes and $ ..... interest on capital notes.

(i) Includes $ ..... depreciation on real estate and $ ..... depreciation on other invested assets.

# EXHIBIT OF CAPITAL GAINS (LOSSES)

| | | 1<br>Realized Gain (Loss) On Sales or Maturity | 2<br>Other Realized Adjustments | 3<br>Total Realized Capital Gain (Loss) (Columns 1 + 2) | 4<br>Change in Unrealized Capital Gain (Loss) | 5<br>Change in Unrealized Foreign Exchange Capital Gain (Loss) |
|---|---|---|---|---|---|---|
| 1. | U.S. Government bonds | 0 | (122,445) | (122,445) | 0 | 0 |
| 1.1 | Bonds exempt from U.S. tax | | | 0 | | |
| 1.2 | Other bonds (unaffiliated) | 0 | 0 | 0 | 0 | 0 |
| 1.3 | Bonds of affiliates | 0 | 0 | 0 | 0 | 0 |
| 2.1 | Preferred stocks (unaffiliated) | 0 | 0 | 0 | 0 | 0 |
| 2.11 | Preferred stocks of affiliates | 0 | 0 | 0 | 0 | 0 |
| 2.2 | Common stocks (unaffiliated) | 0 | 0 | 0 | 0 | 0 |
| 2.21 | Common stocks of affiliates | 0 | 0 | 0 | 0 | 0 |
| 3. | Mortgage loans | | 0 | 0 | 0 | 0 |
| 4. | Real estate | | 0 | 0 | | 0 |
| 5. | Contract loans | | | 0 | | |
| 6. | Cash, cash equivalents and short-term investments | (854) | | (854) | | |
| 7. | Derivative instruments | | | 0 | | |
| 8. | Other invested assets | | 0 | 0 | 0 | 0 |
| 9. | Aggregate write-ins for capital gains (losses) | 0 | 0 | 0 | 0 | 0 |
| 10. | Total capital gains (losses) | (854) | (122,445) | (123,299) | 0 | 0 |
| | **DETAILS OF WRITE-INS** | | | | | |
| 0901. | | | | | | |
| 0902. | | | | | | |
| 0903. | | | | | | |
| 0998. | Summary of remaining write-ins for Line 9 from overflow page | 0 | 0 | 0 | 0 | 0 |
| 0999. | Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above) | 0 | 0 | 0 | 0 | 0 |

# EXHIBIT OF NON-ADMITTED ASSETS

| | | 1<br>Current Year Total Nonadmitted Assets | 2<br>Prior Year Total Nonadmitted Assets | 3<br>Change in Total Nonadmitted Assets (Col. 2 - Col. 1) |
|---|---|---|---|---|
| 1. | Bonds (Schedule D) | | 0 | 0 |
| 2. | Stocks (Schedule D): | | | |
| | 2.1 Preferred stocks | | 0 | 0 |
| | 2.2 Common stocks | | 0 | 0 |
| 3. | Mortgage loans on real estate (Schedule B): | | | |
| | 3.1 First liens | | | 0 |
| | 3.2 Other than first liens | | | 0 |
| 4. | Real estate (Schedule A): | | | |
| | 4.1 Properties occupied by the company | | | 0 |
| | 4.2 Properties held for the production of income | | | 0 |
| | 4.3 Properties held for sale | | | 0 |
| 5. | Cash (Schedule E - Part 1), cash equivalents (Schedule E - Part 2) and short-term investments (Schedule DA) | | | 0 |
| 6. | Contract loans | | | 0 |
| 7. | Derivatives (Schedule DB) | | 0 | 0 |
| 8. | Other invested assets (Schedule BA) | | | 0 |
| 9. | Receivables for securities | | | 0 |
| 10. | Securities lending reinvested collateral assets (Schedule DL) | | 0 | 0 |
| 11. | Aggregate write-ins for invested assets | 0 | 0 | 0 |
| 12. | Subtotals, cash and invested assets (Lines 1 to 11) | 0 | 0 | 0 |
| 13. | Title plants (for Title insurers only) | | | 0 |
| 14. | Investment income due and accrued | 0 | 0 | 0 |
| 15. | Premiums and considerations: | | | |
| | 15.1 Uncollected premiums and agents' balances in the course of collection | 0 | 0 | 0 |
| | 15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due | | | 0 |
| | 15.3 Accrued retrospective premiums and contracts subject to redetermination | 0 | 0 | 0 |
| 16. | Reinsurance: | | | |
| | 16.1 Amounts recoverable from reinsurers | 0 | | 0 |
| | 16.2 Funds held by or deposited with reinsured companies | | | 0 |
| | 16.3 Other amounts receivable under reinsurance contracts | | | 0 |
| 17. | Amounts receivable relating to uninsured plans | 0 | 0 | 0 |
| 18.1 | Current federal and foreign income tax recoverable and interest thereon | 0 | | 0 |
| 18.2 | Net deferred tax asset | 0 | 0 | 0 |
| 19. | Guaranty funds receivable or on deposit | 0 | | 0 |
| 20. | Electronic data processing equipment and software | 0 | | 0 |
| 21. | Furniture and equipment, including health care delivery assets | 0 | | 0 |
| 22. | Net adjustment in assets and liabilities due to foreign exchange rates | 0 | | 0 |
| 23. | Receivable from parent, subsidiaries and affiliates | 0 | 0 | 0 |
| 24. | Health care and other amounts receivable | 5,382,556 | 7,090,229 | 1,707,673 |
| 25. | Aggregate write-ins for other than invested assets | 0 | 317,100 | 317,100 |
| 26. | Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25) | 5,382,556 | 7,407,329 | 2,024,773 |
| 27. | From Separate Accounts, Segregated Accounts and Protected Cell Accounts | | | 0 |
| 28. | Total (Lines 26 and 27) | 5,382,556 | 7,407,329 | 2,024,773 |
| | **DETAILS OF WRITE-INS** | | | |
| 1101. | | | | |
| 1102. | | | | |
| 1103. | | | | |
| 1198. | Summary of remaining write-ins for Line 11 from overflow page | 0 | 0 | 0 |
| 1199. | Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above) | 0 | 0 | 0 |
| 2501. | Intangible Assets and Amortization | | 317,100 | 317,100 |
| 2502. | | | | |
| 2503. | | | | |
| 2598. | Summary of remaining write-ins for Line 25 from overflow page | 0 | 0 | 0 |
| 2599. | Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above) | 0 | 317,100 | 317,100 |

# EXHIBIT 1 - ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY

| Source of Enrollment | Total Members at End of | | | | | 6 |
|---|---|---|---|---|---|---|
| | 1<br>Prior Year | 2<br>First Quarter | 3<br>Second Quarter | 4<br>Third Quarter | 5<br>Current Year | Current Year<br>Member Months |
| 1. Health Maintenance Organizations | 50,421 | 48,011 | 46,347 | 44,793 | 45,032 | 557,267 |
| 2. Provider Service Organizations | | | | | | |
| 3. Preferred Provider Organizations | | | | | | |
| 4. Point of Service | | | | | | |
| 5. Indemnity Only | | | | | | |
| 6. Aggregate write-ins for other lines of business | 0 | 0 | 0 | 0 | 0 | 0 |
| 7. Total | 50,421 | 48,011 | 46,347 | 44,793 | 45,032 | 557,267 |
| **DETAILS OF WRITE-INS** | | | | | | |
| 0601. | | | | | | |
| 0602. | | | | | | |
| 0603. | | | | | | |
| 0698. Summary of remaining write-ins for Line 6 from overflow page | 0 | 0 | 0 | 0 | 0 | 0 |
| 0699. Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above) | 0 | 0 | 0 | 0 | 0 | 0 |

# NOTES TO FINANCIAL STATEMENTS

1. Summary of Significant Accounting Policies and Going Concern

A. Accounting Practices

The accompanying statutory financial statements of Aetna Better Health of Michigan, Inc. (the "Company"), indirectly a wholly-owned subsidiary of CVS Health Corporation ("CVS Health"), have been prepared in conformity with accounting practices prescribed or permitted by the Michigan Insurance Department (Michigan Department) (Michigan Accounting Practices) The Michigan Department recognizes only statutory accounting practices prescribed or permitted by the State of Michigan for determining and reporting the financial condition and results of operations of an insurance company, which include accounting practices and procedures adopted by the National Association of Insurance Commissioners' ("NAIC") *Accounting Practices and Procedures Manual* ("NAIC SAP"). On November 28, 2018, CVS Health acquired Aetna Inc. ("Aetna") and at that date became the Company's ultimate parent (the "Aetna Acquisition").

A reconciliation of the Company's net income and capital and surplus between NAIC SAP and practices prescribed and permitted by the State of Michigan for the years ending December 31, 2018 and 2017 is as follows:

| | SSAP # | F/S Page | F/S Line # | 2018 | 2017 |
|---|---|---|---|---|---|
| NET INCOME | | | | | |
| (1) State basis (Page 4, Line 32, Columns 2 & 3) | XXX | XXX | XXX | 12,916,343 | 3,164,285 |
| (2) State Prescribed Practices that increase/(decrease) NAIC SAP: | | | | | |
| (3) State Permitted Practices that increase/(decrease) NAIC SAP: | | | | | |
| (4) NAIC SAP (1-2-3=4) | XXX | XXX | XXX | 12,916,343 | 3,164,285 |
| SURPLUS | | | | | |
| (5) State basis (Page 3, Line 33, Columns 3 & 4) | XXX | XXX | XXX | 54,596,492 | 41,505,916 |
| (6) State Prescribed Practices that increase/(decrease) NAIC SAP: | | | | | |
| (7) State Permitted Practices that increase/(decrease) NAIC SAP: | | | | | |
| (8) NAIC SAP (5-6-7=8) | XXX | XXX | XXX | 54,596,492 | 41,505,916 |

B. Use of Estimates in the Preparation of the Financial Statements

The preparation of these financial statements in conformity with Michigan Accounting Practices requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses. Actual results could differ from those estimates.

C. Accounting Policies

The Company applies the following significant accounting policies:

(1) Cash, Cash Equivalents and Short-Term Investments

Cash, cash equivalents and short-term investments, consisting primarily of money market instruments and other debt issues with an original maturity of up to one year, are carried at amortized cost. Short-term investments consist primarily of investments purchased with an original maturity date of greater than

three months but less than one year. Cash equivalents consist of highly liquid instruments, which mature within three months from the date of purchase. The carrying amount of cash, cash equivalents and short-term investments approximates fair value. Cash accounts with positive balances shall not be reported separately from cash accounts with negative balances. If in the aggregate, the reporting entity has a net negative cash balance, it shall be reported as a negative asset and shall not be recorded as a liability.

(2) Bonds

Bonds, which include special deposits, are carried at amortized cost except for those bonds with an NAIC designation of 3 through 6, which are carried at the lower of amortized cost or fair value. The amount carried at fair value is not material to the financial statements. Bond premiums and discounts are amortized using the scientific interest method. When quoted prices in active markets for identical assets are available, the Company uses these quoted market prices to determine the fair value of bonds. This is used primarily for U.S. government securities. In other cases where a quoted market price for identical assets in an active market is either not available or not observable, the Company estimates fair values using valuation methodologies based on available and observable market information or by using a matrix pricing model. If quoted market prices are not available, the Company determines fair value using broker quotes or an internal analysis of each investment's financial performance and cash flow projections. The Company had no investments where fair value was determined using broker quotes or an internal analysis of financial performance and cash flow projections at December 31, 2018 and 2017. Bonds include all investments whose maturity is greater than one year when purchased. Loan-backed and structured securities are carried at amortized cost adjusted for unamortized premiums and discounts. Premiums and discounts on loan-backed and structured securities are amortized using the interest method over the estimated remaining term of the securities, adjusted for anticipated prepayments. All adjustments between amortized cost and carrying value are reflected in unrealized capital gains and losses and are reported as direct adjustments to surplus. Bonds are recorded as purchases or sales on the trade date.

The Company periodically reviews its bonds to determine whether a decline in fair value below the carrying value is other-than-temporary. For bonds, other than loan-backed and structured securities, an other-than-temporary impairment ("OTTI") shall be recorded if it is probable that the Company will be unable to collect all amounts due according to the contractual terms in effect at the date of acquisition. Declines deemed to be OTTI in the cost basis are recognized as realized capital losses. Yield-related impairments are deemed other-than-temporary when the Company intends to sell an investment at the reporting date before recovery of the cost of the investment.

For loan-backed and structured securities, the Company records OTTI when the fair value of the loan-backed or structured security is less than the amortized cost basis at the balance sheet date and (1) the Company intends to sell the investment, or (2) the Company does not have the intent and ability to retain the investment for the time sufficient to recover the amortized cost basis, or (3) the Company does not expect to recover the entire amortized cost basis of the security, even if it does not intend to sell the security and has the intent and ability to hold. If it is determined an OTTI has occurred because of (1) or (2), the amount of the OTTI is equal to the difference between the amortized cost and the fair value of the security at the balance sheet date and this difference is recorded as a realized capital loss. If it is determined an OTTI has occurred because of (3), the amount of the OTTI is equal to the difference between the amortized cost and the present value of cash flows expected to be collected, discounted at the loan-backed or structured security's effective interest rate and this difference is also accounted for as a realized capital loss.

The Company analyzes all relevant facts and circumstances for each investment when performing its analysis to determine whether an OTTI exists. Among the factors considered in evaluating whether a decline is other-than-temporary, management considers whether the decline in fair value results from a change in the quality of the investment security itself, whether the decline results from a downward movement in the market as a whole, the prospects for realizing the carrying value of the bond based on the investee's current and short-term prospects for recovery and other factors. The risks inherent in assessing the impairment of an investment include the risk that market factors may differ from the Company's expectations and the risk that facts and circumstances factored into its assessment may change with the passage of time. Unexpected changes to market factors and circumstances that were not present in past reporting periods may result in a current period decision to sell securities that were not other-than-temporarily-impaired in prior reporting periods.

(3) Common Stocks

Common stocks of non-affiliates are carried at fair value. Common stocks of affiliates are reported using the equity method. Common stocks of affiliates that are unaudited are nonadmitted. Declines in the cost basis deemed to be OTTI are recognized as realized capital losses. Common stocks are recorded as purchases or sales on the trade date.

(4) The Company did not own any preferred stock at December 31, 2018 or 2017.

(5) The Company did not have any mortgage loans at December 31, 2018 or 2017.

(6) Securities Lending

The Company engages in securities lending by lending certain securities from its investment portfolio to other institutions for short periods of time. Borrowers must post cash collateral in the amount of 102% to 105% of the fair value of a loaned security. The fair value of the loaned securities is monitored on a daily basis, with additional collateral obtained or refunded as the fair value of the loaned securities fluctuates. The collateral is retained and invested by a lending agent according to the Company's guidelines to generate additional investment income for the Company. Pursuant to SSAP No. 103R - *Transfers and Servicing of Financial Assets and Extinguishments of Liabilities* ("SSAP No. 103R"), collateral required under the Company's securities lending program is carried on the Company's Statutory Statements of Assets and Liabilities, Capital and Surplus as both a receivable and payable. Also pursuant to SSAP No. 103, if the collateral received from a counterparty is less than 100 percent at the reporting date, the difference between the actual collateral and 100 percent is nonadmitted. Collateral value is measured and compared to the loaned securities in aggregate by counterparty.

The Company did not have any loaned securities at December 31, 2018 and 2017.

(7) The Company did not have any investments in subsidiaries, controlled or affiliated companies at December 31, 2018 or 2017.

(8) The Company did not have any investments in any joint ventures, partnerships and limited liability companies at December 31, 2018 or 2017.

(9) The Company did not have any derivatives at December 31, 2018 or 2017.

(10) Aggregate Health Policy Reserves and Related Expenses

Premium deficiency reserves ("PDR") are recognized when it is probable that the expected future hospital and medical costs, including maintenance costs, will exceed anticipated future premiums and reinsurance recoveries on existing contracts. Where allowed, anticipated investment income is considered in the calculation of any PDR. For purposes of calculating a PDR, contracts are grouped in a manner consistent with the method of acquiring, servicing and measuring the profitability of such contracts. The Company had no PDR at December 31, 2018 and 2017.

Additional amounts associated with contracts subject to redetermination of $406,976 and $0 were included in aggregate policy reserves at December 31, 2018 and 2017, respectively.

(11) Hospital and Medical Costs and Claims Adjustment Expenses and Related Reserves

Hospital and medical costs consist principally of fee-for-service medical claims and capitation costs. Claims unpaid and aggregate health claim reserves include the Company's estimate of payments to be made on claims reported but not yet paid and for health care services rendered to enrollees but not yet reported to the Company as of the Statutory Statements of Assets and Liabilities, Capital and Surplus date. Such estimates are developed using actuarial principles and assumptions, which consider, among other things, historical and projected claim submission and processing payment patterns, medical cost trends, historical utilization of health care services, claim inventory levels, medical inflation, contract requirement changes in membership and product mix, seasonality and other relevant factors. The Company reflects changes in estimates in hospital and medical costs in the Statutory Statements of Revenue and Expenses in the period they are determined. Capitation costs, which are recorded in hospital and medical expenses in the Statutory Statements of Revenue and Expenses, represent contractual monthly fees paid to participating physicians and other medical providers for providing medical care, regardless of the medical services provided to the enrollee.

The Company uses the triangulation method to estimate reserves for claims incurred but not reported. The method of triangulation makes estimates of completion factors that are then applied to the total paid

claims (net of coordination of benefits) to date for each incurral month. This provides an estimate of the total projected incurred claims and total amount outstanding or claims incurred but not reported (claims unpaid). For the most current dates of service where there is insufficient paid claim data to rely solely on the triangulation method, the Company examines cost and utilization trends as well as environmental factors, plan changes, provider contracts, changes in membership and/or benefits, and historical seasonal patterns to estimate the reserve required for these months.

Claims adjustment expenses, which include cost containment expenses, represent the costs incurred related to the claim settlement process such as costs to record, process and adjust claims. These expenses are included in the Company's management agreement with an affiliate described in Note 10.

(12) As a result of CVS Health's acquisition of Aetna Inc. ("Aetna"), Aetna modified its capitalization policy from the prior period related to furniture and equipment ("F&E") and prepaid assets. Under the revised policy, F&E will be capitalized if greater than $1,000 versus the previous threshold of $500. Under the new policy, prepaid assets will be capitalized if greater than $250,000 versus the previous threshold of $50,000. These revisions are not expected to have a material impact on the financial results of Aetna or its affiliates, including the Company.

(13) Pharmaceutical Rebate Receivables

The Company estimates pharmaceutical rebate receivables based upon historical payment trends, actual utilization and other variables. Pharmaceutical rebates for a quarter are billed to the vendor within forty five days of the completion of the quarter with any adjustment to previously recorded amounts reflected at the time of billing. The Company reports pharmaceutical rebate receivables as health care receivables. Pharmacy rebate receivables not in accordance with SSAP No. 84 – *Health Care and Government Insured Plan Receivables* or are over 90 days past due are nonadmitted. All rebates are processed and settled with an affiliated entity. The pharmaceutical rebate receivables are more fully discussed in Note 28.

(14) Premiums and Amounts Due and Unpaid

Premium revenue for prepaid health or dental care products is recognized as income in the month in which enrollees are entitled to health or dental care services. Premiums collected before the effective period are reported as premiums received in advance. Premiums related to unexpired contractual coverage periods are reported as unearned premiums in the Statutory Statements of Liabilities, Capital and Surplus (refer to discussion of aggregate health policy reserves and related expenses above).

Nonadmitted amounts consist of all premiums due and unpaid greater than 90 days past due, with the exception of amounts due under government insured plans, which may be admitted assets under certain circumstances. In addition, for any customer for which the premiums due and unpaid greater than 90 days past due is more than a de minimus portion of the entire balance of premiums due and unpaid for that customer, the entire balance of premiums due and unpaid for that customer is nonadmitted. Management also performs a specific review of accounts and based on the results of the review, additional amounts may be nonadmitted. Uncollectible amounts are generally written-off and charged to revenue in the period in which the customer reconciliations are completed and agreed to by the customer (retroactivity) or when the account is determined to be uncollectible by the Company.

(15) Aggregate Health Claim Reserves

The reserve for future contingent benefits includes the estimated cost of services that will continue to be incurred after the Statutory Statements of Liabilities, Capital and Surplus date if the Company is obligated to pay for such services in accordance with contract provisions or regulatory requirements. These balances are recorded in aggregate health claim reserves in the Statutory Statements of Liabilities, Capital and Surplus and are estimated using a percentage of current hospital and medical costs, which is based on the Company's historical cost experience.

(16) Investment Income Due and Accrued

Accrued investment income consists primarily of interest. Interest is recognized on an accrual basis and dividends are recorded as earned on the ex-dividend date. Due and accrued income is not recorded on: (a) bonds in default; and (b) bonds delinquent more than 90 days or where collection of interest is improbable. At December 31, 2018 and 2017, the Company did not have any nonadmitted investment income due and accrued.

(17) Covered and Uncovered Expenses and Related Liabilities

Covered expenses and related liabilities represent costs for health care expenses for which a member is not responsible in the event of the insolvency of the Company. Uncovered expenses and related liabilities represent costs to the Company for health care services that are the obligation of the Company and for which a member may also be liable in the event of the Company's insolvency.

(18) Fees Paid to the Federal Government by Health Insurers

SSAP No. 106 - *Affordable Care Act Section 9010 Assessment* ("SSAP No. 106") required (1) that the health insurer fee be recognized in full on January 1 of the fee year (the calendar year in which the assessment must be paid to the federal government), in the operating expense category of insurance taxes, licenses and fees, excluding federal income taxes and (2) that in each data year preceding a fee year a reporting entity pro-ratably accrue by reclassifying from unassigned funds (surplus) to aggregate write-ins for special surplus funds an amount equal to its estimated subsequent fee year assessment. This reclassification has no impact on total capital and surplus and is reversed in full on January 1 of the fee year. On January 22, 2018, Public Law No: 115-120 was signed into law and it imposes a moratorium on the health insurer fee for calendar year 2019. As interpreted in INT 18-02: ACA Section 9010 Assessment Moratoriums, because there is not an ACA Section 9010 fee due in September 2019, there is not an accrual of a liability on January 1, 2019 based on 2018 data year net written premiums. Accrual of a liability on January 1, 2020 for the ACA Section 9010 assessment based on 2019 data year net written premiums and the reclassification from unassigned funds (surplus) to aggregate write-ins for special surplus funds equal to the estimated 2020 fee year assessment accrued in data year 2019 will both continue as prescribed under SSAP No. 106. See Note 22 for disclosure of all amounts related to the health insurer fee for the Company.

(19) The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010's (collectively, "Health Care Reform") Risk Adjustment

Risk Adjustment

Health Care Reform established a permanent risk adjustment program to transfer funds from qualified individual and small group insurance plans with below average risk scores to plans with above average risk scores. Based on the risk of the Company's qualified plan members relative to the average risk of members of other qualified plans in comparable markets, the Company estimates its ultimate risk adjustment receivable or payable for the current calendar year and reflects the impact as an adjustment to its premium revenue in accordance with SSAP No. 107.

(20) Federal and State Income and Premium Taxes

The Company was included in the consolidated federal income tax return of its parent company, Aetna and Aetna's other wholly-owned subsidiaries through November 27, 2018 pursuant to the terms of a tax sharing agreement. For the tax period ending December 31, 2018, Aetna and its wholly-owned subsidiaries are included in the consolidated federal income tax return of its parent, CVS Health, pursuant to the terms of a tax sharing agreement (and a Supplemental Tax Sharing Agreement where applicable) between CVS Health and the Company. In accordance with both agreements, the Company's current federal and state income tax provisions are generally computed as if the Company were filing a separate federal and state income tax return; current income tax benefits, including those resulting from net operating losses, are recognized to the extent realized in the consolidated return. Pursuant to these agreements, the Company has the enforceable right to recoup federal and state income taxes paid in prior years in the event of future net losses, which it may incur, or to recoup its net losses carried forward as an offset to future net income subject to federal and state income taxes.

Income taxes are accounted for under the asset and liability method. Deferred income tax assets ("DTAs") and liabilities ("DTLs") represent the expected future tax consequences of temporary differences generated by statutory accounting as defined in SSAP No. 101 - Income Taxes. DTAs and DTLs are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. DTAs and DTLs are computed by means of identifying temporary differences which are measured using a balance sheet approach whereby statutory and tax basis balance sheets are compared. Current income tax recoverables include all current income taxes, including interest, reasonably expected to be recovered in a subsequent accounting period.

Pursuant to SSAP No. 101, gross DTAs are first reduced by a statutory valuation allowance adjustment to an amount that is more likely than not to be realized ("adjusted gross DTAs"). Adjusted gross DTAs are then admitted in an amount equal to the sum of paragraphs a. b. and c. below:

a. Federal income taxes paid in prior years that can be recovered through loss carrybacks for existing temporary differences that reverse during a timeframe corresponding with Internal Revenue Service ("IRS") tax loss carryback provisions.

b. The amount of adjusted gross DTAs, after the application of paragraph a. above, expected to be realized within the applicable period and that is no greater than the applicable percentage as determined using the applicable Realization Threshold Limitation Table. The applicable period refers to the number of years in which the DTA will reverse in the Company's tax return and the applicable percentage refers to the percentage of the Company's statutory capital and surplus as required to be shown on the statutory balance sheet adjusted to exclude any net DTAs, electronic data processing equipment and operating system software and any net positive goodwill ("Stat Cap ExDTA").

   The Realization Threshold Limitation Tables allow DTAs to be admitted based upon either realization within 3 years and 15% of Stat Cap ExDTA, 1 year and 10% of Stat Cap ExDTA, or no DTA admitted pursuant to this paragraph b. In general, the Realization Threshold Limitation Tables allow the Company to admit more DTAs if total DTAs as reported by the Company are a smaller percentage of statutory capital and surplus.

c. The amount of gross DTAs, after the application of paragraphs a. and b. above that can be offset against existing gross DTLs. In applying this offset, the Company considers the character (i.e. ordinary versus capital) of the DTAs and DTLs such that offsetting would be permitted in the tax return under existing enacted federal income tax laws and regulations and the reversal patterns of temporary differences.

Changes in DTAs and DTLs are recognized as a separate component of gains and losses in surplus ("Change in net deferred income tax") except to the extent allocated to changes in unrealized gains and losses. Changes in DTAs and DTLs allocated to unrealized gains and losses are netted against the related changes in unrealized gains and losses and are reported as "Change in net unrealized capital gains (losses)", also a separate component of gains and losses in surplus.

The Company is subject to state income taxes in various states. State income tax expense is recorded in general administrative expenses in the Statutory Statements of Revenue and Expenses. For the years ended December 31, 2018 and 2017, the Company incurred state income tax expenses of $220,442 and $350,118, respectively. The Company's had no state income tax payables at December 31, 2018 and 2017. The Company's state income tax receivables of $268,530 and $0 at December 31, 2018 and 2017, respectively, were included as an aggregate write-in in the Statutory Statement of Assets.

The Company is subject to premium taxes in various states. These tax expenses were recorded in general administrative expenses in the Statutory Statements of Revenue and Expenses. The expenses for these taxes were $0 and $62,136 for the years ended December 31, 2018 and 2017, respectively. The Company's had no premium tax payables at December 31, 2018 and 2017. The Company's had no prepaid premium taxes receivables at December 31, 2018 and 2017,Respectively, were included as an aggregate write-in in the statutory statement of assets.

(21) Reinsurance

In the normal course of business, the Company seeks to reduce the loss that may arise from catastrophes or other events that cause unfavorable underwriting results and to help balance its risks and capital by reinsuring certain levels of risk with other insurance enterprises. The reinsurance coverage does not relieve the Company of its primary obligations. Reinsurance premiums and reserves related to reinsured business are accounted for on a basis consistent with those used in accounting for the original policies issued and the terms of the reinsurance contracts. Premiums ceded for medical losses and the related unpaid reserves have been reported as reductions of these items. The reinsurance agreements are more fully discussed in Notes 10 and 23.

D. Going Concern

After evaluation at December 31, 2018, management has no concern over the Company's ability to continue as a going concern at this time. Management will continuously evaluate the Company's ability to continue as a

going concern and will take appropriate action and will make appropriate disclosures if there is any change in any condition or events that would raise substantial doubt about the Company's ability to continue as a going concern.

2. Accounting Changes and Corrections of Errors

The Company did not have any accounting changes or correction of errors in the years ended December 31, 2018 and 2017.

3. Business Combinations and Goodwill

The Company was not a part of any business combinations that involved the statutory purchase method, a statutory merger, an assumption reinsurance, or an impairment loss in the years ending December 31, 2018 and 2017.

4. Discontinued Operations

The Company did not have any discontinued operations in the years ending December 31, 2018 and 2017.

5. Investments

A. The Company did not have any mortgage loans, including Mezzanine Real Estate Loans, at December 31, 2018 or 2017.

B. The Company did not have any debt restructuring in the years ending December 31, 2018 and 2017.

C. The Company did not have any reverse mortgages at December 31, 2018 or 2017.

D. Loan-Backed Securities

(1) Prepayment assumptions for single class and multi-class mortgage-backed/loan-backed securities were obtained from industry market sources.

(2) The Company did not recognize any other-than-temporary impairments ("OTTI") on loan-backed and structured securities in which the Company had the (1) intent to sell, (2) did not have the intent and ability to retain for a period of time sufficient to recover the amortized cost basis or (3) present value of cash flows expected to be collected is less than the amortized cost basis of the securities in accordance with SSAP No. 43R - *Loan-Backed and Structured Securities* ("SSAP No. 43R") at December 31, 2018.

(3) The Company had no recognized OTTI on loan-backed and structured securities currently held, in which the present value of cash flows expected to be collected is less than the amortized cost basis at December 31, 2018.

(4) The Company had no unrealized loss position on loan-backed and structured securities held by the Company at December 31, 2018 is as follows:

(5) The Company has reviewed the loan-backed and structured securities in accordance with SSAP No. 43R in the table above and has concluded that these are performing assets generating investment income to support the needs of the business. Furthermore, the Company has no intention to sell the securities at December 31, 2018 before their cost can be recovered and does have the intent and ability to retain the securities for the time sufficient to recover the amortized cost basis; therefore, no OTTI write-down to fair value was determined to have occurred on these securities.

E. Dollar Repurchase Agreements and/or Securities Lending Transactions

(1) The Company did not have any repurchase agreements or loaned securities transactions at December 31, 2018.

(2) The Company did not pledge any of its assets as collateral, which are classified as securities pledged to creditors as of December 31, 2018.

(3) Neither the Company nor its agent has accepted collateral that is permitted by contract or custom to sell or repledge as of December 31, 2018.

(4) The Company did not have securities lending transactions administered by an affiliated agent which is "one line" reported at December 31, 2018.

(5) The Company did not have any repurchase agreements, loaned securities or dollar repurchase agreements at December 31, 2018.

(6) The Company has not accepted collateral that is not permitted by contract or custom to sell or repledge as of December 31, 2018.

(7) The Company did not have any collateral for transactions that extend beyond one year from the reporting date.

F. The Company did not have any repurchase agreements transactions accounted for as secured borrowing at December 31, 2018.

G. The Company did not have any reverse repurchase agreements transactions accounted for as secured at December 31, 2018.

H. The Company did not have any repurchase agreements transactions accounted for as a sale at December 31, 2018.

I. The Company did not have any reverse repurchase agreements transactions accounted for as a sale at December 31, 2018.

J. The Company did not have any real estate at December 31, 2018.

K. The Company did not have any low-income housing tax credits at December 31, 2018 or 2017.

L. Restricted Assets

(1) Restricted assets (including pledged):

| Restricted Asset Category | 1<br>Total Gross (Admitted & Nonadmitted) Restricted from Current Year | 2<br>Total Gross (Admitted & Nonadmitted) Restricted from Prior Year | 3<br>Increase/ (Decrease) (1 minus 2) | 4<br>Total Current Year Nonadmitted Restricted | 5<br>Total Current Year Admitted Restricted (1 minus 4) | 6<br>Gross (Admitted & Nonadmitted) Restricted to Total Assets | 7<br>Admitted Restricted to Total Admitted Assets (b) |
|---|---|---|---|---|---|---|---|
| a. Subject to contractual obligation for which liability is not shown | | | | | | 0.000 | 0.000 |
| b. Collateral held under security lending agreements | | | | | | 0.000 | 0.000 |
| c. Subject to repurchase agreements | | | | | | 0.000 | 0.000 |
| d. Subject to reverse repurchase agreements | | | | | | 0.000 | 0.000 |
| e. Subject to dollar repurchase agreements | | | | | | 0.000 | 0.000 |
| f. Subject to dollar reverse repurchase agreements | | | | | | 0.000 | 0.000 |
| g. Placed under option contracts | | | | | | 0.000 | 0.000 |
| h. Letter stock or securities restricted as to sale - excluding FHLB capital stock | | | | | | 0.000 | 0.000 |
| i. FHLB capital stock | | | | | | 0.000 | 0.000 |
| j. On deposit with states | 1,199,763 | 1,200,283 | (520) | | 1,199,763 | 0.846 | 0.879 |
| k. On deposit with other regulatory bodies | | | | | | 0.000 | 0.000 |
| l. Pledged collateral to FHLB (including assets backing funding agreements) | | | | | | 0.000 | 0.000 |
| m. Pledged as collateral not captured in other categories | | | | | | 0.000 | 0.000 |
| n. Other restricted assets | | | | | | 0.000 | 0.000 |
| o. Total Restricted Assets | 1,199,763 | 1,200,283 | (520) | 0 | 1,199,763 | 0.846 | 0.879 |

(a) Column 1 divided by Asset Page, Column 1, Line 28
(b) Column 5 divided by Asset Page, Column 3, Line 28

(2) The Company did not have any assets pledged as collateral not captured in other categories at December 31, 2018.

(3) The Company did not have any other restricted assets at December 31, 2018.

(4) The Company did not have any collateral received and reflected within its financial statements at December 31, 2018.

M. The Company did not have any working capital finance investments at December 31, 2018.

N. The Company did not have any offsetting and netting of derivative, repurchase and reverse repurchase, and securities borrowing and securities lending assets or liabilities at December 31, 2018.

O. The Company did not have any structured notes at December 31, 2018.

P. The Company did not have any 5GI* securities at December 31, 2018 or 2017.

Q. The Company did not have any short sales within the reporting period. December 31, 2018.

R. The Company did not have any prepayment penalty and acceleration fees at December 31, 2018.

6. Joint Ventures, Partnerships, and Limited Liability Companies

A. The Company did not have any joint ventures, partnerships, or limited liability companies that exceeded 10% of its admitted assets at December 31, 2018 or 2017.

B. The Company does not have any impaired investments in joint ventures, partnerships, or limited liability companies at December 31, 2018 or 2017.

7. Investment Income

A. Due and accrued income was excluded from surplus on the following bases:

Bonds - where collection of interest is uncertain.
Preferred stock - where collection of dividends is uncertain.
Mortgage loans - all due and accrued interest on loans delinquent for more than one year and on other loans where collection of interest is uncertain.
Real estate - where rent is in arrears for more than three months.
Contract loans - where accrued interest is in excess of loan value.

B. There was no amount excluded at December 31, 2018 or 2017.

8. Derivative Instruments

The Company did not have any derivative instruments at December 31, 2018 or 2017.

9. Income Taxes

A.

(1) The components of the net DTAs recognized in the Company's Statutory Statements of Assets and Liabilities, Capital and Surplus are as follows:

| | As of End of Current Period | | | 12/31/2017 | | | Change | | |
|---|---|---|---|---|---|---|---|---|---|
| | (1) Ordinary | (2) Capital | (3) (Col. 1 + 2) Total | (4) Ordinary | (5) Capital | (6) (Col. 4 + 5) Total | (7) (Col. 1 - 4) Ordinary | (8) (Col. 2 - 5) Capital | (9) (Col. 7 + 8) Total |
| (a) Gross Deferred Tax Assets | 2,328,581 | 27,717 | 2,356,298 | 2,807,618 | 7 | 2,807,625 | (479,037) | 27,710 | (451,327) |
| (b) Statutory Valuation Allowance Adjustment | — | 18,435 | 18,435 | 2,803,303 | — | 2,803,303 | (2,803,303) | 18,435 | (2,784,867) |
| (c) Adjusted Gross Deferred Tax Assets (1a - 1b) | 2,328,581 | 9,281 | 2,337,862 | 4,315 | 7 | 4,322 | 2,324,266 | 9,275 | 2,333,541 |
| (d) Deferred Tax Assets Nonadmitted | — | — | — | — | — | — | — | — | — |
| (e) Subtotal Net Admitted Deferred Tax Asset (1c - 1d) | 2,328,581 | 9,281 | 2,337,862 | 4,315 | 7 | 4,322 | 2,324,266 | 9,274 | 2,333,541 |
| (f) Deferred Tax Liabilities | 84,081 | 4,318 | 88,399 | — | 4,318 | 4,318 | 84,081 | — | 84,081 |
| (g) Net Admitted Deferred Tax Asset/(Net Deferred Tax Liability) (1e - 1f) | 2,244,500 | 4,963 | 2,249,463 | 4,315 | (4,311) | 4 | 2,240,185 | 9,275 | 2,249,460 |

2.

| | As of End of Current Period | | | 12/31/2017 | | | Change | | |
|---|---|---|---|---|---|---|---|---|---|
| | (1) Ordinary | (2) Capital | (3) (Col. 1 + 2) Total | (4) Ordinary | (5) Capital | (6) (Col. 4 + 5) Total | (7) (Col. 1 - 4) Ordinary | (8) (Col. 2 - 5) Capital | (9) (Col. 7 + 8) Total |
| Admission Calculation Components SSAP No. 101 | | | | | | | | | |
| (a) Federal Income Taxes Paid In Prior Years Recoverable Through Loss Carrybacks. | 2,264,999 | 4,964 | 2,269,963 | — | 4 | 4 | 2,264,999 | 4,960 | 2,269,959 |
| (b) Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below) | 63,582 | — | 63,582 | — | — | — | 63,582 | — | 63,582 |
| 1. Adjusted Gross Deferred Tax Assets Expected to be Realized Following the Balance Sheet Date. | 63,582 | — | 63,582 | — | — | — | 63,582 | — | 63,582 |
| 2. Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold. | | | 7,852,054 | | | 6,225,887 | | | 1,626,167 |
| (c) Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Liabilities. | — | 4,318 | 4,318 | 4,315 | 3 | 4,318 | (4,315) | 4,315 | — |
| (d) Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c)) | 2,328,581 | 9,282 | 2,337,863 | 4,315 | 7 | 4,322 | 2,324,266 | 9,275 | 2,333,541 |

3.

| | 2018 | 2017 |
|---|---|---|
| a. Ratio Percentage Used To Determine Recovery Period And Threshold Limitation Amount. | 527% | 394% |
| b. Amount Of Adjusted Capital And Surplus Used To Determine Recovery Period And Threshold Limitation In 2(b)2 Above. | 52,347,028 | 41,505,912 |

4.

| | As of End of Current Period | | 12/31/2017 | | Change | |
|---|---|---|---|---|---|---|
| | (1) Ordinary | (2) Capital | (3) Ordinary | (4) Capital | (5) (Col. 1 - 3) Ordinary | (6) (Col. 2 - 4) Capital |
| Impact of Tax Planning Strategies: | | | | | | |
| (a) Determination of adjusted gross deferred tax assets and net admitted deferred tax assets, by tax character as a percentage. | | | | | | |
| 1. Adjusted Gross DTAs amount from Note 9A1(c) | 2,328,581 | 9,282 | 4,315 | 7 | 2,324,266 | 9,275 |
| 2. Percentage of adjusted gross DTAs by tax character attributable to the impact of tax planning strategies | | | — | — | — | — |
| 3. Net Admitted Adjusted Gross DTAs amount from Note 9A1(e) | 2,328,581 | 9,282 | 4,315 | 7 | 2,324,266 | 9,275 |
| 4. Percentage of net admitted adjusted gross DTAs by tax character admitted because of the impact of tax planning strategies | | | — | — | — | — |

b. Do the Company's tax-planning strategies include the use of reinsurance? Yes [ ] No [ X ]

C. Current income taxes incurred consist of the following major components:

| | (1)<br>As of End of Current Period | (2)<br>12/31/2017 | (3)<br>(Col. 1 - 2)<br>Change |
|---|---|---|---|
| 1. Current Income Tax | | | |
| (a) Federal | 4,803,972 | (1,098,312) | 5,902,284 |
| (b) Foreign | | | — |
| (c) Subtotal | 4,803,972 | (1,098,312) | 5,902,284 |
| (d) Federal income tax on net capital gains | (178) | 4,883 | (5,061) |
| (e) Utilization of capital loss carry-forwards | | | — |
| (f) Other | | | — |
| (g) Federal and foreign income taxes incurred | 4,803,794 | (1,093,429) | 5,897,223 |
| 2. Deferred Tax Assets: | | | |
| (a) Ordinary: | | | |
| (1) Discounting of unpaid losses | 1,038,484 | 1,145,643 | (107,159) |
| (2) Unearned premium reserve | | | — |
| (3) Policyholder reserves | | | — |
| (4) Investments | | | — |
| (5) Deferred acquisition costs | | | — |
| (6) Policyholder dividends accrual | | | — |
| (7) Fixed Assets | | | — |
| (8) Compensation and benefits accrual | | | — |
| (9) Pension accrual | | | — |
| (10) Receivables - nonadmitted | 1,130,337 | 1,488,948 | (358,611) |
| (11) Net operating loss carry-forward | | | — |
| (12) Tax credit carry-forward | | | — |
| (13) Other (including items <5% of total ordinary tax assets) | 159,760 | 173,027 | (13,267) |
| (99) Subtotal | 2,328,581 | 2,807,618 | (479,037) |
| (b) Statutory valuation allowance adjustment | | 2,803,303 | (2,803,303) |
| (c) Nonadmitted | | | — |
| (d) Admitted ordinary deferred tax assets (2a99 - 2b - 2c) | 2,328,581 | 4,315 | 2,324,266 |
| (e) Capital: | | | |
| (1) Investments | 27,717 | 7 | 27,710 |
| (2) Net capital loss carry-forward | | | — |
| (3) Real estate | | | — |
| (4) Other (including items <5% of total ordinary tax assets) | | | — |
| (99) Subtotal | 27,717 | 7 | 27,710 |
| (f) Statutory valuation allowance adjustment | 18,435 | | 18,435 |
| (g) Nonadmitted | | | — |
| (h) Admitted capital deferred tax assets (2e99 - 2f - 2g) | 9,282 | 7 | 9,275 |
| (i) Admitted deferred tax assets (2d + 2h) | 2,337,863 | 4,322 | 2,333,541 |
| 3. Deferred Tax Liabilities: | | | |
| (a) Ordinary: | | | |
| (1) Investments | 3,230 | | 3,230 |
| (2) Fixed assets | | | — |
| (3) Deferred and uncollected premium | | | — |
| (4) Policyholder reserves | | | — |
| (5) Other (including items <5% of total ordinary tax liabilities) | 80,851 | | 80,851 |
| (99) Subtotal | 84,081 | — | 84,081 |
| (b) Capital: | | | |
| (1) Investments | 4,318 | 4,318 | — |
| (2) Real estate | | | — |
| (3) Other (including items <5% of total capital tax liabilities) | | | — |
| (99) Subtotal | 4,318 | 4,318 | — |
| (c) Deferred tax liabilities (3a99 + 3b99) | 88,399 | 4,318 | 84,081 |
| 4. Net deferred tax assets/liabilities (2i - 3c) | 2,249,464 | 4 | 2,249,460 |

The change in net deferred income taxes is comprised of the following:

| | 12/31/2018 | 12/31/2017 | Change |
|---|---|---|---|
| Total Deferred Tax Assets | $2,337,863 | $4,322 | $2,333,541 |
| Total Deferred Tax Liabilities | (88,399) | (4,318) | (84,081) |
| Net Deferred Tax Assets/(Liabilities) | 2,249,461 | 4 | 2,249,460 |
| Tax Effect of Unrealized Gains/(Losses) | | | 0 |
| Change in Net Deferred Income Tax | | | $2,249,460 |

The valuation allowance adjustment to gross DTAs was $18,435 and $2,803,303 for December 31, 2018 and December 31, 2017, respectively.

D. The provision for federal income taxes is different from that which would be obtained by applying the statutory federal income tax rate to income before income taxes. The items causing this difference were as follows:

| | 12/31/2018 | Effective Tax Rate | 12/31/2017 | Effective Tax Rate |
|---|---|---|---|---|
| Provision computed at statutory rate | 3,721,228 | 21 % | 724,798 | 35 % |
| Health Insurer Fee | 1,496,387 | 8 % | — | 0 % |
| Transfer Pricing Adjustment | (847,798) | (5)% | (2,320,607) | (112)% |
| Tax-Exempt Interest | — | 0 % | — | 0 % |
| Change in Nonadmitted Assets | 358,611 | 2 % | (975,848) | (47)% |
| Prior Year True-Up | 544,225 | 3 % | 331,370 | 16 % |
| Change in Valuation Allowance Adjustment | (2,784,868) | (16)% | 4,377,563 | 211 % |
| Other | 66,549 | 0 % | 117,186 | 6 % |
| Total | 2,554,334 | 14 % | 2,254,459 | 109 % |
| Federal and foreign income taxes incurred | 4,803,794 | 27 % | (1,093,429) | (53)% |
| Change in net deferred income taxes | (2,249,459.94) | (13)% | 3,347,888 | 162 % |
| Total statutory income taxes | 2,554,334 | 14 % | 2,254,459 | 109 % |

The transfer pricing adjustment allows taxpayers to apply different methods to price current period intercompany services at arm's length prices as compared to what would be charged to an unrelated entity, which results in a permanent deduction for tax reporting purposes.

E.

(1) At December 31, 2018 and 2017, the Company had no net capital loss or net operating loss carryforwards for tax purposes.

(2) The amount of federal income taxes incurred that is available for recoupment in the event of future net losses is as follows:

| Year | Ordinary | Capital | Total |
|---|---|---|---|
| 2018 | 354,384 | — | 354,384 |
| 2018 | 3,898,223 | — | 3,898,223 |
| 2017 | N/A | 4,964 | 4,964 |
| Total | 4,252,607 | 4,964 | 4,257,571 |

(3) The Company did not report any deposits as admitted assets under Internal Revenue Code Section 6603 at December 31, 2018 and 2017.

F.

(1) At December 31, 2018, the Company's Federal Income Tax Return was consolidated with the following entities:

| | |
|---|---|
| Aetna Inc. | CVS Health Corporation |
| @ Credentials Inc. | Accendo Insurance Company |
| Accordant Common, LLC | Accordant Health Services, LLC |
| Accuscript MO, Inc. | ACS Acqco Corp. |
| Active Health Management, Inc. | Adminco, Inc. |
| Administrative Enterprises, Inc. | Advanced Care Scripts, Inc. |
| Advanced Healthcare Distributors, LLC | AdvancePCS Specialty Rx, LLC |
| ADVANCERX.COM, LLC | Aetna Asset Advisors, LLC |
| Aetna Behavioral Health, LLC | Aetna Better Health Inc. (Georgia) |
| Aetna Better Health Inc. (IL) | Aetna Better Health Inc. (NJ) |
| Aetna Better Health Inc. (NY) | Aetna Better Health Inc. (OH) |
| Aetna Better Health Inc. (Tennessee) | Aetna Better Health of California, Inc. |
| Aetna Better Health of Iowa, Inc. | Aetna Better Health of Kansas Inc. |
| Aetna Better Health of Kentucky Insurance Co. | Aetna Better Health of Michigan, Inc. |
| Aetna Better Health of Missouri LLC | Aetna Better Health of Nevada Inc. |

Aetna Better Health of North Carolina, Inc.
Aetna Better Health of Texas, Inc.
Aetna Better Health, Inc. (Connecticut)
Aetna Better Health, Inc. (PA)
Aetna Card Solutions, LLC
Aetna Dental Inc. (Texas)
Aetna Financial Holdings, LLC
Aetna Health Holdings, LLC
Aetna Health Inc. (Florida)
Aetna Health Inc. (LA)
Aetna Health Inc. (Michigan)
Aetna Health Inc. (NY)
Aetna Health Inc. (Texas)
Aetna Health Insurance Company of New York
Aetna Health of California Inc.
Aetna Health of Utah, Inc.
Aetna Integrated Informatics, Inc.
Aetna Ireland Inc.
Aetna Medicaid Administrators LLC
Aetna Pharmacy Management Services, LLC
Aetna Rx Home Delivery, LLC
Aetna Student Health Agency, Inc.
Alabama CVS Pharmacy, LLC
Alaska CVS Pharmacy, LLC
AMC - New York, Inc.
American Drug Stores Delaware, LLC
Apria Finance Holdings, Inc.
APS-Summit Care Pharmacy, LLC
Arkansas CVS Pharmacy, LLC
ASCO HealthCare, LLC
AUSHC Holdings, Inc. (CT)
Badger Acquisition of Kentucky, LLC
Badger Acquisition of Ohio, LLC
Best Care LTC Acquisition Company, LLC
BPNY Acquisition Corp
bswift, LLC
Campo's Medical Pharmacy, Inc.
Care4, LP
Carecenter Pharmacy, LLC
Caremark Arizona Specialty Pharmacy Holding, LLC
Caremark California Specialty Pharmacy Holding, LLC
Caremark Dallas Pharmacy, LLC
Caremark Hawaii Mail Pharmacy, LLC
Caremark Irving Resource Center Holding, LLC
Caremark Ohio Specialty Pharmacy Holding, LLC
Caremark PA Specialty Pharmacy Holding, LLC
Caremark Pennsylvania Specialty Pharmacy, LLC
Caremark Puerto Rico Holding, LLC
Caremark Puerto Rico Specialty Pharmacy, LLC
Caremark Redlands Pharmacy, LLC
Caremark Texas Mail Pharmacy Holding, LLC
Caremark Ulysses Holding Corp.
CaremarkPCS Alabama Mail Pharmacy Holding, LLC
CaremarkPCS Health, LLC
CaremarkPCS Pennsylvania Mail Pharmacy, LLC
CCRx Holdings, LLC
CCRx of North Carolina, LLC
Choice Source Therapeutic Of Houston, Texas, LLC
CHP Acquisition Corp.
Claims Administration Corporation
Compass Health Services, LLC
Connecticut CVS Pharmacy, LLC
Coram Alternate Site Services, Inc.
Aetna Better Health of Oklahoma Inc.
Aetna Better Health of Washington, Inc.
Aetna Better Health, Inc. (LA)
Aetna Capital Management, LLC
Aetna Dental Inc. (New Jersey)
Aetna Dental of California, Inc.
Aetna Florida, Inc.
Aetna Health Inc. (Connecticut)
Aetna Health Inc. (Georgia)
Aetna Health Inc. (Maine)
Aetna Health Inc. (New Jersey)
Aetna Health Inc. (Pennsylvania)
Aetna Health Insurance Company
Aetna Health Management, LLC
Aetna Health of Iowa, Inc
Aetna HealthAssurance Pennsylvania, Inc.
Aetna International Inc.
Aetna Life & Casualty (Bermuda) Limited
Aetna Network Services LLC
Aetna Risk Assurance Company of Connecticut
Aetna Specialty Pharmacy, LLC
Aetna Workers' Comp Access, LLC
Alajasper Realty Services, LLC
Allviant Corporation
AMC - Tennessee, Inc.
American Health Holding, Inc.
APS Acquisition LLC
Arizona CVS Stores, LLC
ASCO Healthcare of New England Limited Partnership
ASI Wings, LLC
Badger Acquisition LLC
Badger Acquisition of Minnesota, LLC
Baumel Eisner Neuromedical Institute, LLC
Bluegrass Pharmacy of Lexington, LLC
Bruin Acquisition Co., Inc.
Busse CVS, LLC #3110
Care Pharmaceutical Services, LP
Carecenter Pharmacy, LLC
Carefree Insurance Services, Inc.
Caremark Arizona Specialty Pharmacy, LLC
Caremark California Specialty Pharmacy, LLC
Caremark Hawaii Mail Pharmacy Holding, LLC
Caremark Illinois Mail Pharmacy Holding, LLC
Caremark Irving Resource Center, LLC
Caremark Ohio Specialty Pharmacy, LLC
Caremark PCS, LLC
Caremark PHC, LLC
Caremark Puerto Rico Specialty Pharmacy Holding, LLC
Caremark Puerto Rico, LLC
Caremark Rx, LLC
Caremark Texas Mail Pharmacy, LLC
Caremark, LLC
CaremarkPCS Alabama Mail Pharmacy, LLC
CaremarkPCS Pennsylvania Mail Pharmacy Holding, LLC
CC Advertising & Marketing, LLC
CCRx of North Carolina Holdings, LLC
Central Rx Services, LLC
Choice Source, LLC
Circle Tallahassee Re, LLC
Cofinity, Inc.
CompScript, LLC
Continuing Care RX, LLC
Coram Clinical Trials, Inc.

Coram Healthcare Corporation of Alabama
Coram Healthcare Corporation Of Florida
Coram Healthcare Corporation Of Greater D.C.
Coram Healthcare Corporation of Greater New York
Coram Healthcare Corporation of Indiana
Coram Healthcare Corporation of Massachusetts
Coram Healthcare Corporation of Mississippi
Coram Healthcare Corporation of Nevada
Coram Healthcare Corporation of North Texas
Coram Healthcare Corporation of Northern California
Coram Healthcare Corporation of Southern California
Coram Healthcare Corporation Of Southern Florida
Coram Healthcare Corporation of Utah
Coram LLC
Coram Specialty Infusion Services, LLC
CoramRX, LLC
Corporate Benefit Strategies, Inc.
Coventry Consumer Advantage, Inc.
Coventry Health and Life Insurance Company
Coventry Health Care National Accounts, Inc.
Coventry Health Care National Network, Inc.
Coventry Health Care of Florida, Inc.
Coventry Health Care of Illinois, Inc.
Coventry Health Care of Kansas, Inc.
Coventry Health Care of Missouri, Inc.
Coventry Health Care of Nebraska, Inc.
Coventry Health Care of Virginia, Inc.
Coventry Health Care of West Virginia, Inc.
Coventry Health Care Workers Compensation, Inc.
Coventry Health Plan of Florida, Inc.
Coventry HealthCare Management Corporation
Coventry Prescription Management Services, Inc.
Coventry Rehabilitation Services, Inc.
Coventry Transplant Network, Inc.
CP Acquisition Corp.
CP Services LLC
CSR, Inc.
CVS 1001 MA, LLC
CVS 10015 MA, LLC
CVS 10019 AR, LLC
CVS 10024 VA, LLC
CVS 10049 KY, LLC
CVS 10078 FL, LLC
CVS 10099 DE, LLC
CVS 10117 VA, LLC
CVS 10125 MA, LLC
CVS 10154 GA, LLC
CVS 10170 VA, LLC
CVS 10175 OK, LLC
CVS 10196 MA, LLC
CVS 10201 MN, LLC
CVS 10206 AL, LLC
CVS 10208 AL, LLC
CVS 10238 DE, LLC
CVS 10242 NE, LLC
CVS 10251 VA, LLC
CVS 10273 OK, LLC
CVS 10275 OK, LLC
CVS 10279 KY, LLC
CVS 10286 VA, LLC
CVS 10320 VA, LLC
CVS 10326 OK, LLC
CVS 10346 FL, LLC
CVS 10374 OH, LLC
CVS 10376 DE, LLC
CVS 10396 MN, LLC
CVS 1041 MA, LLC
CVS 10410 NE, LLC
CVS 10419 WI, LLC
CVS 10422 VA, LLC
CVS 10430 AR, LLC
CVS 10432 AR, LLC
CVS 10453 VA, LLC
CVS 10454 VA, LLC
CVS 10501 MA, LLC
CVS 10504 FL, LLC
CVS 10515 TN, LLC
CVS 10518 AR, LLC
CVS 10533 WI, LLC
CVS 10534 AR, LLC
CVS 10539 AR, LLC
CVS 10560 OK, LLC
CVS 10563 VA, LLC
CVS 10586 VA, LLC
CVS 10589 GA, LLC
CVS 10644 FL, LLC
CVS 10666 AR, LLC
CVS 10683 KY, LLC
CVS 10684 VA, LLC
CVS 10746 VA, LLC
CVS 10756 MN, LLC
CVS 10768 VA, LLC
CVS 10770 VA, LLC
CVS 10779 AR, LLC
CVS 10781 CO, LLC
CVS 10782 CO, LLC
CVS 10783 CO, LLC
CVS 10784 CO, LLC
CVS 10785 CO, LLC
CVS 10787 SC, LLC
CVS 10788 KY, LLC
CVS 1079 GA, LLC
CVS 10811 AL, LLC
CVS 10812 KY, LLC
CVS 10816 AR, LLC
CVS 10830 CO, LLC
CVS 10831 CO, LLC
CVS 10836 MA, LLC
CVS 10893 OH, LLC
CVS 10898 AL, LLC
CVS 10937 VA, LLC
CVS 10949 TN, LLC
CVS 10958 CO, LLC
CVS 10967 VA, LLC
CVS 10968 VA, LLC
CVS 10975 AR, LLC
CVS 10976 OK, LLC
CVS 10990 VA, LLC
CVS 10992 VA, LLC
CVS 11000 CO, LLC
CVS 11001 CO, LLC
CVS 11002 CO, LLC
CVS 11016 AL, LLC
CVS 11017 GA, LLC
CVS 11019 KY, LLC
CVS 11024 CO, LLC

CVS 11056 VA, LLC
CVS 11083 VA, LLC
CVS 11089 KY, LLC
CVS 11093 AR, LLC
CVS 11105 CO, LLC
CVS 11155 OH, LLC
CVS 11179 VA, LLC
CVS 1126 FL, LLC
CVS 11337 CO, LLC
CVS 1200 SC, LLC
CVS 1420 GA, LLC
CVS 1435 MD, LLC
CVS 1461 MD, LLC
CVS 1538 VA, LLC
CVS 1556 VA, LLC
CVS 1589 MI, LLC
CVS 180 SC, LLC
CVS 2003 VA, LLC
CVS 2019 VA, LLC
CVS 2065 RI, LLC
CVS 2545 CT, LLC
CVS 2747 FL, LLC
CVS 2829 FL, LLC
CVS 301 MA, LLC
CVS 3121 FL, LLC
CVS 3227 FL, LLC
CVS 3250 FL, LLC
CVS 326 RI, LLC
CVS 3269 FL, LLC
CVS 3301 OH, LLC
CVS 3320 OH, LLC
CVS 3353 OH, LLC
CVS 3380 SC, LLC
CVS 3416 OH, LLC
CVS 3432 OH, LLC
CVS 3460 VA, LLC
CVS 3471 OH, LLC
CVS 3558 NV, LLC
CVS 3625 AZ, LLC
CVS 373 MA, LLC
CVS 3749 AZ, LLC
CVS 3818 FL, LLC
CVS 3833 NC, LLC
CVS 3965 AZ, LLC
CVS 397 RI, LLC
CVS 3987 NC, LLC
CVS 4015 FL, LLC
CVS 4073 MA, LLC
CVS 4110 TN, LLC
CVS 4225 MD, LLC
CVS 433 MA, LLC
CVS 4380 WI, LLC
CVS 4480 FL, LLC
CVS 449 MA, LLC
CVS 4523 SC, LLC
CVS 4536 MS, LLC
CVS 4639 FL, LLC
CVS 4672 GA, LLC
CVS 4738 FL, LLC (f/k/a CVS 75462 FL, LLC)
CVS 4795 AZ, LLC
CVS 4840 AL, LLC
CVS 4896 OK, LLC
CVS 4905 AL, LLC
CVS 11070 MN, LLC
CVS 11086 OH, LLC
CVS 11092 OK, LLC
CVS 11104 CO, LLC
CVS 11115 VA, LLC
CVS 11158 AR, LLC
CVS 11233 VA, LLC
CVS 1131 MA, LLC
CVS 1194 SC, LLC
CVS 1383 VA, LLC
CVS 1427, LLC
CVS 1452 MD, LLC
CVS 1525 VA, LLC
CVS 1547 VA, LLC
CVS 1561 VA, LLC
CVS 1743 AZ, LLC
CVS 1803 MA, LLC
CVS 2004 VA, LLC
CVS 2048 RI, LLC
CVS 2212 GA, LLC
CVS 264 NJ, LLC
CVS 2776 VA, LLC
CVS 2948 Henderson, LLC #2948
CVS 3042 DE, LLC
CVS 3186 WV, LLC
CVS 3232 NC, LLC
CVS 3257 FL, LLC
CVS 3268 Gilbert, LLC #3268
CVS 3271 FL, LLC
CVS 3318 FL, LLC
CVS 3343 OH, LLC
CVS 3356 OH, LLC
CVS 3407 OH, LLC
CVS 3418 FL, LLC
CVS 3452 OH, LLC
CVS 3468 OH, LLC
CVS 3537 SC, LLC
CVS 3563 NC, LLC
CVS 3667 FL, LLC
CVS 3745 Peoria, LLC #3745
CVS 3805 SC, LLC
CVS 3831 NC, LLC
CVS 3923 FL, LLC
CVS 3967 AZ, LLC
CVS 3973 NC, LLC
CVS 3988 NC, LLC
CVS 4016 MA, LLC
CVS 410 FL, LLC
CVS 4153 SC, LLC
CVS 4300 OH, LLC
CVS 4331 OH, LLC
CVS 4419 WV, LLC
CVS 4485 FL, LLC
CVS 4519 MS, LLC
CVS 4533 TN, LLC
CVS 4544 RI, LLC (f/k/a CVS 75566 RI, LLC)
CVS 4669 GA, LLC
CVS 4695 GA, LLC
CVS 4769 SC, LLC
CVS 4832 AL, LLC
CVS 4853 AL, LLC
CVS 4900 AL, LLC
CVS 4944 AL, LLC

CVS 4976 AL, LLC
CVS 4981 MA, LLC
CVS 4993 MS, LLC
CVS 5018 TN, LLC
CVS 5021 VA, LLC
CVS 5029 AZ, LLC
CVS 5089 NY, LLC
CVS 5111 FL, LLC
CVS 5112 FL, LLC
CVS 5113 NV, LLC
CVS 5131 AZ, LLC
CVS 516 VA, LLC
CVS 5165 FL, LLC
CVS 5168 MS, LLC
CVS 5180 FL, LLC
CVS 5271 KS, LLC
CVS 5282 LA, LLC
CVS 5354 LA, LLC
CVS 5374 LA, LLC
CVS 5375 FL, LLC
CVS 5382 IL, LLC
CVS 5419 SC, LLC
CVS 5432 LA, LLC
CVS 5448 FL, LLC
CVS 5467 VA, LLC
CVS 5469 LA, LLC
CVS 5492 MN, LLC
CVS 5523 GA, LLC
CVS 5537 NC, LLC
CVS 5542 SC, LLC
CVS 5545 NC, LLC
CVS 5552 SC, LLC
CVS 5568 NC, LLC
CVS 5577 NC, LLC
CVS 5585 NC, LLC
CVS 5589 FL, LLC
CVS 5595 NC, LLC
CVS 5616 MN, LLC
CVS 5622 GA, LLC
CVS 5625 MO, LLC
CVS 5680 GA, LLC
CVS 5683 GA, LLC
CVS 5740 MS, LLC
CVS 5779 AZ, LLC
CVS 5783 IL, LLC
CVS 5791 AZ, LLC
CVS 5793 AZ, LLC
CVS 5801 MS, LLC
CVS 5812 AZ, LLC
CVS 5815 FL, LLC
CVS 5816 FL, LLC
CVS 582 MA, LLC
CVS 5828 CA, LLC
CVS 5829 IL, LLC
CVS 5849 AZ, LLC
CVS 5850 MS, LLC
CVS 5851 IL, LLC
CVS 5856 MA, LLC
CVS 5890 AZ, LLC
CVS 5891 AZ, LLC
CVS 5892 AZ, LLC
CVS 5893 AZ, LLC
CVS 590 RI, LLC
CVS 5931 AZ, LLC
CVS 5934 AZ, LLC
CVS 6009 OK, LLC
CVS 6012 GA, LLC
CVS 6073 NJ, LLC
CVS 6089 OH, LLC
CVS 6116 KY, LLC
CVS 612 MA, LLC
CVS 6135 NJ, LLC
CVS 6142 OK, LLC
CVS 6201 MN, LLC
CVS 6233 OK, LLC
CVS 6304 TN, LLC
CVS 6305 WV, LLC
CVS 6306 WV, LLC
CVS 6342 KY, LLC
CVS 6349 OH, LLC
CVS 6363 TN, LLC
CVS 6384 KY, LLC
CVS 6395 TN, LLC
CVS 6413 TN, LLC
CVS 6423, LLC
CVS 6429 TN, LLC
CVS 6572 IN. II, LLC
CVS 6572 IN., LLC
CVS 6796 MA, LLC
CVS 6852 VA, LLC
CVS 6867 NV, LLC
CVS 6869 DE, LLC
CVS 6874 IN, LLC
CVS 6941 KY, LLC
CVS 6972 FL, LLC
CVS 7036, LLC
CVS 7047, LLC
CVS 7057 NC, LLC
CVS 7070 MS, LLC
CVS 709 FL, LLC
CVS 7109 MA, LLC
CVS 7133 FL, LLC
CVS 7148 NC, LLC
CVS 7157 NC, LLC
CVS 7173 FL, LLC
CVS 7180 AL, LLC
CVS 7200, LLC
CVS 7215 AL, LLC
CVS 7382 NC, LLC
CVS 75024 AL, LLC
CVS 75121 SC, LLC
CVS 75124 MI, LLC
CVS 75129 FL, LLC
CVS 75137 MD, LLC
CVS 75139 NJ, LLC
CVS 75144 RI, LLC
CVS 75151 OH, LLC
CVS 75156 NV, LLC
CVS 75157 MI, LLC
CVS 75160 SC, LLC
CVS 75161 AZ, LLC
CVS 75162 AZ, LLC
CVS 75163 GA, LLC
CVS 75165 GA, LLC
CVS 7519 MN, LLC
CVS 75195 FL, LLC

CVS 75235 RI, LLC
CVS 75249 FL, LLC
CVS 75257 NJ, LLC
CVS 75269 MI, LLC
CVS 75275 TN, LLC
CVS 75280 NC, LLC
CVS 75294 FL, LLC
CVS 75307 KS, LLC
CVS 75312 VA, LLC
CVS 75334 FL, LLC
CVS 75363 GA, LLC
CVS 75365 GA, LLC
CVS 75374 NJ, LLC
CVS 75377 NC, LLC
CVS 75380 GA, LLC
CVS 75393 DE, LLC
CVS 75408 FL, LLC
CVS 75416 KY, LLC
CVS 75441 GA, LLC
CVS 75444 NV, LLC
CVS 75461 AL, LLC
CVS 75485 NC, LLC
CVS 75486 KS, LLC
CVS 75503 GA, LLC
CVS 75536 GA, LLC
CVS 75558 FL, LLC
CVS 75560 NJ, LLC
CVS 75561 NJ, LLC
CVS 75562 VA, LLC
CVS 75563 MD, LLC
CVS 75569 GA, LLC
CVS 75572 NC, LLC
CVS 75583 MA, LLC
CVS 75584 MA, LLC
CVS 75590 MN, LLC
CVS 75615 FL, LLC
CVS 75619 NJ, LLC
CVS 75626 GA, LLC
CVS 75636 NV, LLC
CVS 75642 VA, LLC
CVS 75651 SC, LLC
CVS 75659 OK, LLC
CVS 75660 OK, LLC
CVS 75669 MA, LLC
CVS 75676 KY, LLC
CVS 75679 SC, LLC
CVS 75707 FL, LLC
CVS 75718 OH, LLC
CVS 75719 MN, LLC
CVS 75733 NV, LLC
CVS 75738 RI, LLC
CVS 75740 NJ, LLC
CVS 75743 NJ, LLC
CVS 75770 NC, LLC
CVS 75771 NC, LLC
CVS 75774 MA, LLC
CVS 75795 DE, LLC
CVS 75799 NJ, LLC
CVS 75849 NC, LLC
CVS 75896 MA, LLC
CVS 75905 NJ, LLC
CVS 75924 FL, LLC
CVS 75935 NV, LLC
CVS 75946 VA, LLC
CVS 75947 GA, LLC
CVS 75952 WI, LLC
CVS 75958 MN, LLC
CVS 75959 MN, LLC
CVS 75961 SC, LLC
CVS 75977 MN, LLC
CVS 75978 FL, LLC
CVS 75995 DE, LLC
CVS 7648 KY, LLC
CVS 770 FL, LLC
CVS 7701, LLC
CVS 7885 GA, LLC
CVS 7888 GA, LLC
CVS 8003 MI, LLC
CVS 8009 MI, LLC
CVS 8067 MI, LLC
CVS 8071 MI, LLC
CVS 8078 MI, LLC
CVS 8086 MI, LLC
CVS 8103 MI, LLC
CVS 8123 MI, LLC
CVS 8133 MI, LLC
CVS 8165 MI, LLC
CVS 8207 MI, LLC
CVS 8281 MD, LLC
CVS 8302 MI, LLC
CVS 8303 TN, LLC
CVS 8415 NE, LLC
CVS 8549 MI, LLC
CVS 8615 NE, LLC
CVS 866 FL, LLC
CVS 8774 WI, LLC
CVS 8776 WI, LLC
CVS 8909 NC, LLC
CVS 8956 MS, LLC
CVS 8975 SC, LLC
CVS 8993 MS, LLC
CVS 920 MA, LLC
CVS 921 IL, LLC
CVS 932 FL, LLC
CVS 962 GA, LLC
CVS 9674 CA, LLC
CVS 976 FL, LLC
CVS AL Distribution, LLC
CVS ALBANY, LLC
CVS AOC Services, LLC
CVS ARCLIGHT, INC.
CVS Bay City 8207 MI, LLC
CVS Bellmore Avenue, LLC #2154
CVS Caremark Advanced Technology Pharmacy, LLC
CVS Caremark Indemnity Ltd.
CVS Caremark Part D Services, LLC
CVS Durham 7042, LLC
CVS EGL 5624 MO, LLC
CVS EGL 571 FL, LLC
CVS EGL 7958 FL, LLC
CVS ETB Holding Company, LLC
CVS Falmouth KY, LLC
CVS Foreign, Inc. #9736
CVS Gilbert 3272, LLC #3272
CVS Grand Bay 4782, LLC
CVS Greensboro, LLC

CVS Indiana, LLC #0877
CVS Lagrange 4540, LLC
CVS Manchester NH, LLC #0200
CVS Montgomery 6094, LLC
CVS Orlando FL Distribution, LLC
CVS Pharmacy Inc.
CVS PR Center, Inc.
CVS RCI, LLC
CVS Rx Services, Inc. #0886
CVS SC Distribution, LLC
CVS State Capital, LLC #0800
CVS Transportation, LLC
CVS Vero FL Distribution, LLC
CVS Weymouth 1853, LLC
D&R Pharmaceutical Services, LLC
Delaware CVS Pharmacy, LLC
DG Danville KY, LLC
Digital Enterprise Realty, LLC
E.T.B., INC.
Eckerd Corporation Of FL, Inc.
Enloe Drugs, LLC
Escalante Solutions, Llc
Evergreen Pharmaceutical, LLC
First Health Group Corp.
First Script Network Services, Inc.
FOCUS Healthcare Management, Inc.
Generation Health, LLC
Geneva Woods LTC Pharmacy, LLC
Geneva Woods Pharmacy Alaska, LLC
Geneva Woods Pharmacy Wyoming, LLC
Geneva Woods Retail Pharmacy, LLC
German Dobson CVS, LLC #5038
Grand St. Paul CVS, LLC
Group Dental Service of Maryland, Inc.
HCP Acquisition Sub, LLC
Health Data & Managment Solutions, Inc.
Healthagen LLC
Highland Park CVS, LLC
Home Care Pharmacy, LLC
Hook-Superx, LLC
Idaho CVS Pharmacy, LLC
Interlock Pharmacy Systems, LLC
Ironbound CVS Urban Renewal, LLC
JEC Funding, Inc.
Kansas CVS Pharmacy, LLC
Langsam Health Services, LLC
LHS Acquisition Sub, LLC
Lo-Med Prescription Services, LLC
Longs Drug Stores, LLC
Managed Care Coordinators, Inc.
Martin Health Services, Inc.
Massachusetts CVS Pharmacy, Inc.
Medical Arts Health Care, Inc.
Member Health, LLC
Mental Health Network of New York IPA, Inc.
Merwin IV & Specialty Pharmacy, LLC
Merwin Rx-Compounding Pharmacy, LLC
MHHP Acquisition Company, LLC
MHNet of Florida, Inc.
Minuteclinic Diagnostic Of Alabama, LLC
Minuteclinic Diagnostic Of Florida, LLC
Minuteclinic Diagnostic Of Hawaii, LLC
Minuteclinic Diagnostic Of Kentucky, LLC
CVS International, LLC
CVS Logan 3454, LLC
CVS Michigan, LLC #9415
CVS NV Holding Company, LLC
CVS PA Distribution, LLC
CVS PR Center Inc.
CVS PR Holding Company, LLC
CVS RS Arizona, LLC
CVS Safir Sourcing, LLC
CVS SP 5897 FL, LLC
CVS TN Distribution, LLC
CVS TX Holding Company, LLC
CVS Washington 6448, LLC
CVS WWRE, INC.
D.A.W., LLC
Delaware Physicians Care, Inc.
Digital EHealth, LLC
District Of Columbia CVS Pharmacy, LLC
Echo Merger Sub, Inc
Employee Assistance Services, LLC
Enterprise Safety Organization, LLC
Evergreen Pharmaceutical of California, Inc.
Express Pharmacy Services of PA, LLC
First Health Life and Health Insurance Company
Florida Health Plan Administrators, LLC
Garfield Beach CVS, LLC
Geneva Woods Health Services, LLC
Geneva Woods Management, LLC
Geneva Woods Pharmacy Washington, LLC
Geneva Woods Pharmacy, Inc.
Georgia CVS Pharmacy, LLC
Goodyear CVS, LLC #3749
Grandview Pharmacy, LLC
Group Dental Service, Inc.
Health and Human Resource Center, Inc.
Health Re, Inc.
HealthAssurance Pennsylvania, Inc.
Holiday CVS, LLC
Home Pharmacy Services, LLC
Horizon Behavioral Services, LLC
Institutional Health Care Services, LLC
Iowa CVS Pharmacy, LLC
iTriage, LLC
JHC Acquisition, LLC
Kentucky CVS Pharmacy, LLC
LCPS Acquisition, LLC
Lobos Acquisition, LLC
Longs Drug Stores California, LLC
Louisiana CVS Pharmacy, LLC
Managed Healthcare, Inc.
Maryland CVS Pharmacy, LLC
Med World Acquisition Corp.
Melville Realty Co., Inc.
Mental Health Associates, Inc.
Meritain Health, Inc.
Merwin Long Term Care, Inc.
MetraComp, Inc.
MHNet Life and Health Insurance Company
MHNet Specialty Services LLC
Minuteclinic Diagnostic Of Arizona, LLC
Minuteclinic Diagnostic Of Georgia, LLC
Minuteclinic Diagnostic Of Illinois, LLC
Minuteclinic Diagnostic Of Louisiana, LLC

Minuteclinic Diagnostic Of Maine, LLC
Minuteclinic Diagnostic Of Massachusetts, LLC
Minuteclinic Diagnostic Of New Hampshire, LLC
Minuteclinic Diagnostic Of Ohio, LLC
Minuteclinic Diagnostic Of Oregon, LLC
Minuteclinic Diagnostic Of Rhode Island, LLC
Minuteclinic Diagnostic Of Texas, LLC
Minuteclinic Diagnostic Of Virginia, LLC
Minuteclinic Diagnostic Of Wisconsin, LLC
Minuteclinic Telehealth Services, LLC
Mississippi CVS Pharmacy, LLC
Montana CVS Pharmacy, LLC
NCS Healthcare of Illinois, LLC
NCS Healthcare of Iowa, LLC
NCS Healthcare of Kentucky, Inc.
NCS Healthcare of New Hampshire, Inc.
NCS Healthcare of Ohio, LLC
NCS Healthcare of Tennessee, Inc.
NCS Healthcare, LLC
Nebraska CVS Pharmacy, LLC
NeighborCare of Indiana, LLC
NeighborCare of Virginia, LLC
NeighborCare Pharmacy of Virginia, LLC
NeighborCare Services Corporation
Nevada CVS Pharmacy, LLC
NH Acquisition Sub, LLC
NIV Acquisition, LLC
North Shore Pharmacy Services LLC
NS Acquisition Sub, LLC
Ocean Acquisition Sub, LLC
OCR-RA Acquisition, LLC
Oklahoma CVS Pharmacy, LLC
Omnicare ESC LLC
Omnicare Headquarters LLC
Omnicare Indiana Partnership Holding Company LLC
Omnicare of New York, LLC
Omnicare Pharmacies of Pennsylvania West LLC
Omnicare Pharmacy and Supply Services LLC
Omnicare Pharmacy of Maine LLC
Omnicare Pharmacy of North Carolina, LLC
Omnicare Pharmacy of Tennessee, LLC
Omnicare Pharmacy of Texas 2, LP
Omnicare Property Management, LLC
OPGP Acquisition Sub, LLC
Oregon CVS Pharmacy, LLC
PayFlex Holdings, Inc.
Pennsylvania CVS Pharmacy, LLC
Performax, Inc.
Pharmacare Pharmacy, LLC
Pharmacy Associates of Glens Falls, Inc.
Pharmacy Holding #1, LLC
PharmaSource Healthcare, Inc.
Pharmed Holdings, Inc.
Phoenix Data Solutions LLC
PP Acquisition Company, LLC
PrimeNet, Inc.
Procare 4268 Yankee, LLC
Procare Pharmacy, LLC
Professional Pharmacy Services, Inc.
PSI Arkansas Acquisition, LLC
Red Oak Sourcing, LLC
Retrac, Inc. #107
Richmond Heights Acquisition Corp.
Minuteclinic Diagnostic Of Maryland, LLC
Minuteclinic Diagnostic Of Nebraska, LLC
Minuteclinic Diagnostic Of New Mexico, LLC
Minuteclinic Diagnostic Of Oklahoma, LLC
Minuteclinic Diagnostic Of Pennsylvania, LLC
Minuteclinic Diagnostic Of South Carolina, LLC
Minuteclinic Diagnostic Of Utah, LLC
Minuteclinic Diagnostic Of Washington, LLC
Minuteclinic Online Diagnostic Services, LLC
Minuteclinic, LLC
Missouri CVS Pharmacy, LLC
Mountain Grove Investment Group LLC
NCS Healthcare of Indiana LLC
NCS Healthcare of Kansas, LLC
NCS Healthcare of Montana, Inc.
NCS Healthcare of New Mexico, Inc.
NCS Healthcare of South Carolina, Inc.
NCS Healthcare of Wisconsin, LLC
NCSH Acquisition Sub, LLC
NeighborCare Holdings, Inc.
NeighborCare of New Hampshire, LLC
NeighborCare Pharmacies, LLC
NeighborCare Pharmacy Services, Inc.
NeighborCare, Inc.
New Jersey CVS Pharmacy, LLC
Niagara Re, Inc.
North Carolina CVS Pharmacy, LLC
Novologix, LLC
NSPS Acquisition Sub, LLC
OCR Services Corporation
Ohio CVS Stores, LLC
Omnicare Distribution Center LLC
Omnicare Foundation
Omnicare Holding Company
Omnicare of Nevada, LLC
Omnicare Pharmacies of Pennsylvania East LLC
Omnicare Pharmacies of the Great Plains Holding Company
Omnicare Pharmacy of Florida, LP
Omnicare Pharmacy of Nebraska, LLC
Omnicare Pharmacy of Pueblo, LLC
Omnicare Pharmacy of Texas 1, LP
Omnicare Pharmacy of the Midwest, LLC
Omnicare, Inc.
OPM Acquisition Sub, LLC
Part D Holding Co., LLC
PayFlex Systems USA, Inc.
Pennsylvania Life Insurance Company
Pharmacare Holding Company
Pharmacare Specialty Healthcare Distributors, LLC
Pharmacy Consultants, LLC
Pharmacy Holding #2, LLC
Pharm-Corp of Maine LLC
Pharmore, Inc.
PMRP Acquisition Company, LLC
Precision Benefit Services, Inc.
PRN Pharmaceutical Services, LP
Procare Pharmacy Direct, LLC
Prodigy Health Group, Inc.
Professional Risk Management, Inc.
Puerto Rico CVS Pharmacy, LLC
Resources for Living, LLC
Rhode Island CVS Pharmacy, LLC
Roeschen's Healthcare LLC

| | |
|---|---|
| Rx Innovations 4439, LLC | RxAMERICA, LLC |
| RXC Acquisition Company | Schaller Anderson Medical Administrators Inc |
| Scrip World, LLC | Sheffield Avenue CVS, LLC #3690 |
| Shore Pharmaceutical Providers, LLC | Silverscript Insurance Company |
| Sky Acquisition LLC | South Carolina CVS Pharmacy, LLC |
| South Wabash CVS, LLC #3674 | Specialized Pharmacy Services, LLC |
| Specialty Services Holding LLC | Speedwell CVS Urban Renewal, LLC |
| Sterling Healthcare Services, Inc. | Strategic Resource Company |
| Suburban Medical Services, LLC | Superior Care Pharmacy, Inc. |
| T2 Medical, Inc. | TCPI Acquistion Corp. |
| Tennessee CVs Pharmacy, LLC | The Vasquez Group, Inc. |
| Thomas Phoenix CVS, LLC #3625 | Three Forks Apothecary, LLC |
| Thundermist Services, LLC | U.S. Health Care Properties, Inc. |
| UAC Holding, Inc. | UC Acquisition Corp. |
| Uni-Care Health Services of Maine, Inc. | Utah CVS Pharmacy, LLC |
| Value Health Care Services LLC | VAPS Acquisition Company, LLC |
| Vermont CVS Pharmacy, LLC | VHCS Acquisition Sub, LLC |
| Virginia CVS Pharmacy, LLC | Warm Springs Road CVS, LLC #2928 |
| Washington CVS Pharmacy, LLC | Washington Lamb CVS, LLC #3172 |
| Weber Medical Systems LLC | Wellpartner, LLC |
| West Virginia CVS Pharmacy, LLC | Westhaven Services Co, LLC |
| Williamson Drug Company, Incorporated | Wisconsin CVS Pharmacy, LLC |
| Woodruff Realty Associates, LLC #2085 | Woodward Detroit CVS, LLC |
| Work & Family Benefits, Inc. | WP Smart Holdings, LLC |
| ZS Acquisition Company, LLC | 976 Miami RE, LLC |

(2) As explained in Note 1, the Company participates in a tax sharing agreement with its parent and affiliates.

G. The Company does not have any tax loss contingencies for which it is reasonably possible that the total liability will significantly increase within twelve months of the reporting date.

10. Information Concerning Parent, Subsidiaries, Affiliates, and Other Related Parties

A., B. and C.

The Company did not pay any dividends in 2018 or 2017. The Company received $0 and $10,000,000 in capital contributions for 2018 or 2017, respectively.

D. Amounts due to and due from affiliates shown in the accompanying Statutory Statements of Assets and Liabilities, Capital and Surplus and Other Funds include the Company's net receipts and disbursements processed by affiliates and transactions related to its administrative services agreement with Aetna Health Management, LLC ("AHM"), indirectly a wholly-owned subsidiary of Aetna.

At December 31, 2018 and 2017, the Company had the following amounts due to and due from affiliates, which exclude amounts related to pharmacy rebate transactions as discussed more fully in Note 28 and the Company's reinsurance agreement:

| | December 31 | |
|---|---|---|
| | 2018 | 2017 |
| Amounts due to affiliates | | |
| Aetna Health Management | $8,179,489 | $8,704,060 |
| Aetna Medicaid Administrators, LLC | 4,517,996 | 2,836,716 |
| | $12,697,485 | $11,540,776 |

| | December 31 | |
|---|---|---|
| | 2018 | 2017 |
| Amounts due from affiliates | | |
| Aetna Health Management | $0 | $0 |
| Aetna Medicaid Administrators, LLC | 0 | 0 |
| | $0 | $0 |

The terms of settlement require that these amounts be settled within 45 days after the end of the calendar quarter.

E. At December 31, 2018, the Company has a guarantor agreement with Aetna. The agreement provides that in the event of the Company's insolvency, Aetna will pay all expenses and claims incurred by the Company during insolvency pursuant to the obligation with employer groups and subscribers until the end of the subscription contract period for which premiums have been received.

F. As of and for the years ended December 31, 2018 and 2017, the Company had the following significant transactions with affiliates:

Effective October 1, 2016, the Company entered into an Administrative Services Agreement with Aetna Medicaid Administrators LLC ("AMA"), whereby AMA has the expertise, trained personnel, knowledge, technical know-how, proprietary information and other resources and capability to develop, operate and market the Company's Medicaid business. The Company and AMA are parties to an administrative services agreement, under which AMA provides certain administrative services, including accounting and processing of premiums and claims. Under this agreement, the Company will remit a percentage of its earned premium revenue, as applicable, to AMA as a fee. For these services, the Company was charged $33,241,177 and $41,909,951 in 2018 and 2017, respectively. These agreements also provide for interest on all intercompany balances. Interest incurred on amounts due from affiliates was $0 in 2018 and $0 in 2018.

The Company is a party to an agreement which enables the Company to receive manufacturers' pharmacy rebates from AHM under which the Company remits a percentage of its earned pharmaceutical rebates to AHM as a fee. The Company earned pharmaceutical rebates of $9,463,118 and $7,489,958, which were recorded as a reduction of medical costs, in 2018 and 2017, respectively. The Company was charged $0 and $0, which were recorded as administrative expenses, for these services in 2018 and 2017, respectively. At December 31, 2018 and 2017, the Company reported $7,402,389.00 and $4,009,472, respectively, as amounts due from AHM related to the pharmaceutical rebates which were reflected in health care and other amounts receivable. The terms of settlement require that these amounts be settled within 45 days after the end of the calendar quarter.

The amounts reported on the Underwriting and Investment Exhibit, Part 3 represent the expenses incurred under the terms of the administrative agreement, allocated to the Company in accordance SSAP No. 70 - Allocation of Expenses ("SSAP No. 70"). SSAP No. 70 states "shared expenses, including expenses under the terms of a management contract, shall be apportioned to the entities incurring the expense as if the expense had been paid solely by the incurring entity. The apportionment shall be completed based upon specific identification to the entity incurring the expense. Where specific identification is not feasible, apportionment shall be based upon pertinent factors or ratios." The Company allocates these expenses based upon a percentage calculated using actual general and administrative expenses incurred by AHM and AMA.

As explained in Note 1, the Company participates in a tax sharing agreement with Aetna and Aetna's other subsidiaries. All federal income tax receivables/payables are due from/due to Aetna.

G. All outstanding shares of the Company are owned by Aetna Health Holdings, LLC, whose ultimate parent is CVS Health.

H. At December 31, 2018, the Company did not own shares of any upstream intermediate of CVS Health.

I. At December 31, 2018, the Company did not hold any investments in any subsidiary, controlled or affiliated ("SCA") entity that exceeded 10% of the Company's admitted assets.

J. At December 31, 2018, the Company did not hold any investments in any impaired SCA entity.

K. At December 31, 2018, the Company did not hold any investments in any foreign insurance subsidiaries.

L. At December 31, 2018, the Company did not hold any investments in a downstream noninsurance holding company.

M. At December 31, 2018, the Company did not have any SCA investments.

N. At December 31, 2018 , the Company did not have any investments in an insurance SCA

O. The Company did not have any SCA investments where the Company's share of losses in the SCA exceeds its investment in the SCA.

11. Debt

A. The Company did not have any items related to debt, including capital notes at December 31, 2018.

B. The Company did not have any Federal Home Loan Bank agreements at December 31, 2018.

12. Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans

The Company did not have a retirement plan, deferred compensation plan, or other postretirement benefit plan at December 31, 2018 or 2017.

13. Capital and Surplus, Shareholders' Dividend Restrictions and Quasi-Reorganizations

(1) The Company had $1,000 shares of common capital stock authorized, issued and outstanding with a par value of $0.01 per share at December 31, 2018 and 2017.

(2) The Company had no shares of preferred stock issued and outstanding at December 31, 2018 and 2017.

(3) Dividend Restrictions

The Company is subject to limitations, imposed by the State of Michigan, on the payment of dividends to its stockholders. Generally, dividends during any year may not be paid, without prior regulatory approval, in excess of the greatest of (1) 10% of the Company's statutory surplus as of the preceding December 31, or (2) the Company's statutory gain from operations before net realized capital gains on investments for the preceding year

(4) The Company paid dividends in the amount of $4,100,000 and $0 to its parent in 2018 and 2017. The Company received a capital contribution of $10,000,000 on December 21, 2017 and $0 in 2018.

(5) Within the limitations of 3) above, there are no other restrictions placed on the portion of the Company profits that may be paid as ordinary dividends to the stockholder.

(6) There were no restrictions placed on the Company's surplus, including for whom the surplus was being held at December 31, 2018 or 2017, except as noted in Note 21.

(7) Not applicable to the Company.

(8) The Company did not hold any stock for any special purposes at December 31, 2018 or 2017.

(9) Changes in the balances of special surplus funds from the prior year are due to the accrual of estimated ACA health insurer fees reclassified from unassigned funds or surplus to aggregate write-ins for special surplus funds as discussed more fully in Note 1.C and Note 22.

(10) At December 31, 2018 and 2017, there was $0 and $599, respectively, of unassigned funds that was represented or reduced by unrealized gains and losses.

(11) The Company has not issued any surplus notes or debentures or similar obligations at December 31, 2018 or 2017.

(12) The Company did not participate in any quasi-reorganizations during the statement year.

(13) The Company did not participate in any quasi-reorganizations in the past 10 years.

14. Liabilities, Contingencies and Assessments

A. The Company did not have any contingent commitments at December 31, 2018 or 2017.

B. Assessments

Guaranty Fund Assessments

Under guaranty fund laws existing in all states, insurers doing business in those states can be assessed (in most states up to prescribed limits) for certain obligations of insolvent insurance companies to policyholders and claimants. The life and health insurance guaranty associations in which CVS Health and certain of its affiliates, including the Company participate that operate under these laws respond to insolvencies of long-term care insurers as well as health insurers. The Company's assessments generally are based on a formula relating to the Company's health care premiums in the state compared to the premiums of other insurers. Certain states allow assessments to be recovered over time as offsets to premium taxes. Some states have similar laws relating to HMOs and/or other payers such as not-for-profit consumer-governed health plans established under Health Care Reform.

The Company had no assets recognized from paid and accrued premium tax offsets and policy surcharges at December 31, 2018 and 2017.

C. The Company did not have any gain contingencies at December 31, 2018 or 2017.

D. The Company did not have any claims related extra contractual obligation and bad faith losses stemming from lawsuits at December 31, 2018 or 2017.

E. The Company did not have any joint and several liability arrangements at December 31, 2018 or 2017.

F. Various liabilities arise in the normal course of the Company's business and have been recorded. In the opinion of management, any ultimate contingent losses will not have a material adverse effect on the Company's future results of operations and financial position. The Company, to the best of its knowledge, has no assets that it considers impaired that are not already recorded in the Company's books.

The Company has coverage for certain litigation exposures ($10,000,000 per claim and in the aggregate including defense costs) through an unaffiliated insurance company.

15. Leases

The Company did not have any material lease obligations at December 31, 2018 or 2017.

16. Information about Financial Instruments with Off-Balance Sheet Risk and Financial Instruments with Concentrations of Credit Risk

The Company did not have any financial instruments with off-balance sheet risk or financial instruments with concentrations of credit risk at December 31, 2018 or 2017.

17. Sale, Transfer and Servicing of Financial Assets and Extinguishments of Liabilities

A. Transfers of Receivables Reported as Sales

(1) The Company did not have any transfers of receivables as sales for the years ending December 31, 2018 and 2017.

B. Transfer and Servicing of Financial Assets

(1) The Company's policy for requiring collateral or other security for security lending transactions as required in SSAP No. 103R is discussed in Note 1. Excludes repurchase and reverse repurchase transactions as discussed in Notes 5.F. through 5.I. The Company did not have any loaned securities at December 31, 2018 2017.

(2) and (3)

The Company did not have any servicing assets or liabilities at December 31, 2018 or 2017.

(4) The Company did not have any securitized financial assets at December 31, 2018 or 2017.

(5) The Company did not have any transfers of financial assets accounted for as secured borrowing at December 31, 2018 or 2017.

(6) The Company did not have any transfers of receivables with recourse at December 31, 2018 or 2017.

(7) The Company did not have any dollar repurchase or reverse repurchase agreements at December 31, 2018 or 2017.

C. Wash Sales

(1) The Company did not have any wash sales for the years ending December 31, 2018 or 2017.

18. Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans

A. The Company did not serve as an Administrative Services Only for uninsured accident and health plans or the uninsured portion of partially insured plans for the period ended December 31, 2018.

B. The Company did not serve as an Administrative Services Contract (ASC) plan administrator for uninsured accident and health plans or the uninsured portion of partially insured plans for the period ended December 31, 2018.

C. At December 31, 2018 and 2017, the Company had reinsurance and low-income subsidy (cost sharing portion), receivables of $327,988 and $3,337,771. At December 31, 2018 and 2017, the Company had reinsurance and low-income subsidy (cost sharing portion) payable of $223,716 and $1,945,188. These amounts are accounted for as amounts receivable relating to uninsured plans on the Statutory Statements of Assets and liability for amounts held under uninsured plans on the Statutory Statement of Liabilities, Capital and Surplus as per SSAP No. 47 - *Uninsured Plans*. These items relate to the Company's Medicare product offerings.

19. Direct Premium Written/Produced by Managing General Agents/Third Party Administrators

The Company did not have any material direct premiums written through/produced by managing general agents or third party administrators for the years ended December 31, 2018 and 2017.

20. Fair Value Measurements

A. and B.

Certain of the Company's financial instruments are measured at fair value in the financial statements. The fair values of these instruments are based on valuations that include inputs that can be classified within one of three levels of a hierarchy established by U.S. generally accepted accounting principles. The following are the levels of the hierarchy and a brief description of the type of valuation information ("inputs") that qualifies a financial asset or liability for each level:

- **Level 1** – Unadjusted quoted prices for identical assets or liabilities in active markets.
- **Level 2** – Inputs other than Level 1 that are based on observable market data. These include: quoted prices for similar assets in active markets, quoted prices for identical assets in inactive markets, inputs that are observable that are not prices (such as interest rates and credit risks) and inputs that are derived from or corroborated by observable markets.
- **Level 3** – Developed from unobservable data, reflecting the Company's own assumptions.

Financial assets and liabilities are classified based upon the lowest level of input that is significant to the valuation. When quoted prices in active markets for identical assets and liabilities are available, the Company uses these quoted market prices to determine the fair value of financial assets and liabilities and classifies these assets and liabilities as Level 1. In other cases where a quoted market price for identical assets and liabilities in an active market is either not available or not observable, the Company estimates fair value using valuation methodologies based on available and observable market information or by using a matrix pricing model. These financial assets and liabilities would then be classified as Level 2. If quoted market prices are not available, the Company determines fair value using broker quotes or an internal analysis of each investment's financial performance and cash flow projections. Thus, financial assets and liabilities may be classified in Level 3 even though there may be some significant inputs that may be observable.

C. The carrying values and estimated fair values of the Company's financial instruments at December 31, 2018 and 2017 were as follows:

December 31, 2018

| Type of Financial Instrument | Aggregate Fair Value | Admitted Assets | (Level 1) | (Level 2) | (Level 3) | Net Asset Value (NAV) | Not Practicable (Carrying Value) |
|---|---|---|---|---|---|---|---|
| Bonds, Short Term, and Cash Equivalents | 97,395,836 | 97,120,039 | 11,327,353 | 86,068,483 | — | | |

December 31, 2017

| Type of Financial Instrument | Aggregate Fair Value | Admitted Assets | (Level 1) | (Level 2) | (Level 3) | Net Asset Value (NAV) | Not Practicable (Carrying Value) |
|---|---|---|---|---|---|---|---|
| Bonds, Short Term, and Cash Equivalents | 107,033,353 | 107,036,167 | 1,197,469 | 105,835,884 | | | |

The valuation methods and assumptions used by the Company in estimating the fair value of debt securities are discussed in Note 1.

There were no material realized and unrealized capital gains, purchases, sales, settlements, or transfers into or out of the Company's Level 3 financial assets during 2018 or 2017. There were no transfers between the Company's Level 1 or 2 financial assets during 2018 or 2017.

In evaluating the Company's management of interest rate and liquidity risk and currency exposures, the fair values of all assets and liabilities should be taken into consideration, not only those presented above.

D. The Company did not have any financial instruments where it was not practicable to estimate the fair value.

E. The Company has not elected to use the net asset value practical expedient to fair value to measure its investments.

21. Other Items

A. Unusual or Infrequent Items

The Company did not have any unusual or infrequent items for the years ended December 31, 2018 and 2017.

B. Troubled Debt Restructuring

The Company did not have any troubled debt restructuring in the years ended December 31, 2018 and 2017.

C. Other Disclosures

(1) Minimum Capital and Surplus

Pursuant to the laws of the states in which the Company is licensed to do business, the Company is required to maintain a minimum surplus and capital stock as defined by the statutes and regulations of those states. At both December 31, 2018 and 2017, the Company was in compliance with the minimum surplus and capital stock requirements of the states in which it is licensed to do business.

The NAIC and the State of Michigan_adopted risk-based capital ("RBC") standards for health organizations, including HMOs, that are designed to identify weakly capitalized companies by comparing each company's adjusted capital and surplus to its required capital and surplus (the "RBC Ratio"). The RBC Ratio is designed to reflect the risk profile of the company. Within certain ratio ranges, regulators have increasing authority to take action as the RBC Ratio decreases. There are four levels of regulatory action, ranging from requiring insurers to submit a comprehensive plan to the state insurance commissioner to requiring the state insurance commissioner to place the insurer under regulatory control. At December 31, 2018 and 2017, the Company had capital and surplus that exceeded the highest threshold specified by the RBC rules.

(2) Health Care Reform

The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act (collectively, "Health Care Reform" or the "ACA"), has made broad-based changes to the U.S. health care system. If the ACA is not further amended, repealed or replaced, certain of its components will continue to be phased in until 2022. While the Company anticipates continued efforts in 2019 and beyond to invalidate, modify, repeal or replace Health Care Reform, the Company expects aspects of Health Care Reform to continue to significantly impact the Company's business operations and financial results,

including pricing, medical benefit ratios ("MBRs") and the geographies in which the Company's products are available.

While most of the significant aspects of Health Care Reform became effective during or prior to 2014, parts of Health Care Reform continue to evolve through the promulgation of executive orders, regulations and guidance as well as ongoing litigation. Additional changes to Health Care Reform and those regulations and guidance at the federal and/or state level are likely, and those changes are likely to be significant. Growing state and federal budgetary pressures make it more likely that any changes, including changes at the state level in response to changes to, or invalidation, repeal or replacement of, Health Care Reform and/or changes in the funding levels and/or payment mechanisms of federally supported benefit programs, will be adverse to us. For example, if any elements of Health Care Reform are invalidated or repealed at the federal level, the Company expects that some states would seek to enact similar requirements, such as prohibiting pre-existing condition exclusions, prohibiting rescission of insurance coverage, requiring coverage for dependents up to age 26, requiring guaranteed renewability of insurance coverage and prohibiting lifetime limits on insurance coverage.

Potential repeal of Health Care Reform, ongoing legislative, regulatory and administrative policy changes to Health Care Reform, the results of congressional and state level elections, the December 2018 U.S. District Court decision invalidating Health Care Reform and other pending litigation challenging aspects of the law or funding for the law and federal budget negotiations continue to create uncertainty about the ultimate impact of Health Care Reform. The pending litigation challenging Health Care Reform includes challenges by various states of the federal government's decision to curtail payments related to the Cost-Sharing Subsidy Program. The time frame for conclusion and final outcome and ultimate impact of this litigation are uncertain. Given the inherent difficulty of foreseeing the nature and scope of future changes to Health Care Reform and how states, businesses and individuals will respond to those changes, the Company cannot predict the impact on it of future changes to Health Care Reform. It is reasonably possible that invalidation, repeal or replacement of or other changes to Health Care Reform and/or states' responses to such changes, in the aggregate, could have a significant adverse effect on the Company's businesses, financial results and cash flows.

(3) Medicare

The Company does not have any contracts for Medicare Advantage and Standalone Prescription Drug Plan ("PDP") products with CMS.

(4) Medicaid

The Company's Medicaid, dual eligible and dual eligible special needs plan products also are heavily regulated by CMS and state Medicaid agencies, which have the right to audit the Company's performance to determine compliance with CMS contracts and regulations. The Company's Medicaid products, dual eligible products and Children's Health Insurance Program ("CHIP") contracts also are subject to complex federal and state regulations and oversight by state Medicaid agencies regarding the services the Company provides to Medicaid enrollees, payment for those services, network requirements (including mandatory inclusion of specified high-cost providers), and other aspects of these programs, and by external review organizations which audit Medicaid plans on behalf of the state Medicaid agencies. The laws, regulations and contractual requirements applicable to the Company and other participants in Medicaid and dual eligible programs, including requirements that the Company submit encounter data to the applicable state agency, are extensive, complex and subject to change. The Company has invested significant resources to comply with these standards, and its Medicaid and dual eligible program compliance efforts will continue to require significant resources. CMS and/or state Medicaid agencies may fine the Company, withhold payments to the Company, seek premium and other refunds, terminate the Company's existing contracts, elect not to award the Company new contracts or not to renew the Company's existing contracts, prohibit the Company from continuing to market and/or enroll members in or refuse to automatically assign members to one or more of the Company's Medicaid or dual eligible products, exclude the Company from participating in one or more Medicaid or dual eligible programs and/or institute other sanctions and/or civil monetary penalties against the Company if it fails to comply with CMS or state regulations or the Company's contractual requirements. The Company cannot predict whether pending or future federal or state legislation or court proceedings will change various aspects of the Medicaid program, nor can it predict the impact those changes will have on its business operations or financial results, but the effects could be materially adverse. The Company's Medicaid contract with the State of Nebraska was not renewed for 2017.

D. The Company did not have any business interruption insurance recoveries for the years ending December 31, 2018 or 2017.

E. The Company did not have any transferable and non-transferable state tax credits for the years ending December 31, 2018 or 2017.

F. The Company did not have any subprime mortgage related risk exposures at December 31, 2018 or 2017.

G. The Company did not have any retained assets at December 31, 2018 or 2017.

H. The Company did not have any insurance-linked securities ("ILS") contracts at December 31, 2018 or 2017.

22. Events Subsequent

A. Type I - Recognized Subsequent Events

Subsequent events have been considered through February 27, 2019 for the statutory statement issued on March 1, 2019.

The Company had no known reportable recognized subsequent events.

B. Type II - Nonrecognized Subsequent Events

Subsequent events have been considered through February 27, 2019 for the statutory statement issued on March 1, 2019.

As discussed in Note 1, in January 2018, the HIF was suspended for 2019. As a result, there is no annual health insurance industry fee payable on September 30, 2019 and there are no amounts reflected in the Company's aggregate write-ins for special surplus funds related to this payable at December 31, 2018 as a result. There is also no resulting impact to the Company's RBC to assess as of December 31, 2017 as a result of this suspension.

| Type II - Nonrecognized Subsequent Events: | | Current Year | Prior Year |
|---|---|---|---|
| A. Did the reporting entity write accident and health insurance premium that is subject to Section 9010 of the Federal Affordable Care Act (YES/NO)? | YES | | |
| B ACA fee assessment payable for the upcoming year | | | $7,117,000 |
| C ACA fee assessment paid | | $7,125,654 | |
| D Premium written subject to ACA 9010 assessment | | $295,484,513 | $347,992,662 |
| E Total Adjusted Capital before surplus adjustment (Five-Year Historical Line 14) | | $54,596,492 | |
| F. Total Adjusted Capital after surplus adjustment (Five-Year Historical Line 14 minus 22B above) | | $54,596,492 | |
| G Authorized Control Level (Five-Year Historical Line 15) | | $9,927,683 | |
| H. Would reporting the ACA assessment as of Dec. 31, 2017 have triggered an RBC action level (YES/NO)? | NO | | |

23. Reinsurance

Effective April 1, 2017, the Company and Berkley Life and Health Insurance Company ("Berkley") entered into an excess loss reinsurance agreement for Medicare Integrated Dual Members, Medicare Duals, and ABAD Members, TANF, MI Child, Medicaid Expansion and CSHCS. Under this agreement, Berkley is liable for 90% of covered expenses in excess of the specific deductible of $400,000 per covered member for Medicare Integrated Dual Members and $300,000 per covered member for Medicare Duals, ABAD Members, TANF, MI Child, Medicaid Expansion and CSHCS, with a maximum reimbursement of $5,000,000 per member per agreement year. The Company paid reinsurance premiums of $542,760 and $741,380 in 2018 and 2017, respectively. Reinsurance premiums are recorded as net premium income in the Statutory Statements of Revenue and Expenses

A. Ceded Reinsurance Report

Section 1 – General Interrogatories

(1) Are any of the reinsurers, listed in Schedule S as non-affiliated, owned in excess of 10% or controlled, either directly or indirectly, by the company or by any representative, officer, trustee, or director of the company?
Yes ( ) No (X)
If yes, give full details.

(2) Have any policies issued by the company been reinsured with a company chartered in a country other than the United States (excluding U.S. branches of such companies) that is owned in excess of 10% or controlled directly or indirectly by an insured, a beneficiary, a creditor or an insured or any other person not primarily engaged in the insurance business?
Yes ( ) No (X)
If yes, give full details.

Section 2 – Ceded Reinsurance Report – Part A

(1) Does the company have any reinsurance agreements in effect under which the reinsurer may unilaterally cancel any reinsurance for reasons other than nonpayment of premium or other similar credit?
Yes ( ) No (X)

a. If yes, what is the estimated amount of the aggregate reduction in surplus of a unilateral cancellation by the reinsurer as of the date of this statement, for those agreements in which cancellation results in a net obligation of the reporting entity to the reinsurer, and for which such obligation is not presently accrued? Where necessary, the reporting entity may consider the current or anticipated experience of the business reinsured in making this estimate.
$ N/A .

b. What is the total amount of reinsurance credits taken, whether as an asset or as a reduction of liability for these agreements in this statement?
$ N/A .

(2) Does the reporting entity have any reinsurance agreements in effect such that the amount of losses paid or accrued through the statement date may result in a payment to the reinsurer of amounts that, in aggregate and allowing for offset of mutual credits from other reinsurance agreements with the same reinsurer, exceed the total direct premium collected under the reinsured policies?

Yes ( ) No (X)
If yes, give full details.

Section 3 – Ceded Reinsurance Report – Part B

(1) What is the estimated amount of the aggregate reduction in surplus, (for agreements other than those under which the insurer may unilaterally cancel for reasons other than for nonpayment of premium or other similar credits that are reflected in Section 2 above) of termination of ALL reinsurance agreements, by either party, as of the date of this statement? Where necessary, the company may consider the current or anticipated experience of the business reinsured in making this estimate.
$ 0 .

(2) Have any new agreements been executed or existing agreements amended, since January 1 of the year of this statement, to include policies or contracts that were in force or which had existing reserves established by the company as of the effective date of the agreement?
Yes ( ) No (X)
If yes, what is the amount of reinsurance credit, whether an asset or a reduction of liability, taken for such new agreements or amendments? $ N/A .

B. The Company did not have uncollectible reinsurance at December 31, 2018 or 2017.

C. The Company did not have any commutation of ceded reinsurance at December 31, 2018 or 2017.

D. The Company's certified reinsurer's rating has not been downgraded or its status subject to revocation at December 31, 2018 or 2017.

24. Retrospectively Rated Contracts and Contracts Subject to Redetermination

A. and B.

The Company did not have any retrospectively rated contracts in 2018 or 2017.

C. Contracts Subject to Retrospective Rating Features

The Company did not have any contracts subject to retrospective rating features in 2018 or 2017.

D. Medical Loss Ratio Rebates Required Pursuant to the Public Health Service Act

The Company did not have any medical loss ratios required pursuant to the Public Health Service Act in 2018 or 2017.

E. Risk Sharing Provisions of the Affordable Care Act (ACA)

(1) Did the reporting entity write accident and health insurance premium which is subject to the ACA risk sharing provisions (YES/NO)? No

(2) through (5): Not applicable.

25. Change in Incurred Claims and Claims Adjustment Expense

The following table shows the components of the change in claims unpaid, unpaid claims adjustment expense and aggregate health claim reserves for the years ended December 31, 2018 and 2017.

| | 2018 | 2017 |
|---|---|---|
| Balance, January 1 | $63,071,889 | $64,260,634 |
| Health care receivable | (10,338,647) | (4,062,603) |
| Balance, January 1, net of health care receivable | 52,733,242 | 60,198,031 |
| Incurred related to: | | |
| Current year | 275,217,973 | 335,529,952 |
| Prior years | (22,511,703) | (11,449,837) |
| Total incurred | 252,706,270 | 324,080,115 |
| Paid related to: | | |
| Current year | 225,310,314 | 285,364,021 |
| Prior years | 33,606,199 | 46,180,883 |
| Total paid | 258,916,513 | 331,544,904 |
| Balance, December 31, net of health care receivable | 46,523,000 | 52,733,242 |
| Health care receivable | 9,672,423 | 10,338,647 |
| Balance, December 31 | $56,195,423 | $63,071,889 |

In 2018, reserves for incurred claims and claim adjustment expenses attributable to insured events of prior years decreased by $22,511,703 from $63,071,889 in 2017 to $40,560,186 in 2018. In 2017, reserves for incurred claims and claim adjustment expenses attributable to insured events of prior years decreased by $11,449,837 from $64,260,634 in 2016 to $52,810,797 in 2017. The lower than anticipated health care cost trend rates observed in 2018 and 2017 for claims incurred in 2017 and 2016, respectively, were due to moderating outpatient and physician trends and faster than expected claim payment speed. The Company considers historical trend rates together with knowledge of recent events that may impact current trends when developing estimates of current trend rates. Original estimates are increased or decreased as additional information becomes known regarding individual claims. Historical health care cost trend rates are not necessarily representative of current trends. The Company experienced $9,213,727 of unfavorable prior year claim development on retrospectively rated policies, which is included in the net 2017 decrease. However, the business to which it relates is subject to premium adjustments. The Company excluded the impact of the change in health care receivables related to pharmacy rebates from the above roll-forward to conform to NAIC Annual Statement presentation.

The methodology used in calculating the liability has been consistently applied between years. As of December 31, 2018 and 2017, accrued claim adjustment expenses were $1,781,884 and $900,118 respectively. These amounts have been included in the table above. The reserve is determined as a percentage of claims reserves. The Company periodically reassesses the percentage applied based on historical experience. For 2018 and 2017, claim adjustment expenses have been included in the total incurred line in the chart above.

Net coordination of benefits are implicit in the claims incurred but not reported calculation and could not be specifically identified.

26. Intercompany Pooling Arrangements

The Company did not have any intercompany pooling arrangements at December 31, 2018 or 2017.

27. Structured Settlements

Not applicable to health entities.

28. Health Care Receivables

A. Pharmaceutical Rebate Receivables

The Company receives pharmaceutical rebates through an agreement with AHM. AHM has contractual agreements with pharmaceutical companies for rebates, which cover the Company's membership as well as the membership of other Aetna affiliates. The Company receives those rebates from AHM that relate to the Company's membership. The Company estimates pharmaceutical rebate receivables based upon the historical payment trends, actual utilization and other variables. Actual rebates collected are applied to the collection periods below, using a first in first out methodology. At December 31, 2018 and 2017, the Company had pharmaceutical rebate receivables of $7,402,389 and $4,009,473, respectively (refer to the Company's accounting practices related to pharmaceutical rebate receivables in Note 1).

The following table discloses the quarterly revenue and subsequent cash collections relating to the pharmaceutical rebates discussed in Note 10.

| Date | Estimated Pharmacy Rebates as Reported on Financial Statements | Pharmacy Rebates as Billed or Otherwise Confirmed | Actual Rebates Received Within 90 Days of Billing | Actual Rebates Received Within 91 to 180 Days of Billing | Actual Rebates Received More Than 180 Days After Billing |
|---|---|---|---|---|---|
| 12/31/2018 | $3,811,005 | $— | $— | $— | $— |
| 09/30/2018 | 3,716,522 | 4,005,921 | 2,698,887 | — | — |
| 06/30/2018 | 3,877,502 | 4,014,255 | 2,804,291 | — | — |
| 03/31/2018 | 3,758,048 | 3,768,411 | 2,735,307 | 891,369 | — |
| 12/31/2017 | 1,526,083 | 1,336,491 | 1,336,491 | 1,117,411 | (94,379) |
| 09/30/2017 | 1,523,376 | 1,556,071 | 1,556,071 | 415,037 | (112,512) |
| 06/30/2017 | 1,600,977 | 1,512,520 | 1,512,520 | 455,748 | (96,179) |
| 03/31/2017 | 1,738,841 | 1,524,385 | 1,524,385 | 421,160 | 83,046 |
| 12/31/2016 | 1,720,410 | 2,024,154 | 1,020,433 | 1,019,228 | (16,589) |
| 09/30/2016 | 1,579,377 | 1,961,905 | 1,759,333 | 198,957 | 1,489 |
| 06/30/2016 | 1,379,035 | 1,547,342 | 1,423,193 | 95,700 | 27,878 |
| 03/31/2016 | 1,090,702 | 1,430,294 | 1,320,250 | 82,218 | 21,682 |

B. Risk sharing receivables

The Company did not have any admitted risk sharing receivables at December 31, 2018 or 2017.

C. Claim Overpayment Receivables

The Company reported $0 and $0 as claim overpayment receivables at December 31, 2018 and 2017 Respectively.

29. Participating Policies

The Company did not have any participating policies at December 31, 2018 or 2017.

## 30. Premium Deficiency Reserves

| | December 31, 2018 |
|---|---|
| 1. Liability carried for premium deficiency reserves | $0 |
| 2. Date of the most recent evaluation of this liability | 12/31/2018 |
| 3. Was anticipated investment income utilized in the calculation? | Yes |

## 31. Anticipated Salvage and Subrogation

See discussion of hospital and medical costs and claims adjustment expenses and related reserves in Note 1.

# GENERAL INTERROGATORIES

## PART 1 - COMMON INTERROGATORIES
## GENERAL

1.1 Is the reporting entity a member of an Insurance Holding Company System consisting of two or more affiliated persons, one or more of which is an insurer? Yes [ X ] No [ ]
If yes, complete Schedule Y, Parts 1, 1A and 2

1.2 If yes, did the reporting entity register and file with its domiciliary State Insurance Commissioner, Director or Superintendent, or with such regulatory official of the state of domicile of the principal insurer in the Holding Company System, a registration statement providing disclosure substantially similar to the standards adopted by the National Association of Insurance Commissioners (NAIC) in its Model Insurance Holding Company System Regulatory Act and model regulations pertaining thereto, or is the reporting entity subject to standards and disclosure requirements substantially similar to those required by such Act and regulations? Yes [ X ] No [ ] N/A [ ]

1.3 State Regulating? Michigan

1.4 Is the reporting entity publicly traded or a member of a publicly traded group? Yes [ X ] No [ ]

1.5 If the response to 1.4 is yes, provide the CIK (Central Index Key) code issued by the SEC for the entity/group. 0000064803

2.1 Has any change been made during the year of this statement in the charter, by-laws, articles of incorporation, or deed of settlement of the reporting entity? Yes [ X ] No [ ]

2.2 If yes, date of change: 12/19/2018

3.1 State as of what date the latest financial examination of the reporting entity was made or is being made. 12/31/2015

3.2 State the as of date that the latest financial examination report became available from either the state of domicile or the reporting entity. This date should be the date of the examined balance sheet and not the date the report was completed or released. 12/31/2015

3.3 State as of what date the latest financial examination report became available to other states or the public from either the state of domicile or the reporting entity. This is the release date or completion date of the examination report and not the date of the examination (balance sheet date). 06/14/2017

3.4 By what department or departments?
Michigan Department of Insurance and Financial Services

3.5 Have all financial statement adjustments within the latest financial examination report been accounted for in a subsequent financial statement filed with Departments? Yes [ ] No [ ] N/A [ X ]

3.6 Have all of the recommendations within the latest financial examination report been complied with? Yes [ ] No [ ] N/A [ X ]

4.1 During the period covered by this statement, did any agent, broker, sales representative, non-affiliated sales/service organization or any combination thereof under common control (other than salaried employees of the reporting entity), receive credit or commissions for or control a substantial part (more than 20 percent of any major line of business measured on direct premiums) of:
4.11 sales of new business? Yes [ ] No [ X ]
4.12 renewals? Yes [ ] No [ X ]

4.2 During the period covered by this statement, did any sales/service organization owned in whole or in part by the reporting entity or an affiliate, receive credit or commissions for or control a substantial part (more than 20 percent of any major line of business measured on direct premiums) of:
4.21 sales of new business? Yes [ ] No [ X ]
4.22 renewals? Yes [ ] No [ X ]

5.1 Has the reporting entity been a party to a merger or consolidation during the period covered by this statement? Yes [ ] No [ X ]
If yes, complete and file the merger history data file with the NAIC.

5.2 If yes, provide the name of the entity, NAIC Company Code, and state of domicile (use two letter state abbreviation) for any entity that has ceased to exist as a result of the merger or consolidation.

| 1<br>Name of Entity | 2<br>NAIC Company Code | 3<br>State of Domicile |
|---|---|---|
| | | |

6.1 Has the reporting entity had any Certificates of Authority, licenses or registrations (including corporate registration, if applicable) suspended or revoked by any governmental entity during the reporting period? Yes [ ] No [ X ]

6.2 If yes, give full information:

7.1 Does any foreign (non-United States) person or entity directly or indirectly control 10% or more of the reporting entity? Yes [ ] No [ X ]

7.2 If yes,
7.21 State the percentage of foreign control; %
7.22 State the nationality(s) of the foreign person(s) or entity(s) or if the entity is a mutual or reciprocal, the nationality of its manager or attorney-in-fact; and identify the type of entity(s) (e.g., individual, corporation or government, manager or attorney in fact).

| 1<br>Nationality | 2<br>Type of Entity |
|---|---|
| | |

# GENERAL INTERROGATORIES

8.1 Is the company a subsidiary of a bank holding company regulated by the Federal Reserve Board? Yes [ ] No [ X ]

8.2 If response to 8.1 is yes, please identify the name of the bank holding company.

8.3 Is the company affiliated with one or more banks, thrifts or securities firms? Yes [ ] No [ X ]

8.4 If response to 8.3 is yes, please provide below the names and location (city and state of the main office) of any affiliates regulated by a federal regulatory services agency [i.e. the Federal Reserve Board (FRB), the Office of the Comptroller of the Currency (OCC), the Federal Deposit Insurance Corporation (FDIC) and the Securities Exchange Commission (SEC)] and identify the affiliate's primary federal regulator.

| 1<br>Affiliate Name | 2<br>Location (City, State) | 3<br>FRB | 4<br>OCC | 5<br>FDIC | 6<br>SEC |
|---|---|---|---|---|---|
| | | | | | |

9. What is the name and address of the independent certified public accountant or accounting firm retained to conduct the annual audit?
KPMG LLP, One Financial Plaza, 755 Main Street, Hartford, CT 06103

10.1 Has the insurer been granted any exemptions to the prohibited non-audit services provided by the certified independent public accountant requirements as allowed in Section 7H of the Annual Financial Reporting Model Regulation (Model Audit Rule), or substantially similar state law or regulation? Yes [ ] No [ X ]

10.2 If the response to 10.1 is yes, provide information related to this exemption:

10.3 Has the insurer been granted any exemptions related to the other requirements of the Annual Financial Reporting Model Regulation as allowed for in Section 18A of the Model Regulation, or substantially similar state law or regulation? Yes [ ] No [ X ]

10.4 If the response to 10.3 is yes, provide information related to this exemption:

10.5 Has the reporting entity established an Audit Committee in compliance with the domiciliary state insurance laws? Yes [ X ] No [ ] N/A [ ]

10.6 If the response to 10.5 is no or n/a, please explain

11. What is the name, address and affiliation (officer/employee of the reporting entity or actuary/consultant associated with an actuarial consulting firm) of the individual providing the statement of actuarial opinion/certification?
Jeffrey J. Drzazgowski, FSA, MAAA; 151 Farmington Avenue, RE2R; Hartford, CT 06156

12.1 Does the reporting entity own any securities of a real estate holding company or otherwise hold real estate indirectly? Yes [ ] No [ X ]

12.11 Name of real estate holding company

12.12 Number of parcels involved

12.13 Total book/adjusted carrying value $

12.2 If, yes provide explanation:

13. **FOR UNITED STATES BRANCHES OF ALIEN REPORTING ENTITIES ONLY:**

13.1 What changes have been made during the year in the United States manager or the United States trustees of the reporting entity?
N/A

13.2 Does this statement contain all business transacted for the reporting entity through its United States Branch on risks wherever located? Yes [ ] No [ X ]

13.3 Have there been any changes made to any of the trust indentures during the year? Yes [ ] No [ X ]

13.4 If answer to (13.3) is yes, has the domiciliary or entry state approved the changes? Yes [ ] No [ ] N/A [ X ]

14.1 Are the senior officers (principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions) of the reporting entity subject to a code of ethics, which includes the following standards? Yes [ X ] No [ ]
(a) Honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships;
(b) Full, fair, accurate, timely and understandable disclosure in the periodic reports required to be filed by the reporting entity;
(c) Compliance with applicable governmental laws, rules and regulations;
(d) The prompt internal reporting of violations to an appropriate person or persons identified in the code; and
(e) Accountability for adherence to the code.

14.11 If the response to 14.1 is No, please explain:

14.2 Has the code of ethics for senior managers been amended? Yes [ X ] No [ ]

14.21 If the response to 14.2 is yes, provide information related to amendment(s).
Through November 28, 2018, senior management was subject to the Aetna Inc. Code of Conduct. Effective with the acquisition of Aetna Inc. by CVS Health Corporation, senior management become subject to the CVS Health Code of Conduct.

14.3 Have any provisions of the code of ethics been waived for any of the specified officers? Yes [ ] No [ X ]

14.31 If the response to 14.3 is yes, provide the nature of any waiver(s).

# GENERAL INTERROGATORIES

15.1 Is the reporting entity the beneficiary of a Letter of Credit that is unrelated to reinsurance where the issuing or confirming bank is not on the SVO Bank List? Yes [ ] No [ X ]

15.2 If the response to 15.1 is yes, indicate the American Bankers Association (ABA) Routing Number and the name of the issuing or confirming bank of the Letter of Credit and describe the circumstances in which the Letter of Credit is triggered.

| 1<br>American Bankers Association (ABA) Routing Number | 2<br>Issuing or Confirming Bank Name | 3<br>Circumstances That Can Trigger the Letter of Credit | 4<br>Amount |
|---|---|---|---|
| | | | |

## BOARD OF DIRECTORS

16. Is the purchase or sale of all investments of the reporting entity passed upon either by the board of directors or a subordinate committee thereof? Yes [ X ] No [ ]

17. Does the reporting entity keep a complete permanent record of the proceedings of its board of directors and all subordinate committees thereof? Yes [ X ] No [ ]

18. Has the reporting entity an established procedure for disclosure to its board of directors or trustees of any material interest or affiliation on the part of any of its officers, directors, trustees or responsible employees that is in conflict with the official duties of such person? Yes [ X ] No [ ]

## FINANCIAL

19. Has this statement been prepared using a basis of accounting other than Statutory Accounting Principles (e.g., Generally Accepted Accounting Principles)? Yes [ ] No [ X ]

20.1 Total amount loaned during the year (inclusive of Separate Accounts, exclusive of policy loans):
- 20.11 To directors or other officers $
- 20.12 To stockholders not officers $
- 20.13 Trustees, supreme or grand (Fraternal Only) $

20.2 Total amount of loans outstanding at the end of year (inclusive of Separate Accounts, exclusive of policy loans):
- 20.21 To directors or other officers $
- 20.22 To stockholders not officers $
- 20.23 Trustees, supreme or grand (Fraternal Only) $

21.1 Were any assets reported in this statement subject to a contractual obligation to transfer to another party without the liability for such obligation being reported in the statement? Yes [ ] No [ X ]

21.2 If yes, state the amount thereof at December 31 of the current year:
- 21.21 Rented from others $
- 21.22 Borrowed from others $
- 21.23 Leased from others $
- 21.24 Other $

22.1 Does this statement include payments for assessments as described in the Annual Statement Instructions other than guaranty fund or guaranty association assessments? Yes [ ] No [ X ]

22.2 If answer is yes:
- 22.21 Amount paid as losses or risk adjustment $
- 22.22 Amount paid as expenses $
- 22.23 Other amounts paid $

23.1 Does the reporting entity report any amounts due from parent, subsidiaries or affiliates on Page 2 of this statement? Yes [ ] No [ X ]

23.2 If yes, indicate any amounts receivable from parent included in the Page 2 amount: $

## INVESTMENT

24.01 Were all the stocks, bonds and other securities owned December 31 of current year, over which the reporting entity has exclusive control, in the actual possession of the reporting entity on said date? (other than securities lending programs addressed in 24.03) Yes [ X ] No [ ]

24.02 If no, give full and complete information relating thereto

24.03 For security lending programs, provide a description of the program including value for collateral and amount of loaned securities, and whether collateral is carried on or off-balance sheet. (an alternative is to reference Note 17 where this information is also provided)
We are not currently investing in the securities lending program as of 12/31/2018.

24.04 Does the Company's security lending program meet the requirements for a conforming program as outlined in the Risk-Based Capital Instructions? Yes [ ] No [ ] N/A [ X ]

24.05 If answer to 24.04 is yes, report amount of collateral for conforming programs. $

24.06 If answer to 24.04 is no, report amount of collateral for other programs. $

24.07 Does your securities lending program require 102% (domestic securities) and 105% (foreign securities) from the counterparty at the outset of the contract? Yes [ ] No [ ] N/A [ X ]

24.08 Does the reporting entity non-admit when the collateral received from the counterparty falls below 100%? Yes [ ] No [ ] N/A [ X ]

24.09 Does the reporting entity or the reporting entity 's securities lending agent utilize the Master Securities lending Agreement (MSLA) to conduct securities lending? Yes [ ] No [ ] N/A [ X ]

# GENERAL INTERROGATORIES

24.10 For the reporting entity's security lending program state the amount of the following as December 31 of the current year:

24.101 Total fair value of reinvested collateral assets reported on Schedule DL, Parts 1 and 2. $ 0
24.102 Total book adjusted/carrying value of reinvested collateral assets reported on Schedule DL, Parts 1 and 2 $ 0
24.103 Total payable for securities lending reported on the liability page. $ 0

25.1 Were any of the stocks, bonds or other assets of the reporting entity owned at December 31 of the current year not exclusively under the control of the reporting entity, or has the reporting entity sold or transferred any assets subject to a put option contract that is currently in force? (Exclude securities subject to Interrogatory 21.1 and 24.03). Yes [ X ] No [ ]

25.2 If yes, state the amount thereof at December 31 of the current year:

25.21 Subject to repurchase agreements $
25.22 Subject to reverse repurchase agreements $
25.23 Subject to dollar repurchase agreements $
25.24 Subject to reverse dollar repurchase agreements $
25.25 Placed under option agreements $
25.26 Letter stock or securities restricted as to sale - excluding FHLB Capital Stock $
25.27 FHLB Capital Stock $
25.28 On deposit with states $ 1,199,763
25.29 On deposit with other regulatory bodies $
25.30 Pledged as collateral - excluding collateral pledged to an FHLB $
25.31 Pledged as collateral to FHLB - including assets backing funding agreements $
25.32 Other $

25.3 For category (25.26) provide the following:

| 1<br>Nature of Restriction | 2<br>Description | 3<br>Amount |
|---|---|---|
| | | |

26.1 Does the reporting entity have any hedging transactions reported on Schedule DB? Yes [ ] No [ X ]

26.2 If yes, has a comprehensive description of the hedging program been made available to the domiciliary state? Yes [ ] No [ ] N/A [ X ]
If no, attach a description with this statement.

27.1 Were any preferred stocks or bonds owned as of December 31 of the current year mandatorily convertible into equity, or, at the option of the issuer, convertible into equity? Yes [ ] No [ X ]

27.2 If yes, state the amount thereof at December 31 of the current year. $

28. Excluding items in Schedule E - Part 3 - Special Deposits, real estate, mortgage loans and investments held physically in the reporting entity's offices, vaults or safety deposit boxes, were all stocks, bonds and other securities, owned throughout the current year held pursuant to a custodial agreement with a qualified bank or trust company in accordance with Section 1, III - General Examination Considerations, F. Outsourcing of Critical Functions, Custodial or Safekeeping Agreements of the NAIC Financial Condition Examiners Handbook? Yes [ X ] No [ ]

28.01 For agreements that comply with the requirements of the NAIC Financial Condition Examiners Handbook, complete the following:

| 1<br>Name of Custodian(s) | 2<br>Custodian's Address |
|---|---|
| State Street Bank and Trust Company | State Street Financial Center; One Lincoln Street; Boston, MA 02111-2900 |
| | |

28.02 For all agreements that do not comply with the requirements of the NAIC Financial Condition Examiners Handbook, provide the name, location and a complete explanation:

| 1<br>Name(s) | 2<br>Location(s) | 3<br>Complete Explanation(s) |
|---|---|---|
| | | |

28.03 Have there been any changes, including name changes, in the custodian(s) identified in 28.01 during the current year? Yes [ ] No [ X ]
28.04 If yes, give full and complete information relating thereto:

| 1<br>Old Custodian | 2<br>New Custodian | 3<br>Date of Change | 4<br>Reason |
|---|---|---|---|
| | | | |

# GENERAL INTERROGATORIES

28.05 Investment management – Identify all investment advisors, investment managers, broker/dealers, including individuals that have the authority to make investment decisions on behalf of the reporting entity. For assets that are managed internally by employees of the reporting entity, note as such. ["…that have access to the investment accounts"; "…handle securities"]

| 1<br>Name of Firm or Individual | 2<br>Affiliation |
|---|---|
| Kevin J. Casey as Sr. Investment Officer | A |
| | |

28.0597 For those firms/individuals listed in the table for Question 28.05, do any firms/individuals unaffiliated with the reporting entity (i.e. designated with a "U") manage more than 10% of the reporting entity's assets? Yes [ ] No [ X ]

28.0598 For firms/individuals unaffiliated with the reporting entity (i.e. designated with a "U") listed in the table for Question 28.05, does the total assets under management aggregate to more than 50% of the reporting entity's assets? Yes [ ] No [ X ]

28.06 For those firms or individuals listed in the table for 28.05 with an affiliation code of "A" (affiliated) or "U" (unaffiliated), provide the information for the table below.

| 1<br>Central Registration Depository Number | 2<br>Name of Firm or Individual | 3<br>Legal Entity Identifier (LEI) | 4<br>Registered With | 5<br>Investment Management Agreement (IMA) Filed |
|---|---|---|---|---|
| N/A | Kevin J. Casey | | Not registered | |
| - | - | - | - | |
| | | | | |
| | | | | |

29.1 Does the reporting entity have any diversified mutual funds reported in Schedule D, Part 2 (diversified according to the Securities and Exchange Commission (SEC) in the Investment Company Act of 1940 [Section 5(b)(1)])? Yes [ ] No [ X ]

29.2 If yes, complete the following schedule:

| 1<br>CUSIP # | 2<br>Name of Mutual Fund | 3<br>Book/Adjusted Carrying Value |
|---|---|---|
| 29.2999 - Total | | 0 |

29.3 For each mutual fund listed in the table above, complete the following schedule:

| 1<br>Name of Mutual Fund (from above table) | 2<br>Name of Significant Holding of the Mutual Fund | 3<br>Amount of Mutual Fund's Book/Adjusted Carrying Value Attributable to the Holding | 4<br>Date of Valuation |
|---|---|---|---|
| | | | |

30. Provide the following information for all short-term and long-term bonds and all preferred stocks. Do not substitute amortized value or statement value for fair value.

| | 1<br>Statement (Admitted) Value | 2<br>Fair Value | 3<br>Excess of Statement over Fair Value (-), or Fair Value over Statement (+) |
|---|---|---|---|
| 30.1 Bonds | 15,879,939 | 16,155,736 | 275,797 |
| 30.2 Preferred stocks | 0 | 0 | 0 |
| 30.3 Totals | 15,879,939 | 16,155,736 | 275,797 |

30.4 Describe the sources or methods utilized in determining the fair values:

Fair value of long term bonds and preferred stocks are determined based on quoted market prices when available, fair values using valuation methodologies based on available and observable market information, or by using matrix pricing. If quoted market prices are not available, we determine fair value using broker quoted or an internal analysis of each investment's financial performance and cash flow projections. Short-term investments are carried at amortized cost which approximated fair value. The carrying value of cash equivalents approximated fair value.

31.1 Was the rate used to calculate fair value determined by a broker or custodian for any of the securities in Schedule D? Yes [ X ] No [ ]

31.2 If the answer to 31.1 is yes, does the reporting entity have a copy of the broker's or custodian's pricing policy (hard copy or electronic copy) for all brokers or custodians used as a pricing source? Yes [ X ] No [ ]

31.3 If the answer to 31.2 is no, describe the reporting entity's process for determining a reliable pricing source for purposes of disclosure of fair value for Schedule D:

32.1 Have all the filing requirements of the Purposes and Procedures Manual of the NAIC Investment Analysis Office been followed? Yes [ X ] No [ ]

32.2 If no, list exceptions:

# GENERAL INTERROGATORIES

33. By self-designating 5GI securities, the reporting entity is certifying the following elements of each self-designated 5GI security:
    a. Documentation necessary to permit a full credit analysis of the security does not exist or an NAIC CRP credit rating for an FE or PL security is not available.
    b. Issuer or obligor is current on all contracted interest and principal payments.
    c. The insurer has an actual expectation of ultimate payment of all contracted interest and principal.

    Has the reporting entity self-designated 5GI securities? ..... Yes [ ] No [ X ]

34. By self-designating PLGI securities, the reporting entity is certifying the following elements of each self-designated PLGI security:
    a. The security was purchased prior to January 1, 2018.
    b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security.
    c. The NAIC Designation was derived from the credit rating assigned by an NAIC CRP in its legal capacity as a NRSRO which is shown on a current private letter rating held by the insurer and available for examination by state insurance regulators.
    d. The reporting entity is not permitted to share this credit rating of the PL security with the SVO.

    Has the reporting entity self-designated PLGI securities? ..... Yes [ ] No [ X ]

## OTHER

35.1 Amount of payments to trade associations, service organizations and statistical or rating bureaus, if any? ..... $ .....

35.2 List the name of the organization and the amount paid if any such payment represented 25% or more of the total payments to trade associations, service organizations and statistical or rating bureaus during the period covered by this statement.

| 1<br>Name | 2<br>Amount Paid |
|---|---|
| | |

36.1 Amount of payments for legal expenses, if any? ..... $ .....

36.2 List the name of the firm and the amount paid if any such payment represented 25% or more of the total payments for legal expenses during the period covered by this statement.

| 1<br>Name | 2<br>Amount Paid |
|---|---|
| | |

37.1 Amount of payments for expenditures in connection with matters before legislative bodies, officers or departments of government, if any? ..... $ .....

37.2 List the name of the firm and the amount paid if any such payment represented 25% or more of the total payment expenditures in connection with matters before legislative bodies, officers or departments of government during the period covered by this statement.

| 1<br>Name | 2<br>Amount Paid |
|---|---|
| | |

# GENERAL INTERROGATORIES

## PART 2 - HEALTH INTERROGATORIES

1.1 Does the reporting entity have any direct Medicare Supplement Insurance in force? Yes [ ] No [ X ]

1.2 If yes, indicate premium earned on U.S. business only. $

1.3 What portion of Item (1.2) is not reported on the Medicare Supplement Insurance Experience Exhibit? $

1.31 Reason for excluding

1.4 Indicate amount of earned premium attributable to Canadian and/or Other Alien not included in Item (1.2) above $

1.5 Indicate total incurred claims on all Medicare Supplement Insurance. $ 0

1.6 Individual policies:

Most current three years:

1.61 Total premium earned $ 0

1.62 Total incurred claims $ 0

1.63 Number of covered lives 0

All years prior to most current three years:

1.64 Total premium earned $ 0

1.65 Total incurred claims $ 0

1.66 Number of covered lives 0

1.7 Group policies:

Most current three years:

1.71 Total premium earned $ 0

1.72 Total incurred claims $ 0

1.73 Number of covered lives 0

All years prior to most current three years:

1.74 Total premium earned $ 0

1.75 Total incurred claims $ 0

1.76 Number of covered lives 0

2. Health Test:

| | | 1<br>Current Year | 2<br>Prior Year |
|---|---|---|---|
| 2.1 | Premium Numerator | 294,941,753 | 347,251,282 |
| 2.2 | Premium Denominator | 294,941,753 | 347,251,282 |
| 2.3 | Premium Ratio (2.1/2.2) | 1.000 | 1.000 |
| 2.4 | Reserve Numerator | 54,820,515 | 62,171,771 |
| 2.5 | Reserve Denominator | 54,820,515 | 62,171,771 |
| 2.6 | Reserve Ratio (2.4/2.5) | 1.000 | 1.000 |

3.1 Has the reporting entity received any endowment or gift from contracting hospitals, physicians, dentists, or others that is agreed will be returned when, as and if the earnings of the reporting entity permits? Yes [ ] No [ X ]

3.2 If yes, give particulars:

4.1 Have copies of all agreements stating the period and nature of hospitals', physicians', and dentists' care offered to subscribers and dependents been filed with the appropriate regulatory agency? Yes [ X ] No [ ]

4.2 If not previously filed, furnish herewith a copy(ies) of such agreement(s). Do these agreements include additional benefits offered? Yes [ ] No [ ]

5.1 Does the reporting entity have stop-loss reinsurance? Yes [ X ] No [ ]

5.2 If no, explain:

5.3 Maximum retained risk (see instructions)

5.31 Comprehensive Medical $

5.32 Medical Only $

5.33 Medicare Supplement $

5.34 Dental & Vision $

5.35 Other Limited Benefit Plan $

5.36 Other $ 5,000,000

6. Describe arrangement which the reporting entity may have to protect subscribers and their dependents against the risk of insolvency including hold harmless provisions, conversion privileges with other carriers, agreements with providers to continue rendering services, and any other agreements:

Provider contracts contain hold harmless and continuity of coverage provisions.

7.1 Does the reporting entity set up its claim liability for provider services on a service date basis? Yes [ X ] No [ ]

7.2 If no, give details

8. Provide the following information regarding participating providers:

8.1 Number of providers at start of reporting year 14,464

8.2 Number of providers at end of reporting year 16,880

9.1 Does the reporting entity have business subject to premium rate guarantees? Yes [ ] No [ X ]

9.2 If yes, direct premium earned:

9.21 Business with rate guarantees between 15-36 months $

9.22 Business with rate guarantees over 36 months $

# GENERAL INTERROGATORIES

10.1 Does the reporting entity have Incentive Pool, Withhold or Bonus Arrangements in its provider contracts? Yes [ X ] No [ ]

10.2 If yes:

10.21 Maximum amount payable bonuses $ 2,126,256
10.22 Amount actually paid for year bonuses $ 720,020
10.23 Maximum amount payable withholds $ 156,489
10.24 Amount actually paid for year withholds $ 51,005

11.1 Is the reporting entity organized as:

11.12 A Medical Group/Staff Model, Yes [ ] No [ X ]
11.13 An Individual Practice Association (IPA), or, Yes [ ] No [ X ]
11.14 A Mixed Model (combination of above)? Yes [ ] No [ X ]

11.2 Is the reporting entity subject to Statutory Minimum Capital and Surplus Requirements? Yes [ X ] No [ ]
11.3 If yes, show the name of the state requiring such minimum capital and surplus. Michigan
11.4 If yes, show the amount required. $ 19,855,366
11.5 Is this amount included as part of a contingency reserve in stockholder's equity? Yes [ ] No [ X ]
11.6 If the amount is calculated, show the calculation
See Notes to Financial Statement - Note 21, Other Items, C., Other Disclosures.

12. List service areas in which reporting entity is licensed to operate:

| 1<br>Name of Service Area |
|---|
| Duals: Alger, Baraga, Chippewa, Delta, Dickinson, Gogebic, Houghton, Iron, Keweenaw, Luce, Mackinac, Marquette, Menominee, Ontonagon, Schoolcraft, Barry, Berrien, Branch, Calhoun, Cass, Kalamazoo, St. Joseph, Van Buren, Wayne, and Macomb |
| Medicaid/CHIP: Berrien, Branch, Calhoun, Cass, Kalamazoo, St. Joseph, Van Buren, Hillsdale, Jackson, Lenawee, Livingston, Monroe, Washtenaw, Macomb, Oakland, and Wayne |
| |

13.1 Do you act as a custodian for health savings accounts? Yes [ ] No [ X ]

13.2 If yes, please provide the amount of custodial funds held as of the reporting date. $

13.3 Do you act as an administrator for health savings accounts? Yes [ ] No [ X ]

13.4 If yes, please provide the balance of funds administered as of the reporting date. $

14.1 Are any of the captive affiliates reported on Schedule S, Part 3, authorized reinsurers? Yes [ ] No [ ] N/A [ X ]
14.2 If the answer to 14.1 is yes, please provide the following:

| 1<br>Company Name | 2<br>NAIC Company Code | 3<br>Domiciliary Jurisdiction | 4<br>Reserve Credit | Assets Supporting Reserve Credit | | |
|---|---|---|---|---|---|---|
| | | | | 5<br>Letters of Credit | 6<br>Trust Agreements | 7<br>Other |
| | | | | | | |

15. Provide the following for individual ordinary life insurance* policies (U.S. business only) for the current year (prior to reinsurance assumed or ceded):

15.1 Direct Premium Written $
15.2 Total Incurred Claims $
15.3 Number of Covered Lives

| *Ordinary Life Insurance Includes |
|---|
| Term(whether full underwriting, limited underwriting, jet issue, "short form app") |
| Whole Life (whether full underwriting, limited underwriting, jet issue, "short form app") |
| Variable Life (with or without secondary gurarantee) |
| Universal Life (with or without secondary gurarantee) |
| Variable Universal Life (with or without secondary gurarantee) |

16. Is the reporting entity licensed or chartered, registered, qualified, eligible or writing business in at least two states? Yes [ ] No [ X ]

16.1 If no, does the reporting entity assume reinsurance business that covers risks residing in at least one state other than the state of domicile of the reporting entity? Yes [ ] No [ X ]

# FIVE-YEAR HISTORICAL DATA

| | | 1<br>2018 | 2<br>2017 | 3<br>2016 | 4<br>2015 | 5<br>2014 |
|---|---|---|---|---|---|---|
| | **Balance Sheet** (Pages 2 and 3) | | | | | |
| 1. | Total admitted assets (Page 2, Line 28) | 136,487,095 | 121,493,662 | 120,455,966 | 110,365,445 | 49,064,064 |
| 2. | Total liabilities (Page 3, Line 24) | 81,890,603 | 79,987,746 | 86,295,108 | 73,470,048 | 25,454,668 |
| 3. | Statutory minimum capital and surplus requirement | 19,855,366 | 27,752,782 | 27,752,782 | 15,613,874 | 17,091,201 |
| 4. | Total capital and surplus (Page 3, Line 33) | 54,596,492 | 41,505,916 | 34,160,858 | 36,895,398 | 23,609,396 |
| | **Income Statement** (Page 4) | | | | | |
| 5. | Total revenues (Line 8) | 293,605,586 | 349,511,462 | 340,170,006 | 282,130,597 | 187,519,055 |
| 6. | Total medical and hospital expenses (Line 18) | 234,898,721 | 303,582,731 | 287,950,402 | 225,661,623 | 150,574,920 |
| 7. | Claims adjustment expenses (Line 20) | 17,807,549 | 20,497,384 | 17,169,129 | 12,080,123 | 4,769,571 |
| 8. | Total administrative expenses (Line 21) | 25,159,649 | 24,127,033 | 43,836,566 | 34,989,914 | 23,198,280 |
| 9. | Net underwriting gain (loss) (Line 24) | 15,739,667 | 1,304,314 | (8,786,092) | 9,398,937 | 8,976,284 |
| 10. | Net investment gain (loss) (Line 27) | 2,297,748 | 1,078,459 | 2,352,477 | 489,051 | 397,972 |
| 11. | Total other income (Lines 28 plus 29) | (317,100) | (316,800) | (316,800) | 0 | 0 |
| 12. | Net income or (loss) (Line 32) | 12,916,343 | 3,164,285 | (3,518,895) | 5,587,334 | 6,158,983 |
| | **Cash Flow** (Page 6) | | | | | |
| 13. | Net cash from operations (Line 11) | (3,418,761) | (3,088,300) | (23,982,727) | 54,676,301 | 7,949,847 |
| | **Risk-Based Capital Analysis** | | | | | |
| 14. | Total adjusted capital | 54,596,492 | 41,505,916 | 34,160,858 | 36,895,398 | 23,609,396 |
| 15. | Authorized control level risk-based capital | 9,927,683 | 11,292,628 | 10,536,480 | 7,806,937 | 5,352,764 |
| | **Enrollment** (Exhibit 1) | | | | | |
| 16. | Total members at end of period (Column 5, Line 7) | 45,032 | 50,421 | 52,064 | 48,094 | 42,906 |
| 17. | Total members months (Column 6, Line 7) | 557,267 | 633,085 | 608,216 | 572,862 | 511,481 |
| | **Operating Percentage** (Page 4)<br>(Item divided by Page 4, sum of Lines 2, 3 and 5) x 100.0 | | | | | |
| 18. | Premiums earned plus risk revenue (Line 2 plus Lines 3 and 5) | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| 19. | Total hospital and medical plus other non-health (Lines 18 plus Line 19) | 80.0 | 86.9 | 84.7 | 80.0 | 80.3 |
| 20. | Cost containment expenses | 5.6 | 5.3 | 4.4 | 3.3 | 2.0 |
| 21. | Other claims adjustment expenses | 0.5 | 0.6 | 0.6 | 1.0 | 0.5 |
| 22. | Total underwriting deductions (Line 23) | 94.6 | 99.6 | 102.6 | 96.7 | 95.3 |
| 23. | Total underwriting gain (loss) (Line 24) | 5.4 | 0.4 | (2.6) | 3.3 | 4.8 |
| | **Unpaid Claims Analysis**<br>(U&I Exhibit, Part 2B) | | | | | |
| 24. | Total claims incurred for prior years (Line 13, Col. 5) | 39,660,068 | 51,526,199 | 47,639,433 | 17,138,133 | 9,298,738 |
| 25. | Estimated liability of unpaid claims-[prior year (Line 13, Col. 6)] | 51,833,123 | 62,976,037 | 61,790,751 | 20,158,943 | 16,646,510 |
| | **Investments In Parent, Subsidiaries and Affiliates** | | | | | |
| 26. | Affiliated bonds (Sch. D Summary, Line 12, Col. 1) | | | | 0 | 0 |
| 27. | Affiliated preferred stocks (Sch. D Summary, Line 18, Col. 1) | 0 | 0 | | 0 | 0 |
| 28. | Affiliated common stocks (Sch. D Summary, Line 24, Col. 1) | 0 | 0 | | 0 | 0 |
| 29. | Affiliated short-term investments (subtotal included in Schedule DA Verification, Col. 5, Line 10) | 0 | 0 | 0 | 0 | 0 |
| 30. | Affiliated mortgage loans on real estate | | | | | |
| 31. | All other affiliated | | | | | |
| 32. | Total of above Lines 26 to 31 | 0 | 0 | 0 | 0 | 0 |
| 33. | Total investment in parent included in Lines 26 to 31 above. | | | | | |

NOTE: If a party to a merger, have the two most recent years of this exhibit been restated due to a merger in compliance with the disclosure requirements of SSAP No. 3, Accounting Changes and Correction of Errors? Yes [ ] No [ ]

If no, please explain:

# SCHEDULE T PREMIUMS AND OTHER CONSIDERATIONS

**Allocated by States and Territories**

| | | 1 | Direct Business Only | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |
| | States, etc. | Active Status (a) | Accident & Health Premiums | Medicare Title XVIII | Medicaid Title XIX | Federal Employees Health Benefits Plan Premiums | Life & Annuity Premiums & Other Considerations | Property/ Casualty Premiums | Total Columns 2 Through 7 | Deposit-Type Contracts |
| 1. | Alabama AL | N | | | | | | | 0 | |
| 2. | Alaska AK | N | | | | | | | 0 | |
| 3. | Arizona AZ | N | | | | | | | 0 | |
| 4. | Arkansas AR | N | | | | | | | 0 | |
| 5. | California CA | N | | | | | | | 0 | |
| 6. | Colorado CO | N | | | | | | | 0 | |
| 7. | Connecticut CT | N | | | | | | | 0 | |
| 8. | Delaware DE | N | | | | | | | 0 | |
| 9. | District of Columbia DC | N | | | | | | | 0 | |
| 10. | Florida FL | N | | | | | | | 0 | |
| 11. | Georgia GA | N | | | | | | | 0 | |
| 12. | Hawaii HI | N | | | | | | | 0 | |
| 13. | Idaho ID | N | | | | | | | 0 | |
| 14. | Illinois IL | N | | | | | | | 0 | |
| 15. | Indiana IN | N | | | | | | | 0 | |
| 16. | Iowa IA | N | | | | | | | 0 | |
| 17. | Kansas KS | N | | | | | | | 0 | |
| 18. | Kentucky KY | N | | | | | | | 0 | |
| 19. | Louisiana LA | N | | | | | | | 0 | |
| 20. | Maine ME | N | | | | | | | 0 | |
| 21. | Maryland MD | N | | | | | | | 0 | |
| 22. | Massachusetts MA | N | | | | | | | 0 | |
| 23. | Michigan MI | L | | 156,031,893 | 139,452,620 | | | | 295,484,513 | |
| 24. | Minnesota MN | N | | | | | | | 0 | |
| 25. | Mississippi MS | N | | | | | | | 0 | |
| 26. | Missouri MO | N | | | | | | | 0 | |
| 27. | Montana MT | N | | | | | | | 0 | |
| 28. | Nebraska NE | N | | | | | | | 0 | |
| 29. | Nevada NV | N | | | | | | | 0 | |
| 30. | New Hampshire NH | N | | | | | | | 0 | |
| 31. | New Jersey NJ | N | | | | | | | 0 | |
| 32. | New Mexico NM | N | | | | | | | 0 | |
| 33. | New York NY | N | | | | | | | 0 | |
| 34. | North Carolina NC | N | | | | | | | 0 | |
| 35. | North Dakota ND | N | | | | | | | 0 | |
| 36. | Ohio OH | N | | | | | | | 0 | |
| 37. | Oklahoma OK | N | | | | | | | 0 | |
| 38. | Oregon OR | N | | | | | | | 0 | |
| 39. | Pennsylvania PA | N | | | | | | | 0 | |
| 40. | Rhode Island RI | N | | | | | | | 0 | |
| 41. | South Carolina SC | N | | | | | | | 0 | |
| 42. | South Dakota SD | N | | | | | | | 0 | |
| 43. | Tennessee TN | N | | | | | | | 0 | |
| 44. | Texas TX | N | | | | | | | 0 | |
| 45. | Utah UT | N | | | | | | | 0 | |
| 46. | Vermont VT | N | | | | | | | 0 | |
| 47. | Virginia VA | N | | | | | | | 0 | |
| 48. | Washington WA | N | | | | | | | 0 | |
| 49. | West Virginia WV | N | | | | | | | 0 | |
| 50. | Wisconsin WI | N | | | | | | | 0 | |
| 51. | Wyoming WY | N | | | | | | | 0 | |
| 52. | American Samoa AS | N | | | | | | | 0 | |
| 53. | Guam GU | N | | | | | | | 0 | |
| 54. | Puerto Rico PR | N | | | | | | | 0 | |
| 55. | U.S. Virgin Islands VI | N | | | | | | | 0 | |
| 56. | Northern Mariana Islands MP | N | | | | | | | 0 | |
| 57. | Canada CAN | N | | | | | | | 0 | |
| 58. | Aggregate other alien OT | XXX | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 59. | Subtotal | XXX | 0 | 156,031,893 | 139,452,620 | 0 | 0 | 0 | 295,484,513 | 0 |
| 60. | Reporting entity contributions for Employee Benefit Plans | XXX | | | | | | | 0 | |
| 61. | Total (Direct Business) | XXX | 0 | 156,031,893 | 139,452,620 | 0 | 0 | 0 | 295,484,513 | 0 |
| | DETAILS OF WRITE-INS | | | | | | | | | |
| 58001. | | XXX | | | | | | | | |
| 58002. | | XXX | | | | | | | | |
| 58003. | | XXX | | | | | | | | |
| 58998. | Summary of remaining write-ins for Line 58 from overflow page | XXX | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 58999. | Totals (Lines 58001 through 58003 plus 58998)(Line 58 above) | XXX | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

(a) Active Status Counts:

L - Licensed or Chartered - Licensed insurance carrier or domiciled RRG 1
R - Registered - Non-domiciled RRGs 0
E - Eligible - Reporting entities eligible or approved to write surplus lines in the state 0
Q - Qualified - Qualified or accredited reinsurer 0
N - None of the above - Not allowed to write business in the state 56

(b) Explanation of basis of allocation by states, premiums by state, etc.
'Allocation by state is based on the employer group's state of domicile

## SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP

### PART 1 - ORGANIZATIONAL CHART




This organizational chart reflects the insurrance entity reporting system and identifies the relationship between the ultimate parent and all member insurers.
The ultimate controlling company is a Fortune 7 company with numerous subsidiaries, the majority of which do not interact with the insurance entities.
(1) Insurers/HMO's
Percentages are rounded to the nearest whole percent and based on ownership of voting rights.
Double borders indicate entity has subsidiaries shown on the same page.
Bold borders indicate entity has subsidiaries shown on a separate page.

## SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP

### PART 1 - ORGANIZATIONAL CHART




* PHPSNE Parent Corporation is also 45% owned by third parties.

## SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP

### PART 1 - ORGANIZATIONAL CHART




*1 PT. Aetna Global Benefits Indonesia is also 20% owned by Suhatsyah Rivai, Aetna's Nominee.
*2 Aetna Global Benefits (Middle East) LLC is also 51% is owned by Euro Gulf LLC, Aetna's Nominee.
*3 Indian Health Organisation Private Limited is 0.019857% owned by Aetna Global Benefits (Asia Pacific) and 99.980143% owned by Aetna Global Benefits (Singapore) PTE. LTD.
*4 PT Asuransi Aetna Asia is also 23% owned by PT Asuransi Central Asia.
*5 Tianjin An Hai Tai Hua Medical Information Technology Co., Ltd is also 50% owned by Tianjin Hai Tai Group Co., Ltd
*6 Virtual Home Health Care L.L.C. is also 51% owned by CBD Commercial Brokers LLC, Aetna's Nominee
*7 Health Care Management Co. Ltd. Is also owned by Aetna Global Benefits (Bermuda) Limited (1 share).
*8 Aetna Health Insurance (Thailand) Public Company Limited is also owned by Aetna Global Benefits (Bermuda) Limited (1 share), Mr. Sansanapongpherchar (1 Share), Mr. Jitphasong Itsaraphakded (1 Share); Mrs. Suphee Wattana (1 Share); and Mr. Buncha Tamphragom (1 Share)
*9 Aetna Holdings (Thailand) Limited is aslo 51% owned by Mr. Paiboon Sutantivorakoon plus Aetna Benefits (Bermuda) Limited owns 1 share.
*10 Minor Health Entreprise Co, Ltd is is also (1 share) owned by Aetna Global Benefits (Bermuda) Limited
*11 Aetna Services (Thailand) Limited is also (1 share) owned by Aetna Global Benefits (Bermuda) Limited and (1 share) owned by Aetna Global Holdings Limited

## SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP

### PART 1 - ORGANIZATIONAL CHART



## SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP

### PART 1 - ORGANIZATIONAL CHART




*100% owned through Aetna's nominees

## SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP

### PART 1 - ORGANIZATIONAL CHART



## SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP

### PART 1 - ORGANIZATIONAL CHART




*1 Aetna ACO Holdings Inc. is owned by Aetna Life Insurance Company (302 shares); Aetna Health Inc. (PA) (198 shares); and Aetna Health Holdings, LLC (1 share).
*2 Innovation Health Holdings, LLC is also 50% owned by Inova Health System Foundation.
*3 Texas Health + Aetna Health Insurance Holding Company LLC is also 50% owned by Texas Health Resources.
*4 Banner Health and Aetna Health Insurance Holding Company LLC is also 49% owned by Banner Health.
*5 Allina Health and Aetna Insurance Holding Company LLC is also 50% owned by Allina Health.
*6 Sutter Health and Aetna Insurance Holding Company LLC is also 50% owned by Sutter Health Plan Products Organization, LLC.

## SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP

### PART 1 - ORGANIZATIONAL CHART




* Aetna Life Insurance Company owns substantially all of the non-managing member interests of Aetna Partners Diversified Fund, LLC.

## SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP

### PART 1 - ORGANIZATIONAL CHART




*1 Aetna ACO Holdings Inc. is owned by Aetna Life Insurance Company (302 shares); Aetna Health Inc. (PA) (198 shares); and Aetna Health Holdings, LLC (1 share).
*2 Innovation Health Holdings, LLC is also 50% owned by Inova Health System Foundation.
*3 Texas Health + Aetna Health Insurance Holding Company LLC is also 50% owned by Texas Health Resources.
*4 Banner Health and Aetna Health Insurance Holding Company LLC is also 49% owned by Banner Health.
*5 Allina Health and Aetna Insurance Holding Company LLC is also 50% owned by Allina Health.
*6 Sutter Health and Aetna Insurance Holding Company LLC is also 50% owned by Sutter Health Plan Products Organization, LLC.

# OVERFLOW PAGE FOR WRITE-INS

# ALPHABETICAL INDEX

## ANNUAL STATEMENT BLANK


Analysis of Operations By Lines of Business ..... 7
Assets ..... 2
Cash Flow ..... 6
Exhibit 1 - Enrollment By Product Type for Health Business Only ..... 17
Exhibit 2 - Accident and Health Premiums Due and Unpaid ..... 18
Exhibit 3 - Health Care Receivables ..... 19
Exhibit 3A - Analysis of Health Care Receivables Collected and Accrued ..... 20
Exhibit 4 - Claims Unpaid and Incentive Pool, Withhold and Bonus ..... 21
Exhibit 5 - Amounts Due From Parent, Subsidiaries and Affiliates ..... 22
Exhibit 6 - Amounts Due To Parent, Subsidiaries and Affiliates ..... 23
Exhibit 7 - Part 1 - Summary of Transactions With Providers ..... 24
Exhibit 7 - Part 2 - Summary of Transactions With Intermediaries ..... 24
Exhibit 8 - Furniture, Equipment and Supplies Owned ..... 25
Exhibit of Capital Gains (Losses) ..... 15
Exhibit of Net Investment Income ..... 15
Exhibit of Nonadmitted Assets ..... 16
Exhibit of Premiums, Enrollment and Utilization (State Page) ..... 30
Five-Year Historical Data ..... 29
General Interrogatories ..... 27
Jurat Page ..... 1
Liabilities, Capital and Surplus ..... 3
Notes To Financial Statements ..... 26
Overflow Page For Write-ins ..... 44
Schedule A - Part 1 ..... E01
Schedule A - Part 2 ..... E02
Schedule A - Part 3 ..... E03
Schedule A - Verification Between Years ..... SI02
Schedule B - Part 1 ..... E04
Schedule B - Part 2 ..... E05
Schedule B - Part 3 ..... E06
Schedule B - Verification Between Years ..... SI02
Schedule BA - Part 1 ..... E07
Schedule BA - Part 2 ..... E08
Schedule BA - Part 3 ..... E09
Schedule BA - Verification Between Years ..... SI03
Schedule D - Part 1 ..... E10
Schedule D - Part 1A - Section 1 ..... SI05
Schedule D - Part 1A - Section 2 ..... SI08
Schedule D - Part 2 - Section 1 ..... E11
Schedule D - Part 2 - Section 2 ..... E12
Schedule D - Part 3 ..... E13
Schedule D - Part 4 ..... E14
Schedule D - Part 5 ..... E15
Schedule D - Part 6 - Section 1 ..... E16
Schedule D - Part 6 - Section 2 ..... E16
Schedule D - Summary By Country ..... SI04
Schedule D - Verification Between Years ..... SI03
Schedule DA - Part 1 ..... E17
Schedule DA - Verification Between Years ..... SI10
Schedule DB - Part A - Section 1 ..... E18
Schedule DB - Part A - Section 2 ..... E19
Schedule DB - Part A - Verification Between Years ..... SI11
Schedule DB - Part B - Section 1 ..... E20
Schedule DB - Part B - Section 2 ..... E21
Schedule DB - Part B - Verification Between Years ..... SI11
Schedule DB - Part C - Section 1 ..... SI12
Schedule DB - Part C - Section 2 ..... SI13
Schedule DB - Part D - Section 1 ..... E22
Schedule DB - Part D - Section 2 ..... E23
Schedule DB - Verification ..... SI14
Schedule DL - Part 1 ..... E24
Schedule DL - Part 2 ..... E25
Schedule E - Part 1 - Cash ..... E26
Schedule E - Part 2 - Cash Equivalents ..... E27
Schedule E - Part 2 - Verification Between Years ..... SI15
Schedule E - Part 3 - Special Deposits ..... E28

**ANNUAL STATEMENT BLANK (Continued)**


Schedule S - Part 1 - Section 2 ..... 31
Schedule S - Part 2 ..... 32
Schedule S - Part 3 - Section 2 ..... 33
Schedule S - Part 4 ..... 34
Schedule S - Part 5 ..... 35
Schedule S - Part 6 ..... 36
Schedule S - Part 7 ..... 37
Schedule T - Part 2 - Interstate Compact ..... 39
Schedule T - Premiums and Other Considerations ..... 38
Schedule Y - Information Concerning Activities of Insurer Members of a Holding Company Group ..... 40
Schedule Y - Part 1A - Detail of Insurance Holding Company System ..... 41
Schedule Y - Part 2 - Summary of Insurer's Transactions With Any Affiliates ..... 42
Statement of Revenue and Expenses ..... 4
Summary Investment Schedule ..... SI01
Supplemental Exhibits and Schedules Interrogatories ..... 43
Underwriting and Investment Exhibit - Part 1 ..... 8
Underwriting and Investment Exhibit - Part 2 ..... 9
Underwriting and Investment Exhibit - Part 2A ..... 10
Underwriting and Investment Exhibit - Part 2B ..... 11
Underwriting and Investment Exhibit - Part 2C ..... 12
Underwriting and Investment Exhibit - Part 2D ..... 13
Underwriting and Investment Exhibit - Part 3 ..... 14